<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES AND EXCHANGE ACT OF 1934
March 22, 2000
Date of Report (Date of earliest event reported)
------------------
TUBOSCOPE INC.
(Exact name of registrant as specified in its charter)
Delaware 0-18312 76-0252850
(State or other Jurisdiction (Commission File Number) (IRS Employer
of Incorporation) Identification Number)
2835 Holmes Road, Houston, Texas 77051
(Address of principal executive offices) (Zip Code)
(713) 799-5100
(Registrant's telephone number, including area code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
<PAGE>
Item 5. Other Events.
On March 22, 2000, Tuboscope Inc., a Delaware corporation ("Tuboscope"),
and Varco International, Inc., a California corporation ("Varco"), entered into
an Agreement and Plan of Merger (the "Merger Agreement"). Pursuant to the
Merger Agreement, and subject to the conditions set forth therein (including
approval of the transaction by the stockholders of Tuboscope and the
shareholders of Varco), Varco will be merged with and into Tuboscope (the
"Merger"). The name of the combined company will be Varco International, Inc.
(the "Combined Company") and will be organized under the laws of the State of
Delaware. In connection with the Merger, holders of outstanding shares of Varco
common stock will receive, in exchange for each share of Varco common stock held
by them, .7125 (the "Exchange Ratio") shares of Tuboscope common stock. In
addition, the Combined Company will assume all options outstanding under Varco's
existing stock option plans. The Merger is intended to be a tax-free
reorganization under Section 368(a) of the Internal Revenue Code of 1986, as
amended, and is intended to be treated as a pooling of interests for financial
accounting purposes.
In connection with the Merger Agreement, Tuboscope and Varco entered into a
stock option agreement dated as of March 22, 2000, pursuant to which Tuboscope
granted Varco the right, under certain circumstances, to purchase up to
8,908,653 shares of Tuboscope common stock (representing approximately 19.9% of
the issued and outstanding shares of Tuboscope's common stock) at a price of
$17.00 per share. Tuboscope and Varco also entered into a stock option
agreement dated as of March 22, 2000, pursuant to which Varco granted Tuboscope
the right, under certain circumstances, to purchase up to 13,023,985 shares
of Varco common stock (representing approximately 19.9% of the issued
and outstanding shares of Varco's common stock) at a price of $14.56 per share.
The Merger Agreement and the stock option agreements are attached as
Exhibits 2.1, 10.1 and 10.2 hereto, respectively. On the same date, Tuboscope
and Varco issued a joint press release regarding the Merger Agreement which is
attached as Exhibit 99.1 hereto.
Item 7(c). Exhibits.
See Exhibit Index.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Tuboscope Inc.
Date: March 23, 2000 By: /s/ Joseph Winkler
________________________________
Name: Joseph Winkler
Title: Chief Financial Officer
3
<PAGE>
EXHIBIT INDEX
Exhibit
Number Exhibit Description
- ----------- -------------------
2.1 Agreement and Plan of Merger dated as of March 22, 2000, by and
among Varco International, Inc., a California corporation, and
Tuboscope Inc., a Delaware corporation
10.1 Tuboscope Stock Option Agreement dated as of March 22, 2000, by
and between Tuboscope Inc., a Delaware corporation, and Varco
International, Inc., a California corporation
10.2 Varco Stock Option Agreement dated as of March 22, 2000, by and
between Varco International, Inc., a California corporation, and
Tuboscope Inc., a Delaware corporation
99.1 Joint press release dated March 22, 2000
<PAGE>
EXHIBIT 2.1
AGREEMENT AND PLAN OF MERGER
between
Varco International, Inc.
and
Tuboscope Inc.
March 22, 2000
EXECUTION COPY
<PAGE>
TABLE OF CONTENTS
<TABLE>
<CAPTION>
Page
----
<S> <C>
ARTICLE I. THE MERGER.......................................................... 1
Section 1.01 The Merger................................................. 1
Section 1.02 Effective Time of the Merger............................... 2
Section 1.03 Closing.................................................... 2
Section 1.04 Effects of the Merger...................................... 2
Section 1.05 Certificate of Incorporation; Bylaws....................... 2
Section 1.06 Directors and Officers..................................... 2
ARTICLE II. CONVERSION OF SECURITIES........................................... 3
Section 2.01 Conversion of Capital Stock................................ 3
Section 2.02 Exchange of Certificates................................... 4
ARTICLE III. REPRESENTATIONS AND WARRANTIES OF VARCO........................... 7
Section 3.01 Organization of Varco...................................... 7
Section 3.02 Varco Capital Structure.................................... 8
Section 3.03 Authority; No Conflict; Required Filings and Consents...... 9
Section 3.04 SEC Filings; Financial Statements.......................... 11
Section 3.05 No Undisclosed Liabilities................................. 11
Section 3.06 Absence of Certain Changes or Events....................... 11
Section 3.07 Taxes...................................................... 11
Section 3.08 Properties................................................. 12
Section 3.09 Intellectual Property...................................... 13
Section 3.10 Agreements, Contracts and Commitments...................... 13
Section 3.11 Litigation................................................. 13
Section 3.12 Environmental Matters...................................... 13
Section 3.13 Employee Benefit Plans..................................... 14
Section 3.14 Compliance With Laws....................................... 15
Section 3.15 Accounting and Tax Matters................................. 15
Section 3.16 Registration Statement; Proxy Statement/Prospectus......... 15
Section 3.17 Labor Matters.............................................. 16
Section 3.18 Insurance.................................................. 16
Section 3.19 No Existing Discussions.................................... 16
Section 3.20 Opinion of Financial Advisor............................... 16
Section 3.21 Anti-Takeover Laws......................................... 17
Section 3.22 Rights Plan................................................ 17
ARTICLE IV. REPRESENTATIONS AND WARRANTIES OF TUBOSCOPE........................ 17
Section 4.01 Organization of Tuboscope.................................. 17
Section 4.02 Tuboscope Capital Structure................................ 18
Section 4.03 Authority; No Conflict; Required Filings and Consents...... 19
Section 4.04 SEC Filings; Financial Statements.......................... 20
</TABLE>
i
EXECUTION COPY
<PAGE>
<TABLE>
<S> <C>
Section 4.05 No Undisclosed Liabilities................................. 20
Section 4.06 Absence of Certain Changes or Events....................... 20
Section 4.07 Taxes...................................................... 21
Section 4.08 Properties................................................. 21
Section 4.09 Intellectual Property...................................... 22
Section 4.10 Agreements, Contracts and Commitments...................... 22
Section 4.11 Litigation................................................. 22
Section 4.12 Environmental Matters...................................... 22
Section 4.13 Employee Benefit Plans..................................... 23
Section 4.14 Compliance With Laws....................................... 24
Section 4.15 Accounting and Tax Matters................................. 24
Section 4.16 Registration Statement; Proxy Statement/Prospectus......... 24
Section 4.17 Labor Matters.............................................. 25
Section 4.18 Insurance.................................................. 25
Section 4.19 No Existing Discussions.................................... 25
Section 4.20 Opinion of Financial Advisor............................... 25
Section 4.21 Anti-Takeover Laws......................................... 25
ARTICLE V. CONDUCT OF BUSINESS................................................. 26
Section 5.01 Covenants of Varco......................................... 26
Section 5.02 Covenants of Tuboscope..................................... 27
Section 5.03 Reorganization............................................. 29
Section 5.04 Cooperation................................................ 29
Section 5.05 Tuboscope Board Resolutions................................ 29
Section 5.06 Pooling Accounting......................................... 30
ARTICLE VI. ADDITIONAL AGREEMENTS.............................................. 30
Section 6.01 No Solicitation............................................ 30
Section 6.02 Proxy Statement/Prospectus; Registration Statement......... 31
Section 6.03 NYSE Listings.............................................. 31
Section 6.04 Access to Information...................................... 32
Section 6.05 Shareholders/Stockholders Meetings......................... 32
Section 6.06 Legal Conditions to Merger................................. 32
Section 6.07 Public Disclosure.......................................... 34
Section 6.08 Affiliate Legends.......................................... 34
Section 6.09 NYSE Listing............................................... 34
Section 6.10 Stock Plans................................................ 34
Section 6.11 Brokers or Finders......................................... 36
Section 6.12 Indemnification............................................ 37
Section 6.13 Letter of Varco's Accountants.............................. 37
Section 6.14 Letter of Tuboscope's Accountants.......................... 37
Section 6.15 Benefit Plans.............................................. 38
Section 6.16 Rights Plan................................................ 38
Section 6.17 Stock Option Agreements.................................... 38
ii
EXECUTION COPY
</TABLE>
<PAGE>
<TABLE>
<S> <C>
ARTICLE VII. CONDITIONS TO MERGER.............................................. 38
Section 7.01 Conditions to Each Party's Obligation To Effect the Merger. 38
Section 7.02 Additional Conditions to Obligations of Varco.............. 39
Section 7.03 Additional Conditions to Obligations of Tuboscope.......... 40
ARTICLE VIII. TERMINATION AND AMENDMENT........................................ 41
Section 8.01 Termination................................................ 41
Section 8.02 Effect of Termination...................................... 42
Section 8.03 Fees and Expenses.......................................... 42
Section 8.04 Amendment.................................................. 45
Section 8.05 Extension; Waiver.......................................... 45
ARTICLE IX. MISCELLANEOUS...................................................... 45
Section 9.01 Nonsurvival of Representations, Warranties and Agreements.. 45
Section 9.02 Notices.................................................... 45
Section 9.03 Interpretation............................................. 46
Section 9.04 Counterparts............................................... 47
Section 9.05 Entire Agreement; No Third Party Beneficiaries............. 47
Section 9.06 Governing Law.............................................. 47
Section 9.07 Assignment................................................. 47
Section 9.08 Waiver of Jury Trial....................................... 47
</TABLE>
Schedule 1 - List of Corporate Executive Officers
Exhibit "A"....... Tuboscope Stock Option Agreement
Exhibit "B"....... Varco Stock Option Agreement
Exhibit "C"....... Tuboscope Tax Matters Certificate (Pircher, Nichols & Meeks)
Exhibit "D"....... Varco Tax Matters Certificate (Pircher, Nichols & Meeks)
Exhibit "E"....... Tuboscope Tax Matters Certificate (Latham & Watkins)
Exhibit "F"....... Varco Tax Matters Certificate (Latham & Watkins)
iii
EXECUTION COPY
<PAGE>
TABLE OF DEFINED TERMS
Cross Reference
Terms in Agreement
- ----- ---------------
Acquisition Proposal......................................... Section 6.01(a)
Affiliate.................................................... Section 6.08
Affiliate Agreement.......................................... Section 6.08
Agreement.................................................... Preamble
Agreement of Merger.......................................... Section 1.02
Alternative Transaction...................................... Section 8.03(g)
Antitrust Laws............................................... Section 6.06(b)
Bankruptcy and Equity Exception.............................. Section 3.03(a)
Certificate of Merger........................................ Section 1.02
Certificates................................................. Section 2.02(b)
CGCL......................................................... Section 1.02
Closing...................................................... Section 1.03
Closing Date................................................. Section 1.03
Code......................................................... Preamble
Confidentiality Agreement.................................... Section 6.01(a)
Continuing Employee.......................................... Section 6.15(a)
Costs........................................................ Section 6.12(a)
DGCL......................................................... Section 1.01
Effective Time............................................... Section 1.02
Environmental Law............................................ Section 3.12(b)
ERISA........................................................ Section 3.13(a)
ERISA Affiliate.............................................. Section 3.13(a)
Exchange Act................................................. Section 3.03(c)
Exchange Agent............................................... Section 2.02(a)
Exchange Fund................................................ Section 2.02(a)
Exchange Ratio............................................... Section 2.01(b)
Governmental Entity.......................................... Section 3.03(c)
Hazardous Substance.......................................... Section 3.12(c)
HSR Act...................................................... Section 3.03(c)
Indemnified Parties.......................................... Section 6.12(a)
IRS.......................................................... Section 3.07(b)
Joint Proxy Statement........................................ Section 3.16
Matching Transaction......................................... Section 6.01(a)
Material Adverse Change...................................... Section 3.06
Material Leases.............................................. Section 3.08
Merger....................................................... Preamble
NYSE......................................................... Section 2.02(e)
Order........................................................ Section 6.06(b)
Outside Date................................................. Section 8.01(b)
iv
<PAGE>
Cross Reference
Terms in Agreement
- ----- ---------------
Registration Statement....................................... Section 3.16
Rule 145..................................................... Section 6.08
SEC.......................................................... Section 3.03(c)
Securities Act............................................... Section 3.04(a)
Stock Option Agreements...................................... Preamble
Subsidiary................................................... Section 3.01
Superior Proposal............................................ Section 6.01(a)
Surviving Corporation........................................ Section 1.01
Tax.......................................................... Section 3.07(a)
Taxes........................................................ Section 3.07(a)
Third Party.................................................. Section 8.03(g)
Tuboscope.................................................... Preamble
Tuboscope Balance Sheet...................................... Section 4.04(b)
Tuboscope Common Stock....................................... Section 2.01(a)
Tuboscope Disclosure Schedule................................ Article IV
Tuboscope Employee Plans..................................... Section 4.13(a)
Tuboscope Material Adverse Effect............................ Section 4.01
Tuboscope Material Contracts................................. Section 4.10
Tuboscope Preferred Stock.................................... Section 4.02(a)
Tuboscope SEC Reports........................................ Section 4.04(a)
Tuboscope Stockholders' Meeting.............................. Section 3.16
Tuboscope Stock Option Agreement............................. Preamble
Tuboscope Stock Plans........................................ Section 4.02(a)
Tuboscope Voting Proposal.................................... Section 6.05(a)
Varco Disclosure Schedule.................................... Article III
Varco Employee Plans......................................... Section 3.13(a)
Varco Material Adverse Effect................................ Section 3.01
Varco Material Contracts..................................... Section 3.10
Varco 1999 Annual Report..................................... Section 3.04(a)
Varco Preferred Stock........................................ Section 3.02(a)
Varco Rights................................................. Section 3.02(b)
Varco Rights Plan............................................ Section 3.02(b)
Varco SEC Reports............................................ Section 3.04(a)
Varco Stock Option........................................... Section 6.10(a)
Varco Stock Option Agreement................................. Preamble
Varco Stock Plans............................................ Section 3.02(a)
Varco Shareholders' Meeting.................................. Section 3.16
v
<PAGE>
AGREEMENT AND PLAN OF MERGER
----------------------------
AGREEMENT AND PLAN OF MERGER (the "Agreement"), dated as of March 22,
2000, by and between Varco International, Inc., a California corporation
("Varco"), and Tuboscope Inc., a Delaware corporation ("Tuboscope").
WHEREAS, the board of directors of Varco deems it advisable and in the
best interests of Varco and its shareholders, and the board of directors of
Tuboscope deems it advisable and in the best interests of Tuboscope and its
stockholders, that Tuboscope and Varco combine their respective businesses in a
"merger of equals" transaction to be effected as set forth in this Agreement;
WHEREAS, the combination of Varco and Tuboscope shall be effected by
the terms of this Agreement through a merger in which the shareholders of Varco
will become stockholders of Tuboscope (the "Merger");
WHEREAS, concurrently with the execution and delivery of this
Agreement and as a condition and inducement to each of Varco's and Tuboscope's
willingness to enter into this Agreement, Varco and Tuboscope have entered into
(i) a Stock Option Agreement dated as of the date of this Agreement and attached
hereto as Exhibit A (the "Tuboscope Stock Option Agreement"), pursuant to which
---------
Tuboscope granted Varco an option to purchase shares of Common Stock of
Tuboscope under certain circumstances and (ii) a Stock Option Agreement dated as
of the date of this Agreement and attached hereto as Exhibit B (the "Varco Stock
---------
Option Agreement" and together with the Tuboscope Stock Option Agreement, the
"Stock Option Agreements") pursuant to which Varco granted Tuboscope an option
to purchase shares of Common Stock of Varco under certain circumstances; and
WHEREAS, for Federal income tax purposes, it is intended that the
Merger shall qualify as a reorganization within the meaning of Section 368(a) of
the Internal Revenue Code of 1986, as amended (the "Code").
NOW, THEREFORE, in consideration of the foregoing and the respective
representations, warranties, covenants and agreements set forth below, the
parties agree as follows:
ARTICLE I
THE MERGER
Section 1.01 The Merger. Upon the terms and subject to the
----------
conditions of this Agreement and in accordance with the applicable provisions of
the General Corporation Law of the State of Delaware (the "DGCL") and the
California General Corporation Law (the "CGCL"), at the Effective Time (as
defined in Section 1.02 hereof), Varco shall merge with and into Tuboscope, the
separate corporate existence of Varco shall cease and Tuboscope shall continue
as the surviving corporation. Tuboscope, as the surviving corporation after the
Merger, is hereinafter sometimes referred to as the "Surviving Corporation".
EXECUTION COPY
<PAGE>
Section 1.02 Effective Time of the Merger. As early as practicable on
----------------------------
the Closing Date, the parties shall cause the Merger to be consummated by (i)
filing with the Secretary of State of the State of Delaware a certificate of
merger or other appropriate documents (in any such case, the "Certificate of
Merger") in such form as is required by, and executed and, as applicable,
acknowledged in accordance with, the provisions of Section 252 of the DGCL, (ii)
filing with the Secretary of State of the State of California a merger agreement
or other appropriate documents (in any such case, the "Agreement of Merger") in
such form as is required by, and executed in accordance with, the provisions of
Sections 1101, 1102 and 1103 of the CGCL and (iii) making all other filings,
recordings or publications required under the DGCL and the CGCL in connection
with the Merger. The Merger shall become effective at 4:00 p.m., Houston time,
on the later of the date of (i) the filing of the Certificate of Merger with the
Delaware Secretary of State in accordance with the DGCL and (ii) the filing of
the Agreement of Merger with the California Secretary of State in accordance
with the CGCL, or at such other time as the parties may agree and specify in
such filings in accordance with applicable law (the time the Merger becomes
effective being the "Effective Time").
Section 1.03 Closing. The closing of the Merger (the "Closing") will
-------
take place at 10:00 a.m., Houston time, on a date to be specified by Varco and
Tuboscope, which shall be no later than the second business day after
satisfaction of the latest to occur of the conditions set forth in Sections
7.01, 7.02(b) (other than the delivery of the officers' certificate referred to
therein) and 7.03(b) (other than the delivery of the officers' certificate
referred to therein) (provided that the other closing conditions set forth in
Article VII have been met or waived as provided in Article VII at or prior to
the Closing) (the "Closing Date"), at the corporate offices of Tuboscope at the
address indicated in Section 9.02 unless another date, place or time is agreed
to in writing by Varco and Tuboscope.
Section 1.04 Effects of the Merger. At the Effective Time, the effect
---------------------
of the Merger shall be as provided by applicable law, including the DGCL and the
CGCL. Without limiting the generality of the foregoing and subject thereto, at
the Effective Time, all the property, rights, privileges, powers and franchises
of Varco and Tuboscope will vest in the Surviving Corporation, and all of the
debts, liabilities and duties of Varco and Tuboscope will become the debts,
liabilities and duties of the Surviving Corporation.
Section 1.05 Certificate of Incorporation; Bylaws. At the Effective
------------------------------------
Time, the certificate of incorporation of Tuboscope, as amended and restated,
shall be further amended to provide that Article FIRST thereof shall read as
follows: "FIRST: The name of this corporation is Varco International, Inc.
(hereinafter referred to as the "Company").", and, as so amended, such
certificate of incorporation shall be the certificate of incorporation of the
Surviving Corporation until thereafter changed or amended as provided therein or
by applicable law. The by-laws of Tuboscope, as in effect immediately prior to
the Effective Time, shall be the by-laws of the Surviving Corporation until
thereafter changed or amended as provided therein or by applicable law.
Section 1.06 Directors and Officers. Prior to the filing of the Joint
----------------------
Proxy Statement with the SEC, each of Varco and Tuboscope shall designate five
(5) individuals who
2
EXECUTION COPY
<PAGE>
shall be initial directors of the Surviving Corporation effective as of the
Effective Time. The individuals listed on Schedule I hereto shall, from and
after the Effective Time, be initial officers of the Surviving Corporation and
shall serve in the positions set forth next to their names until their
successors have been duly elected and qualified or until their earlier death,
resignation or removal in accordance with the Surviving Corporation's
certificate of incorporation and by-laws.
ARTICLE II.
CONVERSION OF SECURITIES
Section 2.01 Conversion of Capital Stock. As of the Effective Time,
---------------------------
by virtue of the Merger and without any action on the part of the holder of any
shares of capital stock of Tuboscope or Varco:
(a) Cancellation of Treasury Stock and Tuboscope-Owned
--------------------------------------------------
Stock. All shares of Common Stock of Varco ("Varco Common Stock") that are
-----
owned by Varco as treasury stock and any shares of Varco Common Stock owned
by Tuboscope or any Subsidiary (as defined in Section 3.01) of Tuboscope
shall be canceled and retired and shall cease to exist and no stock of
Tuboscope or other consideration shall be delivered in exchange therefor.
All shares of Common Stock of Tuboscope, par value $.01 per share
("Tuboscope Common Stock"), owned by Varco shall be canceled and retired
and shall cease to exist and no stock of Tuboscope or other consideration
shall be delivered in exchange therefor.
(b) Capital Stock of Tuboscope. Except as provided in
--------------------------
Section 2.01(a), each issued and outstanding share of Tuboscope Common
Stock shall be unaffected by the Merger and shall remain outstanding.
(c) Exchange Ratio for Varco Common Stock. Subject to
-------------------------------------
Section 2.02, each issued and outstanding share of Varco Common Stock
(other than dissenting shares referred to in Section 2.01(d) and shares to
be canceled in accordance with Section 2.01(a)) shall be converted into
.7125 shares (the "Exchange Ratio") of Tuboscope Common Stock. All such
shares of Varco Common Stock, when so converted, shall no longer be
outstanding and shall automatically be canceled and retired and shall cease
to exist, and each holder of a certificate representing any such shares
shall cease to have any rights with respect thereto, except the right to
receive certificates representing the shares of Tuboscope Common Stock and
any cash in lieu of fractional shares of Tuboscope Common Stock to be
issued or paid in consideration therefor upon the surrender of such
certificate in accordance with Section 2.02, without interest.
Notwithstanding the foregoing, if between the date of this Agreement and
the Effective Time the outstanding shares of Varco Common Stock or
Tuboscope Common Stock shall have been changed into a different number of
shares or a different class, by reason of any stock dividend, subdivision,
reclassification, recapitalization, split, combination or exchange of
shares, or any similar event shall have occurred, then the Exchange Ratio
contemplated shall be correspondingly adjusted to provide to the holders of
Varco Common Stock the same economic effect as contemplated by this
Agreement prior to such event.
3
EXECUTION COPY
<PAGE>
(d) Dissenting Shares. Notwithstanding anything in this
-----------------
Agreement to the contrary, shares of Varco Common Stock which are
dissenting shares (as defined in Section 1300(b) of the CGCL), if any,
shall not be converted into or represent a right to receive any shares of
Tuboscope Common Stock, but the holders thereof shall be entitled only to
such rights as are granted by the CGCL. Each holder of dissenting shares
who becomes entitled to payment therefor pursuant to the CGCL shall receive
payment from the Surviving Corporation in accordance with the CGCL;
provided, however, that (i) if any such holder of dissenting shares shall
have failed to establish his entitlement to appraisal rights as provided in
the CGCL, (ii) if any such holder of dissenting shares shall have
effectively withdrawn his demand for appraisal thereof or lost his right to
appraisal and payment therefor under the CGCL or (iii) if neither any
holder of dissenting shares nor the Surviving Corporation shall have filed
a petition demanding a determination of the value of all dissenting shares
within the time provided in the CGCL, such holder or holders (as the case
may be) shall forfeit the right to appraisal of such shares of Varco Common
Stock and such shares of Varco Common Stock shall thereupon be deemed to
have been converted, as of the Effective Time, into and represent shares of
Tuboscope Common Stock, without interest thereon, as provided in Section
2.01(c) hereof.
Section 2.02 Exchange of Certificates. The procedures for exchanging
------------------------
certificates which immediately prior to the Effective Time represented
outstanding shares of Varco Common Stock for certificates representing shares of
Tuboscope Common Stock pursuant to the Merger are as follows:
(a) Exchange Agent. At the Effective Time, Tuboscope shall
--------------
make available to a bank or trust company designated by Tuboscope and Varco
(the "Exchange Agent"), in trust for the benefit of the holders of
certificates which immediately prior to the Effective Time represented
outstanding shares of Varco Common Stock, for exchange in accordance with
this Section 2.02, through the Exchange Agent, certificates representing
the shares of Tuboscope Common Stock and an estimated amount of cash in
lieu of fractional shares (such certificates representing shares of
Tuboscope Common Stock, together with any dividends or distributions with
respect thereto, and cash in lieu of fractional shares being hereinafter
referred to as the "Exchange Fund") issuable pursuant to Section 2.01 upon
conversion of outstanding shares of Varco Common Stock.
(b) Exchange Procedures. As soon as reasonably practicable
-------------------
after the Effective Time, Tuboscope shall cause the Exchange Agent to mail
to each holder of record of a certificate or certificates which immediately
prior to the Effective Time represented outstanding shares of Varco Common
Stock (the "Certificates") whose shares were converted pursuant to Section
2.01 into the right to receive certificates representing shares of
Tuboscope Common Stock (i) a letter of transmittal which shall specify that
delivery shall be effected, and risk of loss and title to the Certificates
shall pass, only upon delivery of the Certificates to the Exchange Agent
and shall be in such form and have such other provisions as Tuboscope and
Varco may reasonably specify and (ii) instructions for effecting the
surrender of the Certificates in exchange for certificates representing
shares of Tuboscope Common Stock (plus cash in lieu of fractional shares,
if any, of Tuboscope Common Stock as provided below). Upon surrender of a
Certificate to the Exchange Agent or to such other agent or agents as may
be appointed by Tuboscope,
4
EXECUTION COPY
<PAGE>
together with such letter of transmittal, duly completed and validly
executed in accordance with the instructions thereto, and such other
documents as may reasonably be required by the Exchange Agent, the holder
of such Certificate shall be entitled to receive in exchange therefor a
certificate representing that number of whole shares of Tuboscope Common
Stock into which the holder's shares of Varco Common Stock were converted
pursuant to Section 2.01(c) and a check representing cash in lieu of
fractional shares which the holder has the right to receive pursuant to
Section 2.02(e), and the Certificate so surrendered shall immediately be
canceled. In the event of a transfer of ownership of Varco Common Stock
which is not registered in the transfer records of Varco, a certificate
representing the proper number of shares of Tuboscope Common Stock
determined in accordance with Section 2.01(c) and a check representing cash
in lieu of fractional shares which the holder is entitled to receive
pursuant to Section 2.02(e) may be issued to a transferee if the
Certificate representing such Varco Common Stock is presented to the
Exchange Agent, accompanied by all documents required to evidence and
effect such transfer and by evidence that any applicable stock transfer
taxes have been paid. Until surrendered as contemplated by this Section
2.02, each Certificate shall be deemed at any time after the Effective Time
to represent only the right to receive upon such surrender, a certificate
representing shares of Tuboscope Common Stock into which the holders of
shares of Varco Common Stock were converted pursuant to Section 2.01(c) and
a check representing cash in lieu of any fractional shares of Tuboscope
Common Stock as contemplated by Section 2.02(e).
(c) Treatment of Unexchanged Shares. No dividends or other
-------------------------------
distributions declared or made with respect to Tuboscope Common Stock with
a record date after the Effective Time shall be paid to the holder of any
unsurrendered Certificate with respect to the certificates representing
shares of Tuboscope Common Stock represented thereby that the holder would
be entitled to upon surrender of such Certificate and no cash payment in
lieu of fractional shares shall be paid to any such holder pursuant to
subsection (e) below, until the holder of such Certificate shall surrender
such Certificate in accordance with this Section 2.02. Subject to the
effect of applicable laws, following surrender of any such Certificate,
there shall be paid to the holder of the certificates representing whole
shares of Tuboscope Common Stock issued in exchange therefor, without
interest, (i) at the time of such surrender, the amount of any cash payable
in lieu of a fractional share of Tuboscope Common Stock to which such
holder is entitled pursuant to subsection (e) below and the amount of
dividends or other distributions with a record date after the Effective
Time previously paid with respect to such whole shares of Tuboscope Common
Stock, and (ii) at the appropriate payment date, the amount of dividends or
other distributions with a record date after the Effective Time but prior
to surrender and a payment date subsequent to surrender payable with
respect to such whole shares of Tuboscope Common Stock. For purposes of
determining quorums at meetings of stockholders of the Surviving
Corporation and the stockholders of the Surviving Corporation entitled to
notice of, and to vote at, meetings of stockholders, holders of
unsurrendered Certificates shall be considered record holders of the shares
of Tuboscope Common Stock represented thereby.
(d) No Further Ownership Rights in Varco Common Stock. All
-------------------------------------------------
shares of Tuboscope Common Stock issued upon the surrender for exchange of
Certificates in accordance with the terms hereof and any cash paid pursuant
to subsection (c) or (e) of this
5
EXECUTION COPY
<PAGE>
Section 2.02 shall be deemed to have been issued or paid in full
satisfaction of all rights pertaining to the shares of Varco Common Stock
represented thereby. Notwithstanding the foregoing, Tuboscope is obligated
to pay any dividends or make any other distributions with a record date
prior to the Effective Time which may have been declared or made by Varco
on shares of Varco Common Stock in accordance with the terms of this
Agreement (to the extent permitted under Section 5.01) prior to the date
hereof and which remain unpaid at the Effective Time. From and after the
Effective Time, there shall be no further registration of transfers on the
stock transfer books of Varco of the shares of Varco Common Stock which
were outstanding immediately prior to the Effective Time. If, after the
Effective Time, Certificates are presented to the Surviving Corporation for
any reason, they shall be canceled and exchanged as provided in this
Section 2.02.
(e) No Fractional Shares. No certificate or scrip
--------------------
representing fractional shares of Tuboscope Common Stock shall be issued in
the Merger or upon the surrender for exchange of Certificates, and such
fractional share interests will not entitle the owner thereof to vote or to
any other rights of a shareholder of Tuboscope. Notwithstanding any other
provision of this Agreement, each holder of shares of Varco Common Stock
converted pursuant to the Merger who would otherwise have been entitled to
receive a fraction of a share of Tuboscope Common Stock (after taking into
account all Certificates delivered by such holder) shall receive, in lieu
thereof, cash (without interest) in an amount equal to such fractional
amount multiplied by the average of the last reported sales prices of
Tuboscope Common Stock, as reported on the New York Stock Exchange
("NYSE"), on each of the ten trading days immediately preceding the date of
the Effective Time.
(f) Termination of Exchange Fund. Any portion of the
----------------------------
Exchange Fund which remains undistributed to the holders of Certificates
for 180 days after the Effective Time shall be delivered to the Surviving
Corporation or otherwise on the instruction of the Surviving Corporation,
and any holders of Certificates who have not previously complied with this
Section 2.02 shall thereafter look only to the Surviving Corporation for
the certificates representing shares of Tuboscope Common Stock, any cash in
lieu of fractional shares of Tuboscope Common Stock and any dividends or
distributions with respect to Tuboscope Common Stock to which such holders
are entitled pursuant to Sections 2.01 and 2.02. Any portion of the
Exchange Fund which remains undistributed to the holders of Certificates
for five years after the Effective Time (or such earlier date immediately
prior to such time as the Exchange Fund would otherwise escheat or become
the property of any public official or government) shall, to the extent
permitted by law, become the property of the Surviving Corporation free and
clear of any claims or interest of any holders of Certificates previously
entitled thereto.
(g) No Liability. None of the Surviving Corporation, the
------------
Exchange Agent or any party hereto shall be liable to any former holder of
shares of Varco Common Stock for any portion of the Exchange Fund delivered
to a public official pursuant to any applicable abandoned property, escheat
or similar law.
6
EXECUTION COPY
<PAGE>
(h) Withholding Rights. Each of the Exchange Agent and the
------------------
Surviving Corporation shall be entitled to deduct and withhold from the
consideration otherwise payable pursuant to this Agreement to any former holder
of shares of Varco Common Stock such amounts as it is required to deduct and
withhold with respect to the making of such payment under the Code and the rules
and regulations promulgated thereunder, or any provision of state, local or
foreign tax law. To the extent that amounts are so withheld by the Exchange
Agent or the Surviving Corporation, such withheld amounts shall be treated for
all purposes of this Agreement as having been paid to the holder of the shares
of Varco Common Stock in respect of which such deduction and withholding was
made by the Exchange Agent or the Surviving Corporation.
(i) Lost Certificates. If any Certificate shall have been
-----------------
lost, stolen or destroyed, upon the making of an affidavit of that fact by the
person claiming such Certificate to be lost, stolen or destroyed and, if
required by the Surviving Corporation, the posting by such person of a bond in
such reasonable amount as the Surviving Corporation may direct as indemnity
against any claim that may be made against it on account of the alleged loss,
theft or destruction of such Certificate, the Exchange Agent will issue in
exchange for such lost, stolen or destroyed Certificate the certificate
representing the shares of Tuboscope Common Stock and any cash in lieu of
fractional shares, and unpaid dividends and distributions on the certificate
deliverable in respect thereof pursuant to this Agreement.
ARTICLE III.
REPRESENTATIONS AND WARRANTIES OF VARCO
Varco represents and warrants to Tuboscope that the statements
contained in this Article III are true and correct except as set forth herein
and in the disclosure schedule delivered by Varco to Tuboscope on or before the
date of this Agreement (the "Varco Disclosure Schedule"). The Varco Disclosure
Schedule shall be arranged in paragraphs corresponding to the numbered and
lettered paragraphs contained in this Article III and the disclosure in any
paragraph shall qualify other paragraphs in this Article III only to the extent
that it is reasonably apparent from a reading of such disclosure that it also
qualifies or applies to such other paragraphs.
Section 3.01 Organization of Varco. Each of Varco and its
---------------------
Subsidiaries (as defined below) is a corporation or unincorporated entity duly
organized, validly existing and in good standing under the laws of the
jurisdiction of its incorporation or organization, has all requisite corporate
or entity power to own, lease and operate its property and to carry on its
business as now being conducted and as proposed to be conducted, and is duly
qualified to do business and is in good standing as a foreign corporation or
organization in each jurisdiction in which the failure to be so qualified would
have a material adverse effect on the business, properties, financial condition,
or results of operations of Varco and its Subsidiaries, taken as a whole (a
"Varco Material Adverse Effect"). Except as set forth in the Varco SEC Reports
(as defined in Section 3.04) filed prior to the date hereof, neither Varco nor
any of its Subsidiaries directly or indirectly owns any equity or similar
interest in, or any interest convertible into or exchangeable or exercisable
for, any corporation, partnership, joint venture or other business
7
EXECUTION COPY
<PAGE>
association or entity, excluding securities in any publicly traded company held
for investment by Varco or its Subsidiaries and comprising less than five
percent (5%) of the outstanding stock of such compa ny. As used in this
Agreement, the word "Subsidiary" means, with respect to any party, any
corporation or other organization, whether incorporated or unincorporated, of
which (i) such party or any other Subsidiary of such party is a general partner
(excluding partnerships, the general partnership interests of which held by such
party or any Subsidiary of such party do not have a majority of the voting
interest in such partnership) or (ii) at least a majority of the securities or
other interests having by their terms ordinary voting power to elect a majority
of the board of directors or others performing similar functions with respect to
such corporation or other organization is directly or indirectly owned or
controlled by such party or by any one or more of its Subsidiaries, or by such
party and one or more of its Subsidiaries.
Section 3.02 Varco Capital Structure.
-----------------------
(a) The authorized capital stock of Varco consists of
120,000,000 shares of Common Stock and 10,000,000 shares of Preferred Stock
("Varco Preferred Stock"), of which 80,000 shares have been designated as
"Series A Participating Preferred Stock". As of March 15, 2000, (i) 65,447,165
shares of Varco Common Stock were issued and outstanding, all of which are
validly issued, fully paid and nonassessable, (ii) no shares of Varco Preferred
Stock were issued and outstanding, and (iii) no shares of Varco Common Stock or
Varco Preferred Stock were held in the treasury of Varco or by Subsidiaries of
Varco. The Varco Disclosure Schedule shows the number of shares of Varco Common
Stock reserved for future issuance pursuant to warrants, stock options and
restricted stock awards granted and outstanding as of March 15, 2000 and the
plans under which such options or shares of restricted stock were granted or
issued (collectively, the "Varco Stock Plans"). Except for the issuance of
shares of Varco Common Stock in connection with the Varco Stock Plans (including
the exercise of options thereunder) or pursuant to the Varco 1980 Employee Stock
Purchase Plan and except as set forth in the Varco Disclosure Schedule, no
change in such capitalization has occurred between March 15, 2000 and the date
of this Agreement. All shares of Varco Common Stock subject to issuance as
specified above are duly authorized and, upon issuance on the terms and
conditions specified in the instruments pursuant to which they are issuable,
shall be validly issued, fully paid and nonassessable. There are no obligations,
contingent or otherwise, of Varco or any of its Subsidiaries to repurchase,
redeem or otherwise acquire any shares of Varco Common Stock or the capital
stock of any Subsidiary or to provide funds to or make any material investment
(in the form of a loan, capital contribution or otherwise) in any such
Subsidiary or any other entity other than guarantees of obligations of
Subsidiaries entered into in the ordinary course of business. All of the
outstanding shares of capital stock of each of Varco's Subsidiaries are duly
authorized, validly issued, fully paid and nonassessable and all such shares
(other than directors' qualifying shares in the case of foreign Subsidiaries)
are owned by Varco or another Subsidiary of Varco free and clear of all security
interests, liens, claims, pledges, agreements, limitations on Varco's voting
rights, charges or other encumbrances of any nature.
(b) Except as set forth in this Section 3.02 or as reserved
for future grants of securities under the Varco Stock Plans or the Varco Stock
Option Agreement, and except for the rights (the "Varco Rights") issued and
issuable under the Rights Agreement dated
8
EXECUTION COPY
<PAGE>
as of November 6, 1997 between Varco and Harris Trust Company of California (the
"Varco Rights Plan") and 80,000 shares of Series A Participating Preferred Stock
of Varco reserved for issuance upon the exercise of the Varco Rights, there are
no equity securities of any class of Varco or any security exchangeable into or
exercisable for such equity securities, issued, reserved for issuance or
outstanding. Except as set forth in this Section 3.02, there are no options,
warrants, equity securities, calls, rights, commitments or agreements of any
character to which Varco or any of its Subsidiaries is a party or by which it is
bound obligating Varco or any of its Subsidiaries to issue, deliver or sell, or
cause to be issued, delivered or sold, additional shares of capital stock of
Varco or any of its Subsidiaries or obligating Varco or any of its Subsidiaries
to grant, extend, accelerate the vesting of or enter into any such option,
warrant, equity security, call, right, commitment or agreement. To the best
knowledge of Varco, there are no voting trusts, proxies or other voting
agreements or understandings with respect to the shares of capital stock of
Varco.
Section 3.03 Authority; No Conflict; Required Filings and Consents.
-----------------------------------------------------
(a) Varco has all requisite corporate power and authority to
enter into this Agreement and the Varco Stock Option Agreement and to consummate
the transactions contemplated by this Agreement and the Varco Stock Option
Agreement. The execution and delivery of this Agreement and the Varco Stock
Option Agreement and the consummation of the transactions contemplated by this
Agreement and the Varco Stock Option Agreement by Varco have been duly
authorized by all necessary corporate action on the part of Varco, subject only
to the approval of this Agreement and the Merger by Varco's shareholders under
the CGCL. This Agreement and the Varco Stock Option Agreement have been duly
executed and delivered by Varco and constitute the valid and binding obligations
of Varco, enforceable in accordance with their terms, subject to bankruptcy,
insolvency, fraudulent transfer, reorganization, moratorium and similar laws of
general applicability relating to or affecting creditors' rights and to general
equity principles (the "Bankruptcy and Equity Exception").
(b) The execution and delivery of this Agreement and the
Varco Stock Option Agreement by Varco do not, and the consummation of the
transactions contemplated hereby and thereby will not, (i) conflict with, or
result in any violation or breach of, any provision of the articles of
incorporation or bylaws of Varco, (ii) except as set forth in the Varco
Disclosure Schedule, result in any violation or breach of, or constitute (with
or without notice or lapse of time, or both) a default (or give rise to a right
of termination, cancellation or acceleration of any obligation or loss of any
material benefit) under, or require a consent or waiver under, any of the terms,
conditions or provisions of any note, bond, mortgage, indenture, lease, contract
or other agreement, instrument or obligation to which Varco or any of its
Subsidiaries is a party or by which any of them or any of their properties or
assets may be bound, or (iii) conflict with or violate any permit, concession,
franchise, license, judgment, order, decree, statute, law, ordinance, rule or
regulation applicable to Varco or any of its Subsidiaries or any of its or their
properties or assets, except in the case of (ii) and (iii) for any such
conflicts, violations, defaults, terminations, cancellations or accelerations
which are not, individually or in the aggregate, reasonably likely to have a
Varco Material Adverse Effect.
9
EXECUTION COPY
<PAGE>
(c) No consent, approval, order or authorization of, or
registration, declaration or filing with, any court, administrative agency or
commission or other governmental authority or instrumentality ("Governmental
Entity") is required by or with respect to Varco or any of its Subsidiaries in
connection with the execution and delivery of this Agreement and the Varco Stock
Option Agreement or the consummation of the transactions contemplated hereby or
thereby, except for (i) the filing of the pre-merger notification report under
the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR
Act"), (ii) the filing of the Agreement of Merger with the California Secretary
of State and the Certificate of Merger with the Delaware Secretary of State,
(iii) the filing of the Joint Proxy Statement (as defined in Section 3.16 below)
with the Securities and Exchange Commission (the "SEC") in accordance with the
Securities Exchange Act of 1934, as amended (the "Exchange Act"), (iv) such
consents, approvals, orders, authorizations, registrations, declarations and
filings as may be required under applicable state securities laws and the laws
of any foreign country and the European Union, and (v) such other consents,
authorizations, filings, approvals and registrations which, if not obtained or
made, would not be reasonably likely to have a Varco Material Adverse Effect.
Section 3.04 SEC Filings; Financial Statements.
---------------------------------
(a) Varco has filed and made available to Tuboscope all
forms, reports and documents required to be filed by Varco with the SEC since
January 1, 1997 other than registration statements on Form S-8 (collectively,
the "Varco SEC Reports") and has furnished to Tuboscope and attached to the
Varco Disclosure Schedule a substantially final draft of its Annual Report on
Form 10-K for the year ended December 31, 1999 (the "Varco 1999 Annual Report"),
which for the purposes of this Agreement shall be deemed to have been filed with
the SEC immediately prior to the execution and delivery of this Agreement and,
accordingly, any reference in this Agreement to "the Varco SEC Reports, as filed
prior to the date hereof" shall include the Varco 1999 Annual Report. The Varco
SEC Reports (i) at the time filed, complied in all material respects with the
applicable requirements of the Securities Act of 1933, as amended (the
"Securities Act"), and the Exchange Act, as the case may be, and (ii) did not at
the time they were filed (or if amended or superseded by a filing prior to the
date of this Agreement, then on the date of such filing) contain any untrue
statement of a material fact or omit to state a material fact required to be
stated in such Varco SEC Reports or necessary in order to make the statements in
such Varco SEC Reports, in the light of the circumstances under which they were
made, not misleading. The Varco 1999 Annual Report does not as of the date
hereof contain any untrue statement of a material fact or omit to state a
material fact which would be required to be stated in such Annual Report if such
Annual Report were filed as of the date hereof or necessary in order to make the
statements in such Annual Report, in the light of the circumstances under which
they were made, not misleading. None of Varco's Subsidiaries is required to
file any forms, reports or other documents with the SEC.
(b) Each of the consolidated financial statements
(including, in each case, any related notes) contained in the Varco SEC Reports
complied as to form in all material respects with the applicable published rules
and regulations of the SEC with respect thereto, was prepared in accordance with
generally accepted accounting principles applied on a consistent basis
throughout the periods involved (except as may be indicated in the notes to such
financial
10
EXECUTION COPY
<PAGE>
statements or, in the case of unaudited statements, as permitted by Form 10-Q of
the SEC) and fairly presented the consolidated financial position of Varco and
its Subsidiaries as of the dates and the consolidated results of their
operations and cash flows for the periods indicated, except that the unaudited
interim financial statements were or are subject to normal and recurring year-
end adjustments which were not or are not expected to be material in amount. The
audited balance sheet of Varco as of December 31, 1999 is referred to herein as
the "Varco Balance Sheet."
Section 3.05 No Undisclosed Liabilities. Except as disclosed in the
---------------------------
Varco SEC Reports filed prior to the date hereof, and except for normal or
recurring liabilities incurred since December 31, 1999 in the ordinary course of
business consistent with past practices, Varco and its Subsidiaries do not have
any liabilities, either accrued, contingent or otherwise (whether or not
required to be reflected in financial statements in accordance with generally
accepted accounting principles), and whether due or to become due, which
individually or in the aggregate are reasonably likely to have a Varco Material
Adverse Effect.
Section 3.06 Absence of Certain Changes or Events. Except as disclosed
------------------------------------
in the Varco SEC Reports filed prior to the date hereof, since the date of the
Varco Balance Sheet, Varco and its Subsidiaries have conducted their businesses
only in the ordinary course and in a manner consistent with past practice and,
since such date, there has not been (i) any material adverse change in the
financial condition, results of operations, business or properties (a "Material
Adverse Change") of Varco and its Subsidiaries, taken as a whole, or any
development or combination of developments of which the management of Varco is
aware that, individually or in the aggregate, has had, or is reasonably likely
to have, a Varco Material Adverse Effect; (ii) any damage, destruction or loss
(whether or not covered by insurance) with respect to Varco or any of its
Subsidiaries having a Varco Material Adverse Effect; (iii) any material change
by Varco in its accounting methods, principles or practices to which Tuboscope
has not previously consented in writing; (iv) any revaluation by Varco of any of
its assets having a Varco Material Adverse Effect; or (v) any other action or
event that would have required the consent of Tuboscope pursuant to Section 5.01
of this Agreement had such action or event occurred after the date of this
Agreement and that, individually or in the aggregate, has had or is reasonably
likely to have a Varco Material Adverse Effect.
Section 3.07 Taxes.
-----
(a) For the purposes of this Agreement, a (i) "Tax" or,
collectively, "Taxes," means any and all federal, state, local or foreign gross
receipts, income, profits, sales, use, value added, ad valorem, transfer, gains,
franchise, withholding, payroll, recapture, employment, excise, unemployment,
social security, license, occupation, business organization, stamp,
environmental, property, severance, premium, custom duties, capital stock,
disability, registration, alternative or add-on minimum, estimated, or other tax
of any kind whatsoever, including any interest, penalty or addition thereto,
whether disputed or not, and any obligations under any agreements or
arrangements with any other person with respect to such amounts and any
liability for such amounts of a predecessor entity, and (ii) "Tax Return" shall
mean any return, declaration, report, claim for refund, or information return or
statement, including any
11
EXECUTION COPY
<PAGE>
schedule or attachment thereto, and including any amendment thereof, filed or to
be filed with any tax authority.
(b) Varco and each of its Subsidiaries have timely filed all
Tax Returns and reports required to be filed by them prior to the date of this
Agreement (taking into account extensions), except for any such returns which
are not likely, individually or in the aggregate, to have a Varco Material
Adverse Effect. All such Tax Returns are complete and correct in all respects,
except for any such omissions or errors which are not reasonably likely,
individually or in the aggregate, to have a Varco Material Adverse Effect. Varco
and each of its Subsidiaries have paid (or Varco has paid on its Subsidiaries'
behalf) all Taxes shown as due on such Tax Returns. Varco's most recent
consolidated financial statements reflect an adequate reserve for all Taxes
payable by Varco and its Subsidiaries for all taxable periods and portions
thereof through the date of such financial statements, except to the extent that
any such Taxes are not reasonably likely, individually or in the aggregate, to
have a Varco Material Adverse Effect. Except as set forth in the Varco
Disclosure Schedule, neither the Internal Revenue Service (the "IRS") nor any
other taxing authority has asserted any claim for Taxes, or to the actual
knowledge of the executive officers of Varco, is threatening to assert any
claims for Taxes, which claims, individually or in the aggregate, are reasonably
likely to have a Varco Material Adverse Effect. Except as set forth in the
Varco Disclosure Schedule, no deficiencies for any Taxes (other than those which
are not reasonably likely, individually or in the aggregate, to have a Varco
Material Adverse Effect) have been proposed, asserted or assessed against Varco
or any of its Subsidiaries that have not been fully paid or adequately provided
for in the appropriate financial statements of Varco and its Subsidiaries, no
requests for waivers of the time to assess any Taxes are pending, and none of
Varco or any of its Subsidiaries has waived any statute of limitations in
respect of Taxes or agreed to any extension of time with respect to a Tax
assessment or deficiency. Varco and each of its Subsidiaries have withheld or
collected and paid over to the appropriate governmental authorities (or are
properly holding for such payment) all Taxes required by law to be withheld or
collected. Neither Varco nor any of its Subsidiaries has made an election under
Section 341(f) of the Code. There are no liens for Taxes upon the assets of
Varco or any of its Subsidiaries (other than liens for Taxes that are not yet
due or that are being contested in good faith by appropriate proceedings),
except for liens which are not reasonably likely, individually or in the
aggregate, to have a Varco Material Adverse Effect.
Section 3.08 Properties.
----------
(a) Varco has provided to Tuboscope a true and complete list
of all real property leased by Varco or its Subsidiaries pursuant to leases
providing for the occupancy of facilities in excess of 10,000 square feet
(collectively "Material Leases"). Varco is not in default under any such
Material Leases, except where the existence of such defaults, individually or in
the aggregate, is not reasonably likely to have a Varco Material Adverse Effect.
(b) Varco has provided to Tuboscope a true and complete list of
all real property that Varco or any of its Subsidiaries owns. With respect to
each such item of real property, except for such matters that, individually or
in the aggregate, are not reasonably likely to have a Varco Material Adverse
Effect: (a) Varco or the identified Subsidiary has good and
12
EXECUTION COPY
<PAGE>
clear record and marketable title to such property, free and clear of any
security interest, easement, covenant or other restriction, except for security
interests, easements, covenants and other restrictions which do not materially
impair the current uses or occupancy of such property; and (b) the improvements
constructed on such property are in good condition, and all mechanical and
utility systems servicing such improvements are in good condition, free in each
case of material defects.
Section 3.09 Intellectual Property. Varco owns, or is licensed or
---------------------
otherwise possesses legally enforceable rights to use, all trademarks, trade
names, service marks, copyrights, and any applications for such trademarks,
trade names, service marks and copyrights, know-how, computer software programs
or applications and tangible or intangible proprietary information or material
that are necessary to conduct the business of Varco as currently conducted,
subject to such exceptions that would not be reasonably likely to have a Varco
Material Adverse Effect.
Section 3.10 Agreements, Contracts and Commitments. Varco has not
-------------------------------------
breached, or received in writing any claim or notice that it has breached, any
of the terms or conditions of any material agreement, contract or commitment
filed as an exhibit to the Varco SEC Reports ("Varco Material Contracts") in
such a manner as, individually or in the aggregate, are reasonably likely to
have a Varco Material Adverse Effect. Each Varco Material Contract that has not
expired by its terms is in full force and effect.
Section 3.11 Litigation. Except as described in the Varco SEC Reports
----------
filed prior to the date hereof, there is no action, suit or proceeding, claim,
arbitration or investigation against Varco pending or as to which Varco has
received any written notice of assertion, which, individually or in the
aggregate, is reasonably likely to have a Varco Material Adverse Effect or a
material adverse effect on the ability of Varco to consummate the transactions
contemplated by this Agreement.
Section 3.12 Environmental Matters.
---------------------
(a) Except for matters that are specifically disclosed in
the Varco SEC Reports filed prior to the date hereof (with reference to a
specifically named site or claim) and except for such matters that, individually
or in the aggregate, are not reasonably likely to have a Varco Material Adverse
Effect: (i) Varco and its Subsidiaries comply, and within all applicable
statutes of limitations periods have complied, with all applicable Environmental
Laws (as defined in Section 3.12(b)); (ii) neither Varco nor its Subsidiaries
are subject to liability for any Hazardous Substance disposal or contamination
on any third party property; (iii) neither Varco nor any of its Subsidiaries are
subject to liability for any release of, or any exposure of any person or
property to, any Hazardous Substance; (iv) neither Varco nor any of its
Subsidiaries has received any notice, demand, letter, claim or request for
information alleging that Varco or any of its Subsidiaries may be in violation
of or liable under any Environmental Law; (v) neither Varco nor any of its
Subsidiaries is subject to any orders, decrees or injunctions issued by, or
other arrangements with, any Governmental Entity or is subject to any indemnity
or other agreement with any third party relating to liability under any
Environmental Law or relating to
13
EXECUTION COPY
<PAGE>
Hazardous Substances; and (vi) there are no circumstances or conditions
involving Varco or any of its Subsidiaries that could reasonably be expected to
cause Varco or any of its Subsidiaries to become subject to any claims,
liability, investigations or costs, or to restrictions on the ownership, use or
transfer of any property of Varco or any of its Subsidiaries, pursuant to any
Environmental Law.
(b) As used herein, the term "Environmental Law" means any
federal, state, local or foreign law, regulation, order, decree, permit,
authorization, opinion, common law or agency requirement relating to: (A) the
protection, preservation, investigation, remediation or restoration of
environmental quality, health and safety, or natural resources, or (B) noise,
odor, wetlands, pollution, contamination or any injury or threat of injury to
persons or property.
(c) As used herein, the term "Hazardous Substance" means:
(A) any substance that is listed, classified or regulated pursuant to or that
could result in liability under any Environmental Law; (B) any petroleum product
or by- product, asbestos-containing material, lead-containing paint or plumbing,
polychlorinated biphenyls, radioactive materials or radon; or (C) any other
substance which is the subject of regulatory action by any Governmental Entity
pursuant to any Environmental Law.
Section 3.13 Employee Benefit Plans.
----------------------
(a) Varco has listed in Section 3.13 of the Varco Disclosure
Schedule all employee benefit plans (as defined in Section 3(3) of the Employee
Retirement Income Security Act of 1974, as amended ("ERISA")) and all bonus,
stock option, stock purchase, incentive, deferred compensation, supplemental
retirement, severance and other similar employee benefit plans, and all
unexpired severance agreements, written or otherwise, for the benefit of, or
relating to, any current or former employee of Varco or any trade or business
(whether or not incorporated) which is a member or which is under common control
with Varco (an "ERISA Affiliate") within the meaning of Section 414 of the Code,
or any Subsidiary of Varco (together, the "Varco Employee Plans").
(b) With respect to each Varco Employee Plan, Varco has made
available to Tuboscope, a true and correct copy of (i) the most recent annual
report (Form 5500) filed with the IRS, (ii) such Varco Employee Plan, (iii) each
trust agreement and group annuity contract, if any, relating to such Varco
Employee Plan and (iv) the most recent actuarial report or valuation relating to
a Varco Employee Plan subject to Title IV of ERISA.
(c) With respect to the Varco Employee Plans, individually
and in the aggregate, no event has occurred, and to the knowledge of Varco,
there exists no condition or set of circumstances in connection with which Varco
could be subject to any liability that is reasonably likely to have a Varco
Material Adverse Effect under ERISA, the Code or any other applicable law.
(d) With respect to the Varco Employee Plans, individually
and in the aggregate, there are no funded benefit obligations for which
contributions have not been made or
14
EXECUTION COPY
<PAGE>
properly accrued and there are no unfunded benefit obligations which have not
been accounted for by reserves, or otherwise properly footnoted in accordance
with generally accepted accounting principles, on the financial statements of
Varco, which obligations are reasonably likely to have a Varco Material Adverse
Effect.
(e) Except as disclosed in Varco SEC Reports filed prior to
the date of this Agreement, and except as set forth in the Varco Disclosure
Schedule or as provided for in this Agreement, neither Varco nor any of its
Subsidiaries is a party to any oral or written (i) agreement with any officer or
other key employee of Varco or any of its Subsidiaries, the benefits of which
are contingent, or the terms of which are materially altered, upon the
occurrence of a transaction involving Varco of the nature contemplated by this
Agreement, (ii) agreement with any officer of Varco providing any term of
employment or compensation guarantee extending for a period longer than one year
from the date hereof and for the payment of compensation in excess of $100,000
per annum, or (iii) agreement or plan, including any stock option plan, stock
appreciation right plan, restricted stock plan or stock purchase plan, any of
the benefits of which will be increased, or the vesting of the benefits of which
will be accelerated, by the occurrence of any of the transactions contemplated
by this Agreement or the value of any of the benefits of which will be
calculated on the basis of any of the transactions contemplated by this
Agreement.
Section 3.14 Compliance With Laws. Varco has complied with, is not in
--------------------
violation of, and has not received any notices of violation with respect to, any
federal, state or local statute, law or regulation with respect to the conduct
of its business, or the ownership or operation of its business, except for
failures to comply or violations which, individually or in the aggregate, have
not had and are not reasonably likely to have a Varco Material Adverse Effect.
Section 3.15 Accounting and Tax Matters. To its knowledge, after
--------------------------
consulting with its independent auditors, neither Varco nor any of its
Affiliates (as defined in Section 6.10) has taken or agreed to take any action
which would (i) prevent Varco from accounting for the business combination to be
effected by the Merger as a pooling of interests of (ii) prevent the Merger from
qualifying as a reorganization under Section 368(a) of the Code.
Section 3.16 Registration Statement; Proxy Statement/Prospectus. The
--------------------------------------------------
information to be supplied by Varco for inclusion in the registration statement
on Form S-4 pursuant to which shares of Tuboscope Common Stock issued in the
Merger will be registered under the Securities Act (the "Registration
Statement"), shall not at the time the Registration Statement is declared
effective by the SEC contain any untrue statement of a material fact or omit to
state any material fact required to be stated in the Registration Statement or
necessary in order to make the statements in the Registration Statement, in
light of the circumstances under which they were made, not misleading. The
information supplied by Varco for inclusion in the joint proxy
statement/prospectus to be sent to Varco's shareholders and Tuboscope's
stockholders in connection with the meeting of Varco's shareholders to consider
this Agreement and the Merger (the "Varco Shareholders' Meeting") and in
connection with the meeting of Tuboscope's stockholders (the "Tuboscope
Stockholders' Meeting") to consider this Agreement, the Merger and an amendment
to Tuboscope's certificate of incorporation to increase the number
15
EXECUTION COPY
<PAGE>
of authorized shares of Tuboscope Common Stock from 60,000,000 to 200,000,000
shares (the "Joint Proxy Statement") shall not, on the date the Joint Proxy
Statement is first mailed to Varco's shareholders and Tuboscope's stockholders,
at the time of the Varco Shareholders' Meeting and the Tuboscope Stockholders'
Meeting and at the Effective Time, contain any statement which, at such time and
in light of the circumstances under which it shall be made, is false or
misleading with respect to any material fact, or omit to state any material fact
necessary in order to make the statements made in the Joint Proxy Statement not
false or misleading; or omit to state any material fact necessary to correct any
statement in any earlier communication with respect to the solicitation of
proxies for the Varco Shareholders' Meeting or the Tuboscope Stockholders'
Meeting which has become false or misleading. If at any time prior to the
Effective Time any event relating to Varco or any of its Affiliates, officers or
directors should be discovered by Varco which should be set forth in an
amendment to the Registration Statement or a supplement to the Joint Proxy
Statement, Varco shall promptly inform Tuboscope.
Section 3.17 Labor Matters. Neither Varco nor any of its Subsidiaries
-------------
is a party to or otherwise bound by any collective bargaining agreement,
contract or other agreement or understanding with a labor union or labor
organization, nor is any such contract or agreement presently being negotiated,
nor is there, nor has there been in the last five years, a representation
question respecting any of the employees of Varco or its Subsidiaries, and, to
the best knowledge of the executive officers of Varco, there are no campaigns
being conducted to solicit cards from employees of Varco or its Subsidiaries to
authorize representation by any labor organization, nor is Varco or its
Subsidiaries a party to, or bound by, any consent decree with, or citation by,
any governmental agency relating to employees or employment practices. Nor, as
of the date hereof, is Varco or any of its Subsidiaries the subject of any
material proceeding asserting that Varco or any of its Subsidiaries has
committed an unfair labor practice or is seeking to compel it to bargain with
any labor union or labor organization nor, as of the date of this Agreement, is
there pending or, to the knowledge of the executive officers of Varco,
threatened, any material labor strike, dispute, walkout, work stoppage,
slow-down or lockout involving Varco or any of its Subsidiaries.
Section 3.18 Insurance. All material fire and casualty, general
---------
liability, business interruption, product liability, and sprinkler and water
damage insurance policies maintained by Varco or any of its Subsidiaries are
with reputable insurance carriers and are in character and amount at least
equivalent to that carried by persons engaged in similar businesses and subject
to the same or similar perils or hazards, except for any such failures to
maintain insurance policies that, individually or in the aggregate, are not
reasonably likely to have a Varco Material Adverse Effect.
Section 3.19 No Existing Discussions. As of the date hereof, Varco is
-----------------------
not engaged, directly or indirectly, in any discussions or negotiations with any
other party with respect to an Acquisition Proposal (as defined in Section
6.01(a)).
Section 3.20 Opinion of Financial Advisor. The financial advisor of
----------------------------
Varco, J.P. Morgan Securities Inc., has delivered to Varco its opinion dated the
date of this Agreement to the
16
EXECUTION COPY
<PAGE>
effect that the Exchange Ratio is fair to the holders of Varco Common Stock from
a financial point of view.
Section 3.21 Anti-Takeover Laws. No "fair price," "moratorium," "control
------------------
share acquisition" or other similar anti-takeover statute or regulation is
applicable to Varco or (solely by reason of Varco's participation therein) the
Merger or the other transactions contemplated by this Agreement.
Section 3.22 Rights Plan. The Varco Rights Plan has been amended so that
-----------
(i) Tuboscope is exempt from the definition of "Acquiring Person" contained in
the Varco Rights Plan, and no "Shares Acquisition Date" or "Distribution Date"
or "Triggering Event" (as such terms are defined in the Varco Rights Plan) will
occur as a result of the execution of this Agreement or the Tuboscope Stock
Option Agreement or the consummation of the Merger or the other transactions
contemplated by this Agreement or the Tuboscope Stock Option Agreement and (ii)
the Varco Rights Plan will terminate and the Varco Rights will expire
immediately prior to the Effective Time. The Varco Rights Plan, as so amended,
has not been further amended or modified, and a true and complete copy of such
amendment has been delivered to Tuboscope. The entering into of this Agreement
and the Varco Stock Option Agreement and the consummation of the transactions
contemplated hereby and thereby do not and will not result in the grant of any
rights to any person under the Varco Rights Plan or enable or require the Varco
Rights to be exercised or distributed.
ARTICLE IV.
REPRESENTATIONS AND WARRANTIES OF TUBOSCOPE
Tuboscope represents and warrants to Varco that the statements contained in
this Article IV are true and correct, except as set forth herein and in the
disclosure schedule delivered by Tuboscope to Varco on or before the date of
this Agreement (the "Tuboscope Disclosure Schedule"). The Tuboscope Disclosure
Schedule shall be arranged in paragraphs corresponding to the numbered and
lettered paragraphs contained in this Article IV and the disclosure in any
paragraph shall qualify other paragraphs in this Article IV only to the extent
that it is reasonably apparent from a reading of such disclosure that it also
qualifies or applies to such other paragraphs.
Section 4.01 Organization of Tuboscope. Each of Tuboscope and its
-------------------------
Subsidiaries is a corporation or unincorporated entity duly organized, validly
existing and in good standing under the laws of the jurisdiction of its
incorporation or organization, has all requisite corporate or entity power to
own, lease and operate its property and to carry on its business as now being
conducted and as proposed to be conducted, and is duly qualified to do business
and is in good standing as a foreign corporation or organization in each
jurisdiction in which the failure to be so qualified would have a material
adverse effect on the business, properties, financial condition, or results of
operations of Tuboscope and its Subsidiaries, taken as a whole (a "Tuboscope
Material Adverse Effect"). Except as set forth in the Tuboscope SEC Reports (as
defined in Section 4.04) filed prior to the date hereof, neither Tuboscope nor
any of its Subsidiaries directly or indirectly owns any equity or similar
interest in, or any interest
17
EXECUTION COPY
<PAGE>
convertible into or exchangeable or exercisable for, any corporation,
partnership, joint venture or other business association or entity, excluding
securities in any publicly traded company held for investment by Tuboscope or
its Subsidiaries and comprising less than five percent (5%) of the outstanding
stock of such company.
Section 4.02 Tuboscope Capital Structure.
---------------------------
(a) The authorized capital stock of Tuboscope consists of 60,000,000
shares of Common Stock, $.01 par value, and 5,000,000 shares of Preferred Stock,
$.01 par value ("Tuboscope Preferred Stock"). As of March 15, 2000, (i)
44,767,104 shares of Tuboscope Common Stock were issued and outstanding, all of
which are validly issued, fully paid and nonassessable, (ii) 1,424,700 shares of
Tuboscope Common Stock were held in the treasury of Tuboscope or by Subsidiaries
of Tuboscope and (iii) no shares of Tuboscope Preferred Stock were issued and
outstanding. The Tuboscope Disclosure Schedule shows the number of shares of
Tuboscope Common Stock reserved for future issuance pursuant to warrants, stock
options and restricted stock awards granted and outstanding as of March 15, 2000
and the plans under which such options and restricted stock awards were granted
(collectively, the "Tuboscope Stock Plans"). Except for the issuance of shares
of Tuboscope Common Stock in connection with the Tuboscope Stock Plans
(including the exercise of options thereunder) or pursuant to the Tuboscope
Employee Qualified Stock Purchase Plan, the Tuboscope Deferred Compensation Plan
and the Tuboscope 401(K) Thrift Savings Plan and except as set forth in the
Tuboscope Disclosure Schedule, no change in such capitalization has occurred
between March 15, 2000 and the date of this Agreement. As of the date of this
Agreement, no shares of Tuboscope Preferred Stock are issued and outstanding.
All shares of Tuboscope Common Stock subject to issuance as specified above are
duly authorized and, upon issuance on the terms and conditions specified in the
instruments pursuant to which they are issuable, shall be validly issued, fully
paid and nonassessable. There are no obligations, contingent or otherwise, of
Tuboscope or any of its Subsidiaries to repurchase, redeem or otherwise acquire
any shares of Tuboscope Common Stock or the capital stock of any Subsidiary or
to provide funds to or make any material investment (in the form of a loan,
capital contribution or otherwise) in any such Subsidiary or any other entity
other than guarantees of obligations of Subsidiaries entered into in the
ordinary course of business. All of the outstanding shares of capital stock of
each of Tuboscope's Subsidiaries are duly authorized, validly issued, fully paid
and nonassessable and all such shares (other than directors' qualifying shares
in the case of foreign Subsidiaries) are owned by Tuboscope or another
Subsidiary of Tuboscope free and clear of all security interests, liens, claims,
pledges, agreements, limitations on Tuboscope's voting rights, charges or other
encumbrances of any nature.
(b) Except as set forth in this Section 4.02 or as reserved for
future grants of securities under the Tuboscope Stock Plans or the Tuboscope
Stock Option Agreement, there are no equity securities of any class of Tuboscope
or any security exchangeable into or exercisable for such equity securities,
issued, reserved for issuance or outstanding. Except as set forth in this
Section 4.02, there are no options, warrants, equity securities, calls, rights,
commitments or agreements of any character to which Tuboscope or any of its
Subsidiaries is a party or by which it is bound obligating Tuboscope or any of
its Subsidiaries to issue, deliver or
18
EXECUTION COPY
<PAGE>
sell, or cause to be issued, delivered or sold, additional shares of capital
stock of Tuboscope or any of its Subsidiaries or obligating Tuboscope or any of
its Subsidiaries to grant, extend, accelerate the vesting of or enter into any
such option, warrant, equity security, call, right, commitment or agreement. To
the best knowledge of Tuboscope, there are no voting trusts, proxies or other
voting agreements or understandings with respect to the shares of capital stock
of Tuboscope.
Section 4.03 Authority; No Conflict; Required Filings and Consents.
-----------------------------------------------------
(a) Tuboscope has all requisite corporate power and authority to
enter into this Agreement and the Tuboscope Stock Option Agreement and to
consummate the transactions contemplated hereby and thereby. The execution and
delivery of this Agreement and the Tuboscope Stock Option Agreement and the
consummation of the transactions contemplated hereby and thereby have been duly
authorized by all necessary corporate action on the part of Tuboscope, subject
only to the approval of the Tuboscope Voting Proposal by Tuboscope's
stockholders. This Agreement and the Tuboscope Stock Option Agreement have been
duly executed and delivered by Tuboscope and constitute the valid and binding
obligation of Tuboscope, enforceable in accordance with its terms, subject to
the Bankruptcy and Equity Exception.
(b) The execution and delivery of this Agreement and the Tuboscope
Stock Option Agreement by Tuboscope do not, and the consummation of the
transactions contemplated hereby and thereby will not, (i) conflict with, or
result in any violation or breach of, any provision of the certificate of
incorporation or bylaws of Tuboscope, (ii) result in any violation or breach of,
or constitute (with or without notice or lapse of time, or both) a default (or
give rise to a right of termination, cancellation or acceleration of any
obligation or loss of any material benefit) under, or require a consent or
waiver under, any of the terms, conditions or provisions of any note, bond,
mortgage, indenture, lease, contract or other agreement, instrument or
obligation to which Tuboscope or any of its Subsidiaries is a party or by which
any of them or any of their properties or assets may be bound, or (iii) conflict
with or violate any permit, concession, franchise, license, judgment, order,
decree, statute, law, ordinance, rule or regulation applicable to Tuboscope or
any of its Subsidiaries or any of its or their properties or assets, except in
the case of (ii) and (iii) for any such conflicts, violations, defaults,
terminations, cancellations or accelerations which are not, individually or in
the aggregate, reasonably likely to have a Tuboscope Material Adverse Effect.
(c) No consent, approval, order or authorization of, or registration,
declaration or filing with, any Governmental Entity is required by or with
respect to Tuboscope or any of its Subsidiaries in connection with the execution
and delivery of this Agreement and the Tuboscope Stock Option Agreement or the
consummation of the transactions contemplated hereby or thereby, except for (i)
the filing of the pre-merger notification report under the HSR Act, (ii) the
filing of the Registration Statement with the SEC in accordance with the
Securities Act, (iii) the filing of the Certificate of Merger with the Delaware
Secretary of State and the Agreement of Merger with the California Secretary of
State, (iv) the filing of the Joint Proxy Statement with the SEC in accordance
with the Exchange Act, (v) such consents, approvals,
19
EXECUTION COPY
<PAGE>
orders, authorizations, registrations, declarations and filings as may be
required under applicable state securities laws and the laws of any foreign
country and the European Union, and (vi) such other consents, authorizations,
filings, approvals and registrations which, if not obtained or made, would not
be reasonably likely to have a Tuboscope Material Adverse Effect.
Section 4.04 SEC Filings; Financial Statements.
---------------------------------
(a) Tuboscope has filed and made available to Varco all forms,
reports and documents required to be filed by Tuboscope with the SEC since
January 1, 1997 other than registration statements on Form S-8 (collectively,
the "Tuboscope SEC Reports"). The Tuboscope SEC Reports (i) at the time filed,
complied in all material respects with the applicable requirements of the
Securities Act and the Exchange Act, as the case may be, and (ii) did not at the
time they were filed (or if amended or superseded by a filing prior to the date
of this Agreement, then on the date of such filing) contain any untrue statement
of a material fact or omit to state a material fact required to be stated in
such Tuboscope SEC Reports or necessary in order to make the statements in such
Tuboscope SEC Reports, in the light of the circumstances under which they were
made, not misleading. None of Tuboscope's Subsidiaries is required to file any
forms, reports or other documents with the SEC.
(b) Each of the consolidated financial statements (including, in each
case, any related notes) contained in the Tuboscope SEC Reports complied as to
form in all material respects with the applicable published rules and
regulations of the SEC with respect thereto, was prepared in accordance with
generally accepted accounting principles applied on a consistent basis
throughout the periods involved (except as may be indicated in the notes to such
financial statements or, in the case of unaudited statements, as permitted by
Form 10-Q of the SEC) and fairly presented the consolidated financial position
of Tuboscope and its Subsidiaries as of the dates and the consolidated results
of their operations and cash flows for the periods indicated, except that the
unaudited interim financial statements were or are subject to normal and
recurring year-end adjustments which were not or are not expected to be material
in amount. The audited balance sheet of Tuboscope as of December 31, 1999 is
referred to herein as the "Tuboscope Balance Sheet."
Section 4.05 No Undisclosed Liabilities. Except as disclosed in the
--------------------------
Tuboscope SEC Reports filed prior to the date hereof, and except for normal or
recurring liabilities incurred since December 31, 1999 in the ordinary course of
business consistent with past practices, Tuboscope and its Subsidiaries do not
have any liabilities, either accrued, contingent or otherwise (whether or not
required to be reflected in financial statements in accordance with generally
accepted accounting principles), and whether due or to become due, which
individually or in the aggregate are reasonably likely to have a Tuboscope
Material Adverse Effect.
Section 4.06 Absence of Certain Changes or Events. Except as disclosed in
------------------------------------
the Tuboscope SEC Reports filed prior to the date hereof, since the date of the
Tuboscope Balance Sheet, Tuboscope and its Subsidiaries have conducted their
businesses only in the ordinary course and in a manner consistent with past
practice and, since such date, there has not been (i) any Material Adverse
Change in Tuboscope and its Subsidiaries, taken as a whole, or any
20
EXECUTION COPY
<PAGE>
development or combination of developments of which the management
of Tuboscope is aware that, individually or in the aggregate, has had, or is
reasonably likely to have, a Tuboscope Material Adverse Effect; (ii) any damage,
destruction or loss (whether or not covered by insurance) with respect to
Tuboscope or any of its Subsidiaries having a Tuboscope Material Adverse Effect;
(iii) any material change by Tuboscope in its accounting methods, principles or
practices to which Varco has not previously consented in writing; (iv) any
revaluation by Tuboscope of any of its assets having a Tuboscope Material
Adverse Effect; or (v) any other action or event that would have required the
consent of Varco pursuant to Section 5.02 of this Agreement had such action or
event occurred after the date of this Agreement and that, individually or in the
aggregate, has had or is reasonably likely to have a Tuboscope Material Adverse
Effect.
Section 4.07 Taxes. Tuboscope and each of its Subsidiaries have timely
-----
filed all Tax Returns and reports required to be filed by them prior to the date
of this Agreement (taking into account extensions), except for any such returns
which are not likely, individually or in the aggregate, to have a Tuboscope
Material Adverse Effect. All such Tax Returns are complete and correct in all
respects, except for any such omissions or errors which are not reasonably
likely, individually or in the aggregate, to have a Tuboscope Material Adverse
Effect. Tuboscope and each of its Subsidiaries have paid (or Tuboscope has paid
on its Subsidiaries' behalf) all Taxes shown as due on such Tax Returns.
Tuboscope's most recent consolidated financial statements reflect an adequate
reserve for all Taxes payable by Tuboscope and its Subsidiaries for all taxable
periods and portions thereof through the date of such financial statements,
except to the extent that any such Taxes are not reasonably likely, individually
or in the aggregate, to have a Tuboscope Material Adverse Effect. Neither the
IRS nor any other taxing authority has asserted any claim for Taxes, or to the
actual knowledge of the executive officers of Tuboscope, is threatening to
assert any claims for Taxes, which claims, individually or in the aggregate, are
reasonably likely to have a Tuboscope Material Adverse Effect. No deficiencies
for any Taxes (other than those which are not reasonably likely, individually or
in the aggregate, to have a Tuboscope Material Adverse Effect) have been
proposed, asserted or assessed against Tuboscope or any of its Subsidiaries that
have not been fully paid or adequately provided for in the appropriate financial
statements of Tuboscope and its Subsidiaries, no requests for waivers of the
time to assess any Taxes are pending, and none of Tuboscope or any of its
Subsidiaries has waived any statute of limitations in respect of Taxes or agreed
to any extension of time with respect to a Tax assessment or deficiency.
Tuboscope and each of its Subsidiaries have withheld or collected and paid over
to the appropriate governmental authorities (or are properly holding for such
payment) all Taxes required by law to be withheld or collected. Neither
Tuboscope nor any of its Subsidiaries has made an election under Section 341(f)
of the Code. There are no liens for Taxes upon the assets of Tuboscope or any of
its Subsidiaries (other than liens for Taxes that are not yet due or that are
being contested in good faith by appropriate proceedings), except for liens
which are not reasonably likely, individually or in the aggregate, to have a
Tuboscope Material Adverse Effect.
Section 4.08 Properties.
----------
(a) Tuboscope has provided to Varco a true and complete list of all
21
EXECUTION COPY
<PAGE>
real property leased by Tuboscope or its Subsidiaries pursuant to Material
Leases. Tuboscope is not in default under such Material Leases, except where the
existence of such defaults, individually or in the aggregate, is not reasonably
likely to have a Tuboscope Material Adverse Effect.
(b) Tuboscope has provided to Varco a true and complete list of all
real property that Tuboscope or any of its Subsidiaries owns. With respect to
each such item of real property, except for such matters that, individually or
in the aggregate, are not reasonably likely to have a Tuboscope Material Adverse
Effect: (a) Tuboscope or the identified Subsidiary has good and clear record and
marketable title to such property free and clear of any security interest,
easement, covenant or other restriction, except for security interests,
easements, covenants and other restrictions which do not materially impair the
current uses or occupancy of such property; and (b) the improvements constructed
on such property are in good condition, and all mechanical and utility systems
servicing such improvements are in good condition, free in each case of material
defects.
Section 4.09 Intellectual Property. Tuboscope owns, or is licensed or
---------------------
otherwise possesses legally enforceable rights to use, all trademarks, trade
names, service marks, copyrights, and any applications for such trademarks,
trade names, service marks and copyrights, know-how, computer software programs
or applications, and tangible or intangible proprietary information or material
that are necessary to conduct the business of Tuboscope as currently conducted,
subject to such exceptions that would not be reasonably likely to have a
Tuboscope Material Adverse Effect.
Section 4.10 Agreements, Contracts and Commitments. Tuboscope has not
-------------------------------------
breached, or received in writing any claim or notice that it has breached, any
of the terms or conditions of any material agreement, contract or commitment
filed as an exhibit to the Tuboscope SEC Reports ("Tuboscope Material
Contracts") in such a manner as, individually or in the aggregate, are
reasonably likely to have a Tuboscope Material Adverse Effect. Each Tuboscope
Material Contract that has not expired by its terms is in full force and effect.
Section 4.11 Litigation. Except as described in the Tuboscope SEC Reports
----------
filed prior to the date hereof, there is no action, suit or proceeding, claim,
arbitration or investigation against Tuboscope pending or as to which Tuboscope
has received any written notice of assertion, which, individually or in the
aggregate, is reasonably likely to have a Tuboscope Material Adverse Effect or a
material adverse effect on the ability of Tuboscope to consummate the
transactions contemplated by this Agreement.
Section 4.12 Environmental Matters. Except for matters that are
---------------------
specifically disclosed in the Tuboscope SEC Reports filed prior to the date
hereof (with reference to a specifically named site or claim) and except for
such matters that, individually or in the aggregate, are not reasonably likely
to have a Tuboscope Material Adverse Effect: (i) Tuboscope and its Subsidiaries
comply, and within all applicable statute of limitation periods have complied,
with all applicable Environmental Laws; (ii) neither Tuboscope nor its
Subsidiaries are subject to liability for any Hazardous Substance disposal or
contamination on any third party
22
EXECUTION COPY
<PAGE>
property; (iii) neither Tuboscope nor any of its Subsidiaries are subject to
liability for any release of, or any exposure of any person or property to, any
Hazardous Substance; (iv) neither Tuboscope nor any of its Subsidiaries has
received any notice, demand, letter, claim or request for information alleging
that Tuboscope or any of its Subsidiaries may be in violation of or liable under
any Environmental Law; (v) neither Tuboscope nor any of its Subsidiaries is
subject to any orders, decrees or injunctions issued by, or other arrangements
with, any Governmental Entity or is subject to any indemnity or other agreement
with any third party relating to liability under any Environmental Law or
relating to Hazardous Substances; and (vi) there are no circumstances or
conditions involving Tuboscope or any of its Subsidiaries that could reasonably
be expected to cause Tuboscope or any of its Subsidiaries to become subject to
any claims, liability, investigations or costs, or to restrictions on the
ownership, use or transfer of any property of Tuboscope or any of its
Subsidiaries, pursuant to any Environmental Law.
Section 4.13 Employee Benefit Plans.
----------------------
(a) Tuboscope has listed in Section 4.13 of the Tuboscope Disclosure
Schedule all employee benefit plans (as defined in Section 3(3) of ERISA) and
all bonus, stock option, stock purchase, incentive, deferred compensation,
supplemental retirement, severance and other similar employee benefit plans, and
all unexpired severance agreements, written or otherwise, for the benefit of, or
relating to, any current or former employee of Tuboscope or any ERISA Affiliate
of Tuboscope, or any Subsidiary of Tuboscope (together, the "Tuboscope Employee
Plans").
(b) With respect to each Tuboscope Employee Plan, Tuboscope has made
available to Varco, a true and correct copy of (i) the most recent annual report
(Form 5500) filed with the IRS, (ii) such Tuboscope Employee Plan, (iii) each
trust agreement and group annuity contract, if any, relating to such Tuboscope
Employee Plan and (iv) the most recent actuarial report or valuation relating to
a Tuboscope Employee Plan subject to Title IV of ERISA.
(c) With respect to the Tuboscope Employee Plans, individually and in
the aggregate, no event has occurred, and to the knowledge of Tuboscope, there
exists no condition or set of circumstances in connection with which Tuboscope
could be subject to any liability that is reasonably likely to have a Tuboscope
Material Adverse Effect under ERISA, the Code or any other applicable law.
(d) With respect to the Tuboscope Employee Plans, individually and in
the aggregate, there are no funded benefit obligations for which contributions
have not been made or properly accrued and there are no unfunded benefit
obligations which have not been accounted for by reserves, or otherwise properly
footnoted in accordance with generally accepted accounting principles, on the
financial statements of Tuboscope, which obligations are reasonably likely to
have a Tuboscope Material Adverse Effect.
(e) Except as disclosed in Tuboscope SEC Reports filed prior to the
date of this Agreement, and except as provided for in this Agreement, neither
Tuboscope nor any
23
EXECUTION COPY
<PAGE>
of its Subsidiaries is a party to any oral or written (i) agreement with any
officer or other key employee of Tuboscope or any of its Subsidiaries, the
benefits of which are contingent, or the terms of which are materially altered,
upon the occurrence of a transaction involving Tuboscope of the nature
contemplated by this Agreement, (ii) agreement with any officer of Tuboscope
providing any term of employment or compensation guarantee extending for a
period longer than one year from the date hereof or for the payment of
compensation in excess of $100,000 per annum, or (iii) agreement or plan,
including any stock option plan, stock appreciation right plan, restricted stock
plan or stock purchase plan, any of the benefits of which will be increased, or
the vesting of the benefits of which will be accelerated, by the occurrence of
any of the transactions contemplated by this Agreement or the value of any of
the benefits of which will be calculated on the basis of any of the transactions
contemplated by this Agreement.
Section 4.14 Compliance With Laws. Tuboscope has complied with, is not in
--------------------
violation of, and has not received any notices of violation with respect to, any
federal, state or local statute, law or regulation with respect to the conduct
of its business, or the ownership or operation of its business, except for
failures to comply or violations which, individually or in the aggregate, have
not had and are not reasonably likely to have a Tuboscope Material Adverse
Effect.
Section 4.15 Accounting and Tax Matters. To its knowledge, after
--------------------------
consulting with its independent auditors, neither Tuboscope nor any of its
Affiliates (as defined in Section 6.10) has taken or agreed to take any action
which would (i) prevent Tuboscope from accounting for the business combination
to be effected by the Merger as a pooling of interests of (ii) prevent the
Merger from qualifying as a reorganization under Section 368(a) of the Code.
Section 4.16 Registration Statement; Proxy Statement/Prospectus. The
--------------------------------------------------
information in the Registration Statement (except for information supplied by
Varco for inclusion in the Registration Statement, as to which Tuboscope makes
no representation) shall not at the time the Registration Statement is declared
effective by the SEC contain any untrue statement of a material fact or omit to
state any material fact required to be stated in the Registration Statement or
necessary in order to make the statements in the Registration Statement, in
light of the circumstances under which they were made, not misleading. The
information supplied by Tuboscope for inclusion in the Joint Proxy Statement
shall not, on the date the Joint Proxy Statement is first mailed to Tuboscope's
stockholders or Varco's shareholders, at the time of the Tuboscope Stockholders'
Meeting and the Varco Shareholder's Meeting and at the Effective Time, contain
any statement which, at such time and in light of the circumstances under which
it shall be made, is false or misleading with respect to any material fact, or
omit to state any material fact necessary in order to make the statements made
in the Joint Proxy Statement not false or misleading; or omit to state any
material fact necessary to correct any statement in any earlier communication
with respect to the solicitation of proxies for the Tuboscope Stockholders'
Meeting or the Varco Shareholders' Meetings which has become false or
misleading. If at any time prior to the Effective Time any event relating to
Tuboscope or any of its Affiliates, officers or directors should be discovered
by Tuboscope which should be set forth in an amendment to the Registration
Statement or a supplement to the Joint Proxy Statement, Tuboscope shall promptly
inform Varco.
24
EXECUTION COPY
<PAGE>
Section 4.17 Labor Matters. Neither Tuboscope nor any of its
-------------
Subsidiaries is a party to or otherwise bound by any collective bargaining
agreement, contract or other agreement or understanding with a labor union or
labor organization, nor is any such contract or agreement presently being
negotiated, nor is there, nor has there been in the last five years, a
representation question respecting any of the employees of Tuboscope or its
Subsidiaries, and, to the best knowledge of the executive officers of Tuboscope,
there are no campaigns being conducted to solicit cards from employees of
Tuboscope or its Subsidiaries to authorize representation by any labor
organization, nor is Tuboscope or its Subsidiaries a party to, or bound by, any
consent decree with, or citation by, any governmental agency relating to
employees or employment practices. Nor, as of the date hereof, is Tuboscope or
any of its Subsidiaries the subject of any material proceeding asserting that
Tuboscope or any of its Subsidiaries has committed an unfair labor practice or
is seeking to compel it to bargain with any labor union or labor organization
nor, as of the date of this Agreement, is there pending or, to the knowledge of
the executive officers of Tuboscope, threatened, any material labor strike,
dispute, walkout, work stoppage, slow-down or lockout involving Tuboscope or any
of its Subsidiaries.
Section 4.18 Insurance. All material fire and casualty, general
---------
liability, business interruption, product liability, and sprinkler and water
damage insurance policies maintained by Tuboscope or any of its Subsidiaries are
with reputable insurance carriers and are in character and amount at least
equivalent to that carried by persons engaged in similar businesses and subject
to the same or similar perils or hazards, except for any such failures to
maintain insurance policies that, individually or in the aggregate, are not
reasonably likely to have a Tuboscope Material Adverse Effect.
Section 4.19 No Existing Discussions. As of the date hereof,
-----------------------
Tuboscope is not engaged, directly or indirectly, in any discussions or
negotiations with any other party with respect to an Acquisition Proposal (as
defined in Section 6.01(a)).
Section 4.20 Opinion of Financial Advisor. The financial advisor of
----------------------------
Tuboscope, Credit Suisse First Boston Corporation, has delivered to Tuboscope an
opinion, dated the date of this Agreement, to the effect that the Exchange Ratio
is fair to Tuboscope from a financial point of view.
Section 4.21 Anti-Takeover Laws. The restrictions contained in
------------------
Section 203 of the DGCL with respect to a "business combination" (as defined in
DGCL Section 203) have been rendered inapplicable to the authorization,
execution, delivery and performance of the Agreement by Tuboscope or the
consummation of the Merger by Tuboscope. No other "fair price," "moratorium,"
"control share acquisition" or other similar anti- takeover statute or
regulation is applicable to Tuboscope or (solely by reason of Tuboscope's
participation therein) the Merger or the other transactions contemplated by this
Agreement.
25
EXECUTION COPY
<PAGE>
ARTICLE V.
CONDUCT OF BUSINESS
Section 5.01 Covenants of Varco. During the period from the date of
------------------
this Agreement and continuing until the earlier of the termination of this
Agreement or the Effective Time, Varco agrees as to itself and its Subsidiaries
(except to the extent that Tuboscope shall otherwise consent in writing), to
carry on its business in the usual, regular and ordinary course in substantially
the same manner as previously conducted, to pay its debts and Taxes when due
subject to good faith disputes over such debts or Taxes, to pay or perform its
other obligations when due, and, to the extent consistent with such business,
use all reasonable efforts consistent with past practices and policies to
preserve intact its present business organization, keep available the services
of its present officers and key employees and preserve its relationships with
customers, suppliers, distributors, and others having business dealings with it.
Varco shall promptly notify the other party of any material event or occurrence
not in the ordinary course of business of Varco. Except as expressly
contemplated by this Agreement, Varco shall not (and shall not permit any of its
respective Subsidiaries to), without the written consent of Tuboscope:
(a) Accelerate, amend or change the period of exercisability
or vesting of options or restricted stock granted under any employee stock plan
of such party or authorize cash payments in exchange for any options granted
under any of such plans except as required by the terms of such plans or any
related agreements in effect as of the date of this Agreement;
(b) Declare or pay any dividends on or make any other
distributions (whether in cash, stock or property) in respect of any of its
capital stock, or split, combine or reclassify any of its capital stock or issue
or authorize the issuance of any other securities in respect of, in lieu of or
in substitution for shares of its capital stock, or purchase or otherwise
acquire, directly or indirectly, any shares of its capital stock except from
former employees, directors and consultants in accordance with agreements
providing for the repurchase of shares in connection with any termination of
service to such party;
(c) Issue, deliver or sell, or authorize or propose the
issuance, delivery or sale of, any shares of its capital stock or securities
convertible into shares of its capital stock, or subscriptions, rights, warrants
or options to acquire, or other agreements or commitments of any character
obligating it to issue any such shares or other convertible securities, other
than (i) the issuance of shares of Varco Common Stock pursuant to the exercise
of options, warrants and convertible securities outstanding on the date of this
Agreement or pursuant to Varco's 1980 Employee Stock Purchase Plan and (ii) the
issuance of Varco Rights in respect of shares of Varco Common Stock issued not
in contravention of this Agreement pursuant to Section 3(c) of the Varco Rights
Plan;
(d) Acquire or agree to acquire by merging or consolidating
with, or by purchasing a substantial equity interest in or substantial portion
of the assets of, or by any other manner, any business or any corporation,
partnership or other business organization or division, or otherwise acquire or
agree to acquire any assets (other than inventory and other items
26
EXECUTION COPY
<PAGE>
in the ordinary course of business), except for all such acquisitions involving
aggregate consideration of not more than $3 million;
(e) Sell, lease, license or otherwise dispose of any of its
material properties or assets, except for transactions in the ordinary course of
business;
(f) (i) Increase or agree to increase the compensation
payable or to become payable to its officers or employees, except for increases
in salary or wages of employees in accordance with past practices (including
bonuses), (ii) grant any additional severance or termination pay to, or enter
into any employment or severance agreements with, any employees or officers,
other than payments or agreements paid to or entered into with employees (other
than officers) in the ordinary course of business in accordance with past
practices or the performance of agreements in effect on the date of this
Agreement, (iii) enter into any collective bargaining agreement (other than as
required by law), or (iv) establish, adopt, enter into or amend any bonus,
profit sharing, thrift, compensation, stock option, restricted stock, pension,
retirement, deferred compensation, employment, termination, severance or other
plan, trust, fund, policy or arrangement for the benefit of any directors,
officers or employees;
(g) Amend or propose to amend its charter or bylaws, except
as contemplated by this Agreement;
(h) Incur any indebtedness for borrowed money other than up
to $2 million (which may be denominated in foreign currency) in borrowings
pursuant to credit facilities in effect as of the date hereof and up to $1
million under loan agreements entered into hereafter;
(i) Initiate, compromise, or settle any material litigation
or arbitration proceeding;
(j) Except in the ordinary course of business, modify, amend
or terminate any Varco Material Contract or waive, release or assign any
material rights or claims;
(k) Make or commit to make any capital expenditures that
would cause the aggregate capital budget furnished by Varco to Tuboscope to be
exceeded; or
(l) Take, or agree in writing or otherwise to take, any of
the actions described in Sections (a) through (k) above.
Section 5.02 Covenants of Tuboscope. During the period from the date
----------------------
of this Agreement and continuing until the earlier of the termination of this
Agreement or the Effective Time, Tuboscope agrees as to itself and its
respective Subsidiaries (except to the extent that Varco shall otherwise
consent in writing), to carry on its business in the usual, regular and ordinary
course in substantially the same manner as previously conducted, to pay its
debts and Taxes when due subject to good faith disputes over such debts or
Taxes, to pay or perform its other obligations when due, and, to the extent
consistent with such business, use all reasonable efforts consistent with past
practices and policies to preserve intact its present business
27
EXECUTION COPY
<PAGE>
organization, keep available the services of its present officers and key
employees and preserve its relationships with customers, suppliers,
distributors, and others having business dealings with it. Tuboscope shall
promptly notify the other party of any material event or occurrence not in the
ordinary course of business of Tuboscope. Except as expressly contemplated by
this Agreement, Tuboscope shall not (and shall not permit any of its respective
Subsidiaries to), without the written consent of Varco:
(a) Accelerate, amend or change the period of exercisability
or vesting of options or restricted stock granted under any employee stock plan
of such party or authorize cash payments in exchange for any options granted
under any of such plans except as required by the terms of such plans or any
related agreements in effect as of the date of this Agreement;
(b) Declare or pay any dividends on or make any other
distributions (whether in cash, stock or property) in respect of any of its
capital stock, or split, combine or reclassify any of its capital stock or issue
or authorize the issuance of any other securities in respect of, in lieu of or
in substitution for shares of its capital stock, or purchase or otherwise
acquire, directly or indirectly, any shares of its capital stock except from
former employees, directors and consultants in accordance with agreements
providing for the repurchase of shares in connection with any termination of
service to such party;
(c) Issue, deliver or sell, or authorize or propose the
issuance, delivery or sale of, any shares of its capital stock (including
Tuboscope Common Stock held in treasury) or securities convertible into shares
of its capital stock, or subscriptions, rights, warrants or options to acquire,
or other agreements or commitments of any character obligating it to issue any
such shares or other convertible securities, other than the issuance of shares
of Tuboscope Common Stock pursuant to the exercise of options, warrants or
convertible securities outstanding on the date of this Agreement or pursuant to
the Tuboscope Employee Qualified Stock Purchase Plan, the Tuboscope Deferred
Compensation Plan and the Tuboscope 401(K) Thrift Savings Plan;
(d) Acquire or agree to acquire by merging or consolidating
with, or by purchasing a substantial equity interest in or substantial portion
of the assets of, or by any other manner, any business or any corporation,
partnership or other business organization or division, or otherwise acquire or
agree to acquire any assets (other than inventory and other items in the
ordinary course of business), except for all such acquisitions involving
aggregate consideration of not more than $3 million;
(e) Sell, lease, license or otherwise dispose of any of its
material properties or assets, except for transactions in the ordinary course of
business;
(f) (i) Increase or agree to increase the compensation
payable or to become payable to its officers or employees, except for increases
in salary or wages of employees in accordance with past practices (including
bonuses), (ii) grant any additional severance or termination pay to, or enter
into any employment or severance agreements with, any employees or officers,
other than payments or agreements paid to or entered into with employees
28
EXECUTION COPY
<PAGE>
(other than officers) in the ordinary course of business in accordance with past
practices or the performance of agreements in effect on the date of this
Agreement, (iii) enter into any collective bargaining agreement (other than as
required by law), or (iv) establish, adopt, enter into or amend any bonus,
profit sharing, thrift, compensation, stock option, restricted stock, pension,
retirement, deferred compensation, employment, termination, severance or other
plan, trust, fund, policy or arrangement for the benefit of any directors,
officers or employees;
(g) Amend or propose to amend its charter or bylaws, except
as contemplated by this Agreement;
(h) Incur any indebtedness for borrowed money other than
pursuant to credit agreements in effect as of the date hereof or up to $1
million (which may be denominated in foreign currency) in borrowings under loan
agreements entered into hereafter;
(i) Initiate, compromise, or settle any material litigation
or arbitration proceeding;
(j) Except in the ordinary course of business, modify, amend
or terminate any Tuboscope Material Contract or waive, release or assign any
material rights or claims;
(k) Make or commit to make any capital expenditures that
would cause the aggregate capital budget furnished by Tuboscope to Varco to be
exceeded; or
(l) Take, or agree in writing or otherwise to take, any of
the actions described in Sections (a) through (k) above.
Section 5.03 Reorganization. Varco and Tuboscope shall each use its
--------------
best efforts to cause the Merger to qualify as, and will not take or agree to
take any action that would prevent the Merger from qualifying as, a
reorganization within the meaning of Section 368(a) of the Code.
Section 5.04 Cooperation. Subject to compliance with applicable law,
-----------
from the date hereof until the Effective Time, each of Varco and Tuboscope shall
confer on a regular and frequent basis with one or more representatives of the
other party to report on the general status of ongoing operations and shall
promptly provide the other party or its counsel with copies of all filings made
by such party with any Governmental Entity in connection with this Agreement,
the Merger and the transactions contemplated hereby and thereby.
Section 5.05 Tuboscope Board Resolutions. The board of directors of
---------------------------
Tuboscope shall adopt such resolutions as shall be necessary for the acquisition
of equity securities (including options and other derivative securities) of
Tuboscope by officers or directors of Varco who are to become officers or
directors of Tuboscope in the Merger to be deemed an acquisition from Tuboscope
eligible for Rule 16b-3(d) under the Exchange Act.
29
EXECUTION COPY
<PAGE>
Section 5.06 Pooling Accounting. From and after the date hereof and
------------------
until the Effective Time, neither Varco nor Tuboscope, nor any of their
respective Subsidiaries or other Affiliates shall knowingly take any action, or
knowingly fail to take any action, that is reasonably likely to jeopardize the
treatment of the Merger as a pooling of interests for accounting purposes.
ARTICLE VI.
ADDITIONAL AGREEMENTS
Section 6.01 No Solicitation.
---------------
(a) Varco and Tuboscope each shall not, directly or
indirectly, through any officer, director, employee, financial advisor,
representative or agent of such party (i) solicit, initiate, or encourage any
inquiries or proposals that constitute, or could reasonably be expected to lead
to, a proposal or offer for an Alternative Transaction (as defined below)
involving such party or any of its Subsidiaries (any of the foregoing inquiries
or proposals being referred to in this Agreement as an "Acquisition Proposal"),
(ii) engage in negotiations or discussions concerning, or provide any non-public
information to any person or entity relating to, any Acquisition Proposal, or
(iii) agree to or recommend any Acquisition Proposal; provided, however, that
-------- --------
nothing contained in this Agreement shall prevent Varco or Tuboscope, or their
respective Boards of Directors, from (A) furnishing non-public information to,
or entering into discussions or negotiations with, any person or entity in
connection with an unsolicited bona fide written Acquisition Proposal by such
person or entity or recommending an unsolicited bona fide written Acquisition
Proposal to the shareholders/stockholders of such party, if and only to the
extent that (1) the board of directors of such party believes in good faith
(after consultation with its financial advisor) that such Acquisition Proposal
is reasonably capable of being completed on the terms proposed and would, if
consummated, result in a transaction more favorable to its
shareholders/stockholders than the transaction contemplated by this Agreement
(any such more favorable Acquisition Proposal being referred to in this
Agreement as a "Superior Proposal") and the board of directors of such party
determines in good faith after consultation with outside legal counsel that
failure to take such action would be reasonably likely to constitute a breach of
the fiduciary duties of such board of directors to such party and its
shareholders/stockholders under applicable law, (2) prior to furnishing such
non-public information to, or entering into discussions or negotiations with,
such person or entity, such board of directors receives from such person or
entity an executed confidentiality agreement with terms no less favorable to
such party than those contained in the Agreement dated January 14, 2000 between
Varco and Tuboscope (the "Confidentiality Agreement"), and (3) prior to
furnishing such non-public information or providing access to the properties,
books or records of such party, such party has complied with the provisions of
Section 6.01(b); or (B) complying with Rule 14e-2 promulgated under the Exchange
Act with regard to an Acquisition Proposal. Each party agrees that, in the event
that it receives a Superior Proposal, for the five business day period
commencing on the date on which it delivers notice of such Superior Proposal to
the other party in accordance with Section 6.01(b), it shall offer to negotiate
with, and cause its respective financial and legal advisors to negotiate with,
the other party to attempt to make such commercially reasonable adjustments in
the terms and conditions of this Agreement as would enable such party to proceed
with the transactions contemplated herein.
30
EXECUTION COPY
<PAGE>
(b) Varco and Tuboscope shall each notify the other party
immediately after receipt by Varco or Tuboscope (or their advisors) of any
Acquisition Proposal or any request for nonpublic information in connection with
an Acquisition Proposal or for access to the properties, books or records of
such party by any person or entity that informs such party that it is
considering making, or has made, an Acquisition Proposal. Such notice shall be
made orally and in writing and shall indicate in reasonable detail the identity
of the offeror and the terms and conditions of such proposal, inquiry or
contact. Such party shall, to the extent permitted by law, continue to keep the
other party hereto informed, on a current basis, of the status of any such
discussions or negotiations and the terms being discussed or negotiated.
Section 6.02 Proxy Statement/Prospectus; Registration Statement.
--------------------------------------------------
(a) As promptly as practical after the execution of this
Agreement, Varco and Tuboscope shall prepare and file with the SEC the Joint
Proxy Statement, and Tuboscope shall prepare and file with the SEC the
Registration Statement, in which the Joint Proxy Statement will be included as a
prospectus, provided that Tuboscope may delay the filing of the Registration
Statement until approval of the Joint Proxy Statement by the SEC. Varco and
Tuboscope shall use all reasonable efforts to cause the Registration Statement
to become effective as soon after such filing as practical. The Joint Proxy
Statement, and any amendment or supplement thereto, shall include (i) the
recommendation of the board of directors of Tuboscope in favor of this
Agreement, the Merger (including a declaration that the Merger is advisable in
accordance with Section 251 of the DGCL), an amendment to Tuboscope's Second
Restated Certificate of Incorporation to increase the number of authorized
shares of Tuboscope Common Stock from 60,000,000 to 200,000,000 and (ii) the
recommendation of the board of directors of Varco in favor of this Agreement and
the Merger; provided that the board of directors of Tuboscope may withdraw such
recommendation if (but only if) (i) the board of directors of Tuboscope has
received a Superior Proposal, and (ii) such board of directors after
consultation with its outside legal counsel determines that it is reasonably
likely that a failure to recommend such Superior Proposal would constitute a
breach of its fiduciary duties under applicable law, and the board of directors
of Varco may withdraw such recommendation if (but only if) (i) the board of
directors of Varco has received a Superior Proposal, and (ii) such board of
directors after consultation with its outside legal counsel determines that it
is reasonably likely that a failure to recommend such Superior Proposal would
constitute a breach of its fiduciary duties under applicable law. Nothing is
this Section 6.02(a) shall release the obligations of Varco or Tuboscope to hold
the Varco Shareholders' Meeting and the Tuboscope Stockholders' Meeting,
respectively, in accordance with Section 6.05.
(b) Varco and Tuboscope shall make all necessary filings
with respect to the Merger under the Securities Act, the Exchange Act,
applicable state blue sky laws and the rules and regulations thereunder.
Section 6.03 NYSE Listings. Tuboscope agrees to continue the listing
-------------
of Tuboscope Common Stock on the NYSE during the term of this Agreement. Varco
agrees to continue the listing of Varco Common Stock on the NYSE during the term
of this Agreement.
31
EXECUTION COPY
<PAGE>
Section 6.04 Access to Information. Upon reasonable notice, Tuboscope and
---------------------
Varco shall each (and shall cause each of their respective Subsidiaries to)
afford to the officers, employees, accountants, counsel and other
representatives of the other, access, during normal business hours during the
period prior to the Effective Time, to all its properties, books, contracts,
commitments and records and, during such period, each of Tuboscope and Varco
shall (and shall cause each of their respective Subsidiaries to) furnish
promptly to the other (a) a copy of each report, schedule, registration
statement and other document filed or received by it during such period pursuant
to the requirements of federal securities laws and (b) all other information
concerning its business, properties and personnel as such other party may
reasonably request. Unless otherwise required by law, the parties will hold any
such information which is nonpublic in confidence in accordance with the
Confidentiality Agreement. No information or knowledge obtained in any
investigation pursuant to this Section 6.04 shall affect or be deemed to modify
any representation or warranty contained in this Agreement or the conditions to
the obligations of the parties to consummate the Merger.
Section 6.05 Shareholders/Stockholders Meetings.
----------------------------------
(a) Varco shall call a meeting of its shareholders, and Tuboscope
shall call a meeting of its stockholders, to be held as promptly as practicable
for the purpose of voting, in the case of Varco, upon this Agreement and the
Merger and, in the case of Tuboscope, upon this Agreement, the Merger and an
amendment to Tuboscope's Second Restated Certificate of Incorporation to
increase the number of authorized shares of Tuboscope Common stock from
60,000,000 to 200,000,000 (the "Tuboscope Voting Proposal"). Subject to Section
6.01(a) and Section 6.02(a), Varco and Tuboscope shall use all reasonable
efforts to solicit proxies in favor of such matters. Varco and Tuboscope shall
coordinate and cooperate with respect to the timing of such meetings and shall
use their best efforts to hold such meetings on the same day and as soon as
practicable after the date hereof. The Varco shareholder vote required for the
approval of this Agreement and the Merger shall be a majority of the shares of
Varco Common Stock outstanding on the record date for the Varco Shareholders'
Meeting. The Tuboscope stockholder vote required for approval of the Tuboscope
Voting Proposal shall be a majority of the shares of Tuboscope Common Stock
outstanding on the record date for the Tuboscope Stockholders' Meeting.
(b) Tuboscope may also submit additional routine proposals to its
stockholders at the Tuboscope Stockholders' Meeting, separate from the proposal
referred to in Section 6.05(a), provided that Tuboscope shall consult with Varco
as to the submission of such proposals. The approval by Tuboscope's stockholders
of such additional proposals shall not be a condition to the closing of the
Merger under this Agreement.
Section 6.06 Legal Conditions to Merger.
--------------------------
(a) Tuboscope and Varco shall each use their best efforts to (i)
take, or cause to be taken, all appropriate action, and do, or cause to be done,
all things necessary and proper under applicable law to consummate and make
effective the transactions contemplated hereby as promptly as practicable, (ii)
obtain from any Governmental Entity or any other third
32
EXECUTION COPY
<PAGE>
party any consents, licenses, permits, waivers, approvals, authorizations, or
orders required to be obtained or made by Tuboscope or Varco or any of their
Subsidiaries in connection with the authorization, execution and delivery of
this Agreement and the Stock Option Agreements and the consummation of the
transactions contemplated hereby and thereby including, without limitation, the
Merger, and (iii) as promptly as practicable, make all necessary filings, and
thereafter make any other required submissions, with respect to this Agreement,
the Stock Option Agreements and the Merger required under (A) the Securities Act
and the Exchange Act, and any other applicable federal or state securities laws,
(B) the HSR Act and any related governmental request thereunder, and (C) any
other applicable law. Tuboscope and Varco shall cooperate with each other in
connection with the making of all such filings, including providing copies of
all such documents to the non-filing party and its advisors prior to filing and,
if requested, to accept all reasonable additions, deletions or changes suggested
in connection therewith. Tuboscope and Varco shall use their best efforts to
furnish to each other all information required for any application or other
filing to be made pursuant to the rules and regulations of any applicable law
(including all information required to be included in the Joint Proxy Statement
and the Registration Statement) in connection with the transactions contemplated
by this Agreement.
(b) Varco and Tuboscope agree, and shall cause each of their
respective Subsidiaries, to cooperate and to use their respective best efforts
to obtain any government clearances or approvals required for Closing under the
HSR Act, the Sherman Act, as amended, the Clayton Act, as amended, the Federal
Trade Commission Act, as amended, and any other Federal, state or foreign law
or, regulation or decree designed to prohibit, restrict or regulate actions for
the purpose or effect of monopolization or restraint of trade (collectively
"Antitrust Laws"), to respond to any government requests for information under
any Antitrust Law, and to contest and resist any action, including any
legislative, administrative or judicial action, and to have vacated, lifted,
reversed or overturned any decree, judgment, injunction or other order (whether
temporary, preliminary or permanent) (an "Order") that restricts, prevents or
prohibits the consummation of the Merger or any other transactions contemplated
by this Agreement under any Antitrust Law. The parties hereto will consult and
cooperate with one another, and consider in good faith the views of one another,
in connection with any analyses, appearances, presentations, memoranda, briefs,
arguments, opinions and proposals made or submitted by or on behalf of any party
hereto in connection with proceedings under or relating to any Antitrust Law.
Notwithstanding anything to the contrary in this Section 6.06, neither Varco nor
Tuboscope nor any of their Subsidiaries shall be required to divest any of their
respective businesses, product lines or assets, or to take or agree to take any
other action or agree to any limitation, that could reasonably be expected to
have a material adverse effect on Tuboscope or on Tuboscope combined with Varco
after the Effective Time.
(c) Each of Tuboscope and Varco shall give (or shall cause their
respective Subsidiaries to give) any notices to third parties, and use, and
cause their respective Subsidiaries to use, their best efforts to obtain any
third party consents related to or required in connection with the Merger that
are (A) necessary to consummate the transactions contemplated hereby, (B)
disclosed or required to be disclosed in the Tuboscope Disclosure Schedule or
the Varco Disclosure Schedule, as the case may be, or (C) required to prevent a
Tuboscope Material
33
EXECUTION COPY
<PAGE>
Adverse Effect or a Varco Material Adverse Effect from occurring prior to or
after the Effective Time.
Section 6.07 Public Disclosure. Varco and Tuboscope shall agree on
-----------------
the form and content of the initial joint press release regarding the
transactions contemplated hereby, and thereafter shall consult with each other
before issuing any press release or otherwise making any public statement with
respect to the Merger or this Agreement and shall not issue any such press
release or make any such public statement prior to such consultation, except as
may be required by law.
Section 6.08 Affiliate Legends. Prior to the filing of the Joint
-----------------
Proxy Statement with the SEC, Varco and Tuboscope will provide each other with a
list of those persons who are, in Varco's or Tuboscope's respective reasonable
judgment, "affiliates" of Varco or Tuboscope, respectively, within the meaning
of Rule 145 (each such person who is an "affiliate" of Varco or Tuboscope within
the meaning of Rule 145 is referred to as an "Affiliate") promulgated under the
Securities Act ("Rule 145"). Varco and Tuboscope shall provide each other such
information and documents as Tuboscope or Varco shall reasonably request for
purposes of reviewing such list and shall notify the other party in writing
regarding any change in the identity of its Affiliates prior to the Closing
Date. Varco and Tuboscope shall each use its best efforts to deliver or cause to
be delivered to each other by April 30, 2000 (and in any case prior to the
Effective Time) from each of its Affiliates, an executed Affiliate Agreement, in
form and substance satisfactory to Varco and Tuboscope, by which each Affiliate
of Varco agrees to comply with the applicable requirements of Rule 145 and such
requirements as may be necessary for the Merger to be treated as a pooling of
interests for accounting purposes and each Affiliate of Tuboscope agrees to
comply with such requirements as may be necessary for the merger to be treated
as a pooling of interests for accounting purposes (an "Affiliate Agreement").
Tuboscope shall be entitled to place appropriate legends on the certificates
evidencing any Tuboscope Common Stock to be received by such Affiliates of Varco
pursuant to the terms of this Agreement, and to issue appropriate stop transfer
instructions to the transfer agent for the Tuboscope Common Stock, consistent
with the terms of the Affiliate Agreements (provided that such legends or stop
transfer instructions shall be removed, two years after the Effective Date, upon
the request of any stockholder that is not then an Affiliate of Tuboscope).
Section 6.09 NYSE Listing. Tuboscope shall use its best efforts to
------------
cause the shares of Tuboscope Common Stock to be issued in the Merger to be
approved for listing on the NYSE, subject to official notice of issuance, prior
to the Closing Date.
Section 6.10 Stock Plans.
-----------
(a) At the Effective Time, each outstanding option to
purchase shares of Varco Common Stock (a "Varco Stock Option") under the Varco
Stock Plans, whether vested or unvested, shall constitute an option to acquire,
on the same terms and conditions as were applicable under such Varco Stock
Option, the same number of shares of Tuboscope Common Stock as the holder of
such Varco Stock Option would have been entitled to receive pursuant to the
Merger had such holder exercised such option in full immediately prior to the
Effective Time
34
EXECUTION COPY
<PAGE>
(rounded downward to the nearest whole number), at a price per share (rounded
upward to the nearest whole cent) equal to (y) the aggregate exercise price for
the shares of Varco Common Stock purchasable pursuant to such Varco Stock Option
immediately prior to the Effective Time divided by (z) the number of full shares
of Tuboscope Common Stock deemed purchasable pursuant to such Varco Stock Option
in accordance with the foregoing. It is intended that Varco Stock Options
converted into options to acquire Tuboscope Common Stock in accordance with the
foregoing shall qualify following the Effective Time as incentive stock options
as defined in Section 422 of the Code to the extent such Varco Stock Options
qualified as incentive stock options immediately prior to the Effective Time,
and the provisions of this Section 6.10 shall be applied consistent with such
intent.
(b) As soon as practicable after the Effective Time, Tuboscope
shall deliver to the participants in Varco Stock Plans appropriate notice
setting forth such participants' rights pursuant thereto and the grants pursuant
to Varco Stock Plans shall continue in effect on the same terms and conditions
(subject to the adjustments required by this Section 6.10 after giving effect to
the Merger).
(c) Tuboscope shall take all corporate action necessary to
reserve for issuance a sufficient number of shares of Tuboscope Common Stock for
delivery under Varco Stock Plans assumed in accordance with this Section 6.10.
As soon as practicable after the Effective Time, Tuboscope shall file a
registration statement on Form S-8 (or any successor or other appropriate
forms), or another appropriate form with respect to the shares of Tuboscope
Common Stock subject to such options and shall use its best efforts to maintain
the effectiveness of such registration statement or registration statements (and
maintain the current status of the prospectus or prospectuses contained therein)
for so long as such options remain outstanding.
(d) The board of directors of Varco shall, prior to or as of the
Effective Time, take all necessary actions, if any, pursuant to and in
accordance with the terms of the Varco Stock Plans and the instruments
evidencing the Varco Stock Options, to provide for the conversion of the Varco
Stock Options into options to acquire Tuboscope Common Stock in accordance with
this Section 6.10 without the consent of the holders of the Varco Stock Options.
(e) Prior to the Effective Time, Varco's board of directors (or,
if appropriate, any committee thereof) and Tuboscope's board of directors (or,
if appropriate, any committee thereof) shall adopt appropriate resolutions and
take all other actions necessary to provide that, effective at the Effective
Time, each right to purchase shares of Varco Common Stock outstanding at the
Effective Time (a "Varco Stock Purchase Right") under the Varco 1980 Employee
Stock Purchase Plan shall be assumed by Tuboscope and shall continue in effect
on the same terms and conditions as in effect immediately prior to the Effective
Time (subject to the adjustments in this Section), and each such Varco Stock
Purchase Right shall be converted automatically into a right to purchase shares
of Tuboscope Common Stock (a "New Stock Purchase Right"). Each New Stock
Purchase Right shall entitle the holder thereof to purchase the number of shares
of Tuboscope Common Stock determined under the terms and conditions of the Varco
Stock Purchase Plan, as amended as provided for herein, at the exercise price
determined as provided below. Effective at the Effective Time, Tuboscope shall
assume the
35
EXECUTION COPY
<PAGE>
Varco Stock Purchase Plan, shall amend the Varco Stock Purchase Plan to
substitute references to Tuboscope Common Stock for references to Varco Common
Stock therein and shall continue the Varco Stock Purchase Plan with respect to
the New Stock Purchase Rights; provided, however, that Tuboscope shall reserve
the right to terminate the Varco Stock Purchase Plan upon the exercise or other
termination of all New Stock Purchase Rights in accordance with the terms of the
Varco Stock Purchase Plan. The exercise price for a New Stock Purchase Right
shall be determined under the terms of the Varco Stock Purchase Plan, provided
that the fair market value of the "Stock" (as defined in the Varco Stock
Purchase Plan) on any day prior to the Closing Date shall equal the per share
fair market value of Varco Common Stock on such date, divided by the Exchange
Ratio; and, provided, further, that the fair market value of the "Stock" (as
defined in the Varco Stock Purchase Plan) on any date on or after the Closing
Date shall mean the fair market value of Tuboscope Common Stock on such date.
The adjustment provided herein with respect to any Varco Stock Purchase Right
shall be, and is intended to be, effective in a manner which is consistent with
Section 424(a) of the Code and the treasury registration thereunder, and shall
provide that the excess (if any) of the aggregate fair market value of the
shares of Tuboscope Common Stock over the aggregate exercise price for a New
Stock Purchase Right shall be no greater than the excess (if any) of the
aggregate fair market value of the shares of Varco Common Stock over the
aggregate exercise price for such Varco Stock Purchase Right, and shall provide
that the New Stock Purchase Right shall not give the holder more favorable
benefits than such holder had with respect to the Varco Stock Purchase Right.
Except as provided in this Section, after the Effective Time, each New Stock
Purchase Right shall be exercisable upon the same terms and conditions as were
applicable to the related Varco Stock Purchase Right immediately prior to the
Effective Time (except that with regard to such New Stock Purchase Right, any
references to Varco shall be deemed, as appropriate, to mean Tuboscope).
Tuboscope shall take all action necessary, on or prior to the Effective Time, to
authorize and reserve a number of shares of Tuboscope Common Stock sufficient
for issuance upon the exercise of New Stock Purchase Rights as contemplated by
this Section.
Section 6.11 Brokers or Finders. Each of Varco and Tuboscope
------------------
represents, as to itself, its Subsidiaries and its Affiliates, that no agent,
broker, investment banker, financial advisor or other firm or person is or will
be entitled to any broker's or finder's fee or any other commission or similar
fee in connection with any of the transactions contemplated by this Agreement
except J.P. Morgan Securities Inc. whose fees and expenses will be paid by Varco
in accordance with Varco's agreements with such firm, and Credit Suisse First
Boston Corporation, whose fees and expenses will be paid by Tuboscope in
accordance with Tuboscope's agreement with such firm. Each of Varco and
Tuboscope agrees to indemnify and hold the other harmless from and against any
and all claims, liabilities or obligations with respect to any such fees,
commissions or expenses asserted by any person on the basis of any act or
statement alleged to have been made by such party or any of its Affiliates.
36
EXECUTION COPY
<PAGE>
Section 6.12 Indemnification.
---------------
(a) From and after the Effective Time, Tuboscope agrees that it
will indemnify and hold harmless each present and former director and officer of
Varco and its Subsidiaries (the "Indemnified Parties"), against any costs or
expenses (including attorneys' fees), judgments, fines, losses, claims, damages,
liabilities or amounts paid in settlement (collectively, "Costs") incurred in
connection with any claim, action, suit, proceeding or investigation, whether
civil, criminal, administrative or investigative, arising out of or pertaining
to any act or omission in their capacity as a director or officer occurring at
or prior to the Effective Time, whether asserted or claimed prior to, at or
after the Effective Time, to the fullest extent permitted under Delaware law
(and Tuboscope shall also advance expenses as incurred to the fullest extent
permitted under applicable law, provided the Indemnified Party to whom expenses
are advanced provides an undertaking to repay such advances if it is ultimately
determined that such Indemnified Party is not entitled to indemnification).
(b) The provisions of this Section 6.12 are intended to be
an addition to the rights otherwise available to the current and former officers
and directors of Varco by law, charter, statute, bylaw or agreement, and shall
operate for the benefit of, and shall be enforceable by, each of the Indemnified
Parties, their heirs and their representatives.
Section 6.13 Letter of Varco's Accountants. Varco shall use
-----------------------------
reasonable best efforts to cause to be delivered to Tuboscope and Varco a letter
of Ernst & Young LLP, Varco's independent auditors, dated a date within two
business days before the date on which the Registration Statement shall become
effective and addressed to Tuboscope, in form reasonably satisfactory to
Tuboscope and customary in scope and substance for letters delivered by
independent public accountants in connection with registration statements
similar to the Registration Statement. In connection with Tuboscope's efforts to
obtain such letter, if requested by Ernst & Young LLP, Varco shall provide a
representation letter to Ernst & Young LLP complying with SAS 72, if then
required.
Section 6.14 Letter of Tuboscope's Accountants. Tuboscope shall
---------------------------------
use reasonable best efforts to cause to be delivered to Varco and Tuboscope a
letter of Ernst & Young LLP, Tuboscope's independent auditors, dated a date
within two business days before the date on which the Registration Statement
shall become effective and addressed to Varco, in form reasonably satisfactory
to Varco and customary in scope and substance for letters delivered by
independent public accountants in connection with registration statements
similar to the Registration Statement. In connection with Varco's efforts to
obtain such letter, if requested by Ernst & Young LLP, Tuboscope shall provide a
representation letter to Ernst & Young LLP complying with the SAS 72, if then
required.
37
EXECUTION COPY
<PAGE>
Section 6.15 Benefit Plans. Tuboscope agrees that, during the
-------------
period commencing at the Effective Time and ending December 31, 2000, the
employees of Varco and its Subsidiaries who remain in the employ of Tuboscope or
any of its Subsidiaries (a "Continuing Employee") will continue to be provided
with benefits under health insurance, vision care, life insurance, employee
assistance programs, flexible spending accounts, disability, vacation, holiday,
profit-sharing, section 401(k), dental and sick pay plans and stock option plans
which are not materially less favorable in the aggregate than those currently
provided by Varco and its Subsidiaries to such employees.
Section 6.16 Rights Plan. The board of directors of Varco has
-----------
amended the Varco Rights Plan, and shall take all further action (in addition to
that referred to in Section 3.22) reasonably requested in writing by Tuboscope,
in order to render the Varco Rights Plan inapplicable to the Merger and the
other transactions contemplated by this Agreement and the Stock Option
Agreements. Varco will not without the consent of Tuboscope further amend the
Varco Rights Plan, redeem the Varco Rights issued under the Varco Rights Plan or
terminate the Varco Rights Plan prior to the Effective Date (except as
contemplated by Section 3.22) unless required to do so by a court of competent
jurisdiction; provided, however, that Varco may take any of the foregoing
-------- -------
actions if the board of directors of Varco shall have determined to recommend an
Acquisition Proposal to the shareholders of Varco after determining that such
Acquisition Proposal constitutes a Superior Proposal in accordance with Section
6.02(a).
Section 6.17 Stock Option Agreements. Tuboscope and Varco each
-----------------------
agrees to fully perform their respective obligations under the Stock Option
Agreements.
ARTICLE VII.
CONDITIONS TO MERGER
Section 7.01 Conditions to Each Party's Obligation To Effect the Merger.
----------------------------------------------------------
The respective obligations of each party to this Agreement to effect the Merger
shall be subject to the satisfaction or waiver prior to the Closing Date of the
following conditions:
(a) Stockholder/Shareholder Approval. This Agreement and
--------------------------------
the Merger shall have been approved and adopted by the affirmative vote of the
holders of a majority of the shares of Varco Common Stock outstanding on the
record date for the Varco Shareholders' Meeting and the Tuboscope Voting
Proposal shall have been approved by the affirmative vote of the holders of a
majority of the shares of Tuboscope Common Stock outstanding on the record date
for the Tuboscope Stockholders' Meeting.
(b) Regulatory Approvals. The waiting period applicable
--------------------
to the consummation of the Merger under the HSR Act shall have expired or been
terminated, and approvals and/or clearances shall have been obtained from (or
decisions indicating no objections to the Merger or other indications to that
effect satisfactory to Tuboscope shall have been made by) the European
Commission (if applicable) and under any other antitrust or competition law
applicable to any significant operations.
38
EXECUTION COPY
<PAGE>
(c) Approvals. Other than the filings provided for by
---------
Section 1.02, all authorizations, consents, orders or approvals of, or
declarations or filings with, or expirations of waiting periods imposed by, any
Governmental Entity the failure of which to file, obtain or occur is reasonably
likely to have a Varco Material Adverse Effect or a Tuboscope Material Adverse
Effect shall have been filed, been obtained or occurred.
(d) Registration Statement. The Registration Statement
----------------------
shall have become effective under the Securities Act and shall not be the
subject of any stop order or proceedings seeking a stop order.
(e) No Injunctions. No Governmental Entity or federal, state or
--------------
foreign court of competent jurisdiction shall have enacted, issued, promulgated,
enforced or entered any Order or statute, rule, regulation which is in effect
and which has the effect of making the Merger illegal or otherwise prohibiting
consummation of the Merger.
(f) NYSE. The shares of Tuboscope Common Stock to be issued
----
in the Merger shall have been approved for listing on the NYSE, subject to
official notice of issuance.
(g) Pooling Letters. Varco and Tuboscope shall have received a letter
---------------
from Ernst & Young LLP, addressed to Tuboscope regarding Ernst & Young LLP's
concurrence with Tuboscope's management conclusions, as to the appropriateness
of the pooling of interests accounting, under Accounting Principles Board
Opinion No. 16 for the Merger, as contemplated to be effected as of the date of
the letter, it being agreed that Varco and Tuboscope shall each provide
reasonable best cooperation to Ernst & Young LLP to enable it to issue such a
letter.
Section 7.02 Additional Conditions to Obligations of Varco. The
---------------------------------------------
obligation of Varco to effect the Merger is subject to the satisfaction of each
of the following conditions, any of which may be waived in writing exclusively
by Varco:
(a) Representations and Warranties. The representations and
------------------------------
warranties of Tuboscope set forth in this Agreement shall be true and correct as
of the date of this Agreement and (except to the extent such representations and
warranties speak as of an earlier date) as of the Closing Date as though made on
and as of the Closing Date, except for (i) changes contemplated by this
Agreement and (ii) where the failures to be true and correct, individually or in
the aggregate, have not had and are not reasonably likely to have a Tuboscope
Material Adverse Effect or a material adverse effect upon the consummation of
the transactions contemplated hereby; and Varco shall have received a
certificate signed on behalf of Tuboscope by the chief executive officer and the
chief financial officer of Tuboscope to such effect.
(b) Performance of Obligations of Tuboscope. Tuboscope shall have
---------------------------------------
performed in all material respects all obligations required to be performed by
it under this Agreement at or prior to the Closing Date; and Varco shall have
received a certificate signed on behalf of Tuboscope by the chief executive
officer and the chief financial officer of Tuboscope to such effect.
39
EXECUTION COPY
<PAGE>
(c) Tax Opinion. Varco shall have received a written opinion from
-----------
Pircher, Nichols & Meeks, counsel to Varco, to the effect that the Merger will
be treated for Federal income tax purposes as a reorganization within the
meaning of Section 368(a) of the Code. In rendering such opinion, Pircher,
Nichols & Meeks shall receive and may rely upon representations contained in
certificates of Tuboscope and Varco substantially in the forms of
Exhibits C and D attached hereto.
- ----------------
(d) Dissenting Shares. Effective demands for payment under
-----------------
Chapter 13 of the CGCL shall not have been received by Varco with respect to
more than 10.0% of the outstanding shares of Varco Common Stock.
Section 7.03 Additional Conditions to Obligations of Tuboscope. The
-------------------------------------------------
obligation of Tuboscope to effect the Merger is subject to the satisfaction of
each of the following conditions, any of which may be waived, in writing,
exclusively by Tuboscope:
(a) Representations and Warranties. The representations and
------------------------------
warranties of Varco set forth in this Agreement shall be true and correct as of
the date of this Agreement and (except to the extent such representations and
warranties speak as of an earlier date) as of the Closing Date as though made on
and as of the Closing Date, except for (i) changes contemplated by this
Agreement and (ii) where the failures to be true and correct, individually or in
the aggregate, have not had and are not reasonably likely to have a Varco
Material Adverse Effect or a material adverse effect upon the consummation of
the transactions contemplated hereby; and Tuboscope shall have received a
certificate signed on behalf of Varco by the chief executive officer and the
chief financial officer of Varco to such effect.
(b) Performance of Obligations of Varco. Varco shall have performed
-----------------------------------
in al material respects all obligations required to be performed by it under
this Agreement at or prior to the Closing Date; and Tuboscope shall have
received a certificate signed on behalf of Varco by the chief executive officer
and the chief financial officer of Varco to such effect.
(c) Tax Opinion. Tuboscope shall have received a written opinion from
-----------
Latham & Watkins, counsel to Tuboscope, to the effect that the Merger will be
treated for Federal income tax purposes as a reorganization within the meaning
of Section 368(a) of the Code. In rendering such opinion, Latham & Watkins shall
receive and may rely upon representations contained in certificates of Tuboscope
and Varco substantially in the forms of Exhibits E and F attached hereto.
----------------
(d) Dissenting Shares. Effective demands for payment under Chapter 13
-----------------
of the CGCL shall not have been received by Varco with respect to more than 5.0%
of the outstanding shares of Varco Common Stock.
40
EXECUTION COPY
<PAGE>
ARTICLE VIII.
TERMINATION AND AMENDMENT
Section 8.01 Termination. This Agreement may be terminated at any time
-----------
prior to the Effective Time (with respect to Sections 8.01(b) through 8.01(g),
by written notice by the terminating party to the other party), whether before
or after approval of the matters presented in connection with the Merger by the
shareholders of Varco or the stockholders of Tuboscope:
(a) by mutual written consent of Varco and Tuboscope; or
(b) by either Varco or Tuboscope if the Merger shall not have been
consummated by September 30, 2000 (provided that either Varco or Tuboscope may
extend such date to December 31, 2000 by providing written notice thereof to the
other party on or prior to September 30, 2000; September 30, 2000, as it may be
so extended, shall be referred to herein as the "Outside Date"); provided that
the right to terminate this Agreement under this Section 8.01(b) shall not be
available to any party whose failure to fulfill any obligation under this
Agreement has been the cause of or resulted in the failure of the Merger to
occur on or before such date); or
(c) by either Varco or Tuboscope if a court of competent jurisdiction
or other Governmental Entity shall have issued a nonappealable final order,
decree or ruling or taken any other nonappealable final action, in each case
having the effect of permanently restraining, enjoining or otherwise prohibiting
the Merger; or
(d) by Tuboscope, if, at the Varco Shareholders' Meeting (including
any adjournment or postponement), the requisite vote of the shareholders of
Varco in favor of this Agreement and the Merger shall not have been obtained; or
by Varco if, at the Tuboscope Stockholders' Meeting (including any adjournment
or postponement), the requisite vote of the stockholders of Tuboscope in favor
of the Tuboscope Voting Proposal shall not have been obtained; or
(e) by Varco, if (i) the board of directors of Tuboscope shall have
withdrawn or modified its recommendation of the Tuboscope Voting Proposal or
such board of directors shall have resolved to do so; (ii) after the receipt by
Tuboscope of an Acquisition Proposal, Varco requests in writing that the board
of directors of Tuboscope reconfirm its recommendation of the Tuboscope Voting
Proposal and the board of directors of Tuboscope fails to do so within 10
business days after its receipt of Varco's request; (iii) the board of directors
of Tuboscope shall have recommended to the stockholders of Tuboscope an
Alternative Transaction (as defined in Section 8.03(g)) or such board of
directors shall have resolved to do so; (iv) a tender offer or exchange offer
for 25% or more of the outstanding shares of Tuboscope Common Stock is commenced
(other than by Varco or an Affiliate of Varco) and the board of directors of
Tuboscope recommends that the stockholders of Tuboscope tender their shares in
such tender or exchange offer or the board of directors fails to recommend that
stockholders reject such tender or exchange offer within 10 business days after
receipt of Varco's request to do so; or (v) for any reason Tuboscope fails to
call and hold the Tuboscope Stockholders' Meeting by the Outside
41
EXECUTION COPY
<PAGE>
Date (provided that Varco's right to terminate this Agreement under such clause
(v) shall not be available if at such time Tuboscope would be entitled to
terminate this Agreement under Section 8.01(g)); or
(f) by Tuboscope, if (i) the board of directors of Varco shall have
withdrawn or modified its recommendation of this Agreement or the Merger or such
board of directors shall have resolved to do so; (ii) after the receipt by Varco
of an Acquisition Proposal, Tuboscope requests in writing that the board of
directors of Varco reconfirm its recommendation of this Agreement or the Merger
and the board of directors of Varco fails to do so within 10 business days after
its receipt of Tuboscope's request; (iii) the board of directors of Varco shall
have recommended to the shareholders of Varco an Alternative Transaction (as
defined in Section 8.03(g)) or such board of directors shall have resolved to do
so; (iv) a tender offer or exchange offer for 25% or more of the outstanding
shares of Varco Common Stock is commenced (other than by Tuboscope or an
Affiliate of Tuboscope) and the board of directors of Varco recommends that the
shareholders of Varco tender their shares in such tender or exchange offer or
the board of directors fails to recommend that shareholders reject such tender
or exchange offer within 10 business days after receipt of Tuboscope's request
to do so; or (v) for any reason Varco fails to call and hold the Varco
Shareholders' Meeting by the Outside Date (provided that Tuboscope's right to
terminate this Agreement under such clause (v) shall not be available if at such
time Varco would be entitled to terminate this Agreement under Section 8.01(g));
or
(g) by Varco or Tuboscope, if there has been a breach of any
representation, warranty, covenant or agreement on the part of the other party
set forth in this Agreement, which breach (i) causes the conditions set forth in
Section 7.02(a) or (b) (in the case of termination by Varco) or 7.03(a) or (b)
(in the case of termination by Tuboscope) not to be satisfied, and (ii) shall
not have been cured within 20 business days following receipt by the breaching
party of written notice of such breach from the other party.
Section 8.02 Effect of Termination. In the event of termination of this
---------------------
Agreement as provided in Section 8.01, this Agreement shall immediately become
void and there shall be no liability or obligation on the part of Varco or
Tuboscope or their respective officers, directors, shareholders/stockholders or
Affiliates, except as set forth in Sections 6.11 and 8.03; provided that the
provisions of the Confidentiality Agreement, the Stock Option Agreements and
Sections 6.11 and 8.03 of this Agreement shall remain in full force and effect
and survive any termination of this Agreement.
Section 8.03 Fees and Expenses.
-----------------
(a) Except as set forth in this Section 8.03, all fees and expenses
incurred in connection with this Agreement and the transactions contemplated
hereby shall be paid by the party incurring such expenses, whether or not the
Merger is consummated, except that each of Varco and Tuboscope will bear and pay
one-half of the costs and expenses incurred in connection with the filing,
printing and mailing of the Joint Proxy Statement (including SEC filing fees).
42
EXECUTION COPY
<PAGE>
(b) Tuboscope shall pay Varco up to $5,000,000 as reimbursement for
expenses of Varco actually incurred relating to the transactions contemplated by
this Agreement prior to termination (including, but not limited to, fees and
expenses of Varco's counsel, accountants and financial advisors, but excluding
any discretionary fees paid to such financial advisors), upon the termination of
this Agreement by Varco pursuant to (i) Section 8.01(d) as a result of the
failure to receive the requisite vote for approval of the Tuboscope Voting
Proposal by the stockholders of Tuboscope at the Tuboscope Stockholders' Meeting
(other than in the circumstances set forth in Section 8.03(c)(i)) or (ii)
Section 8.01(b) or Section 8.01(g), in each case as a result of the failure to
satisfy the conditions set forth in Section 7.02(a) and Section 7.02(b).
(c) Upon the earliest to occur of the following events:
(i) the termination of this Agreement by Varco pursuant
to Section 8.01(d), if, prior to the Tuboscope Stockholders' Meeting,
a proposal for an Alternative Transaction (as defined below)
reasonably capable of being performed involving Tuboscope or which is
a Superior Proposal shall have been made and the board of directors of
Tuboscope shall have withdrawn or modified its recommendation or
failed to reconfirm its recommendation of this Agreement or the
Merger;
(ii) the termination of this Agreement by Varco pursuant
to Section 8.01(e); or
(iii) the consummation of an Alternative Transaction
involving Tuboscope within 12 months after the termination of this
Agreement,
Tuboscope shall pay to Varco a fee of $30,000,000 (the "Tuboscope Termination
Fee").
Tuboscope's payment of the Tuboscope Termination Fee pursuant to this
subsection shall be the sole and exclusive remedy of Varco against Tuboscope and
any of its Subsidiaries and their respective directors, officers, employees,
agents, advisors or other representatives with respect to the occurrences giving
rise to such payment (other than as set forth in the Tuboscope Stock Option
Agreement).
(d) Varco shall pay Tuboscope up to $5,000,000 as reimbursement for
expenses of Tuboscope actually incurred relating to the transactions
contemplated by this Agreement prior to termination (including, but not limited
to, fees and expenses of Tuboscope's counsel, accountants and financial
advisors, but excluding any discretionary fees paid to such financial advisors),
upon the termination of this Agreement by Tuboscope pursuant to (i) Section
8.01(d) as a result of the failure to receive the requisite vote for approval of
this Agreement and the Merger by the shareholders of Varco at the Varco
Shareholders' Meeting (other than in the circumstances set forth in Section
8.03(e)(i)) or (ii) Section 8.01(b) or Section 8.01(g), in each
43
EXECUTION COPY
<PAGE>
case as a result of the failure to satisfy the conditions set forth in Section
7.03(a) and Section 7.03(b).
(e) Upon the earliest to occur of the following events:
(i) the termination of this Agreement by Tuboscope
pursuant to Section 8.01(d), if, prior to the Varco Shareholders'
Meeting, a proposal for an Alternative Transaction (as defined below)
reasonably capable of being performed involving Varco or which is a
Superior Proposal shall have been made and the board of directors of
Varco shall have withdrawn or modified its recommendation or failed to
reconfirm its recommendation of this Agreement or the Merger;
(ii) the termination of this Agreement by Tuboscope
pursuant to Section 8.01(f); or
(iii) the consummation of an Alternative Transaction
involving Varco within 12 months after the termination of this
Agreement,
Varco shall pay to Tuboscope a fee of $30,000,000 (the "Varco
Termination Fee").
Varco's payment of the Varco Termination Fee pursuant to this
subsection shall be the sole and exclusive remedy of Tuboscope against Varco and
any of its Subsidiaries and their respective directors, officers, employees,
agents, advisors or other representatives with respect to the occurrences giving
rise to such payment (other than as set forth in the Varco Stock Option
Agreement).
(f) The expenses and fees, if applicable, payable pursuant to
Section 8.03(b), 8.03(c), 8.03(d) or 8.03(e) shall be paid within one business
day after the first to occur of the events described in Section 8.03(b),
8.03(c)(i), (ii) or (iii), 8.03(d) or 8.03(e)(i), (ii) or (iii).
(g) As used in this Agreement, "Alternative Transaction" means
either (i) a transaction pursuant to which any individual, corporation,
partnership, limited partnership, limited liability company, association, trust,
unincorporated organization, entity or group (as defined in the Exchange Act)
other than Varco or Tuboscope or their respective affiliates (a "Third Party"),
acquires more than 25% of the outstanding shares of Tuboscope Common Stock or
Varco Common Stock, as the case may be, pursuant to a tender offer or exchange
offer or otherwise, (ii) a merger or other business combination involving Varco
or Tuboscope pursuant to which any Third Party acquires more than 25% of the
outstanding shares of Tuboscope Common Stock or Varco Common Stock, as the case
may be, or the entity surviving such merger or business combination, (iii) any
other transaction pursuant to which any Third Party acquires control of assets
(including for this purpose the outstanding equity securities of Subsidiaries of
Varco or Tuboscope, and the entity surviving any merger or business combination
including any of them) of Varco or Tuboscope having a fair market value (as
determined by the board of directors of Varco or Tuboscope, as the case may be,
in good faith) equal to more than 25% of
44
EXECUTION COPY
<PAGE>
the fair market value of all the assets of Varco or Tuboscope, as the case may
be, and its Subsidiaries, taken as a whole, immediately prior to such
transaction, or (iv) any public announcement of a proposal, plan or intention to
do any of the foregoing or any agreement to engage in any of the foregoing.
Section 8.04 Amendment. This Agreement may be amended by the parties
---------
hereto, by action taken or authorized by their respective Boards of Directors,
at any time before or after approval of the matters presented in connection with
the Merger by the shareholders of Varco or the stockholders of Tuboscope, but,
after any such approval, no amendment shall be made which by law requires
further approval by such shareholders/stockholders without such further
approval. This Agreement may not be amended except by an instrument in writing
signed on behalf of each of the parties hereto.
Section 8.05 Extension; Waiver. At any time prior to the Effective
-----------------
Time, the parties hereto, by action taken or authorized by their respective
Boards of Directors, may, to the extent legally allowed, (i) extend the time for
the performance of any of the obligations or other acts of the other parties
hereto, (ii) waive any inaccuracies in the representations and warranties
contained herein or in any document delivered pursuant hereto and (iii) waive
compliance with any of the agreements or conditions contained herein. Any
agreement on the part of a party hereto to any such extension or waiver shall be
valid only if set forth in a written instrument signed on behalf of such party.
ARTICLE IX.
MISCELLANEOUS
Section 9.01 Nonsurvival of Representations, Warranties and
----------------------------------------------
Agreements. None of the representations, warranties and agreements in this
- ----------
Agreement or in any instrument delivered pursuant to this Agreement shall
survive the Effective Time, except for the agreements contained in Sections
1.04, 1.05, 1.06, 2.01, 2.02, 6.08, 6.10, 6.12, 6.15 and Article IX.
Section 9.02 Notices. All notices and other communications hereunder
-------
shall be in writing and shall be deemed given if delivered personally,
telecopied (which is confirmed) or mailed by registered or certified mail
(return receipt requested) to the parties at the following addresses (or at such
other address for a party as shall be specified by like notice):
(a) if to Tuboscope, to
2835 Holmes Road
Houston, Texas 77051
Attn: Chief Executive Officer
Telecopy: (713) 799-5183
45
EXECUTION COPY
<PAGE>
with a copy to:
Latham & Watkins
650 Town Center Drive
Costa Mesa, CA 92626-1925
Attn: Patrick T. Seaver, Esq.
Telecopy: (714) 755-8290
(b) if to Varco, to
743 North Eckhoff Street
Orange, California 92668
Attn: Chief Executive Officer
Telecopy: (714) 937-5029
with a copy to:
Pircher, Nichols & Meeks
1999 Avenue of the Stars
Los Angeles, CA 90067
Attn: Larry M. Meeks, Esq.
Telecopy: (310) 201-8922
Section 9.03 Interpretation. When a reference is made in this
--------------
Agreement to Sections, such reference shall be to a Section of this Agreement
unless otherwise indicated. The table of contents and headings contained in this
Agreement are for reference purposes only and shall not affect in any way the
meaning or interpretation of this Agreement. Whenever the words "include,"
"includes" or "including" are used in this Agreement they shall be deemed to be
followed by the words "without limitation." The phrase "made available" in this
Agreement shall mean that the information referred to has been made available if
requested by the party to whom such information is to be made available. The
phrases "the date of this Agreement", "the date hereof," and terms of similar
import, unless the context otherwise requires, shall be deemed to refer to March
22, 2000.
46
EXECUTION COPY
<PAGE>
Section 9.04 Counterparts. This Agreement may be executed in two or
------------
more counterparts, all of which shall be considered one and the same agreement
and shall become effective when two or more counterparts have been signed by
each of the parties and delivered to the other parties, it being understood that
all parties need not sign the same counterpart.
Section 9.05 Entire Agreement; No Third Party Beneficiaries. This
----------------------------------------------
Agreement (including the documents and the instruments referred to herein) (a)
constitute the entire agreement and supersedes all prior agreements and
understandings, both written and oral, among the parties with respect to the
subject matter hereof, and (b) except as provided in Section 6.12 are not
intended to confer upon any person other than the parties hereto any rights or
remedies hereunder; provided that the Confidentiality Agreement shall remain in
full force and effect until the Effective Time. Each party hereto agrees that,
except for the representations and warranties contained in this Agreement,
neither Tuboscope nor Varco makes any other representations or warranties, and
each hereby disclaims any other representations and warranties made by itself or
any of its officers, directors, employees, agents, financial and legal advisors
or other representatives, with respect to the execution and delivery of this
Agreement, the documents and the instruments referred to herein, or the
transactions contemplated hereby or thereby, notwithstanding the delivery or
disclosure to the other or the other's representatives of any documentation or
other information with respect to any one or more of the foregoing.
Section 9.06 Governing Law. Except to the extent that the CGCL shall
-------------
govern the Merger, this Agreement shall be governed and construed in accordance
with the laws of the State of Delaware, without regard to the laws that might be
applicable under conflicts of laws principles.
Section 9.07 Assignment. Neither this Agreement nor any of the
----------
rights, interests or obligations hereunder shall be assigned by any of the
parties hereto (whether by operation of law or otherwise) without the prior
written consent of the other parties. Subject to the preceding sentence, this
Agreement will be binding upon, inure to the benefit of and be enforceable by
the parties and their respective successors and assigns.
Section 9.08 Waiver of Jury Trial. Each party hereto hereby waives
--------------------
any right to a trial by jury in connection with any action, suit or proceeding
brought in connection with this Agreement.
47
EXECUTION COPY
<PAGE>
IN WITNESS WHEREOF, Varco and Tuboscope have caused this Agreement to
be signed by their respective officers thereunto duly authorized as of the date
first written above.
VARCO INTERNATIONAL, INC.
By: /s/ George Boyadjieff
---------------------------
Name: George Boyadjieff
Title: Chief Executive Officer
TUBOSCOPE INC.
By: /s/ John F. Lauletta
---------------------------
Name: John Lauletta
Title: Chief Executive Officer
48
EXECUTION COPY
<PAGE>
Schedule I
----------
Officers
--------
George Boyadjieff Chairman and Chief Executive Officer
John Lauletta President and Chief Operating Officer
Joseph Winkler Chief Financial Officer
<PAGE>
TUBOSCOPE STOCK OPTION AGREEMENT
--------------------------------
STOCK OPTION AGREEMENT, dated as of March 22, 2000 (this "Agreement"), by
---------
and between Varco, a California corporation (the "Grantee"), and Tuboscope, a
-------
Delaware corporation (the "Grantor").
-------
WHEREAS, the Grantee and the Grantor are entering into an Agreement and
Plan of Merger, dated as of the date hereof (the "Merger Agreement"), which
----------------
provides, among other things, for the merger (the "Merger") of the Grantee with
------
and into the Grantor;
WHEREAS, as a condition to its willingness to enter into the Merger
Agreement, the Grantee has requested that the Grantor grant to the Grantee an
option to purchase certain shares of the authorized and unissued Common Stock of
the Grantor (the "Common Stock") upon the terms and subject to the conditions
------------
hereof; and
WHEREAS, in order to induce the Grantee to enter into the Merger Agreement,
the Grantor is willing to grant the Grantee the requested option.
NOW, THEREFORE, in consideration of the representations, warranties and
covenants contained herein and in the Merger Agreement, the parties hereto agree
as follows:
1. The Option; Exercise; Adjustments; Payment of Spread; Termination.
-----------------------------------------------------------------
(a) Contemporaneously herewith the Grantee and the Grantor are
entering into the Merger Agreement. Subject to the other terms and conditions
set forth herein, the Grantor hereby grants to the Grantee an irrevocable option
(the "Option") to purchase up to 8,908,653 shares (representing approximately
------
19.9% of the outstanding shares of Common Stock as of the date hereof) of Common
Stock (the "Option Shares") at a cash purchase price equal to $17.00 per Option
-------------
Share (the "Purchase Price"). Subject to the conditions set forth in Section 2,
--------------
the Option may be exercised by the Grantee, in whole or in part, at any time, or
from time to time, following the occurrence of any event as a result of which
the Grantee is unconditionally entitled to receive the Tuboscope Termination Fee
(as defined in the Merger Agreement) pursuant to Section 8.03(c) of the Merger
Agreement and prior to the termination of the Option in accordance with the
terms of this Agreement.
(b) Without limiting any restriction on the Grantor contained in
this Agreement or the Merger Agreement, in the event of any change in the number
of issued and outstanding shares of Common Stock by reason of any stock
dividend, stock split, split-up, recapitalization, merger or other change in the
corporate or capital structure of the Grantor, the number and type of Option
Shares subject to the Option and the purchase price per Option Share shall be
appropriately adjusted to restore the Grantee to its rights hereunder, including
its right to purchase Option Shares representing 19.9% of the capital stock of
the Grantor entitled to vote generally for the election of the directors of the
Grantor which is issued and outstanding immediately prior to the exercise of the
Option at an aggregate purchase price equal to the Purchase Price multiplied by
8,908,653.
1
EXECUTION COPY
<PAGE>
(c) In the event the Grantee wishes to exercise the Option, the
Grantee shall send a written notice to the Grantor (the "Exercise Notice")
---------------
specifying the total number of Option Shares that the Grantee wishes to purchase
and a date (subject to the requirements of the Hart-Scott-Rodino Antitrust
Improvements Act of 1976, as amended (the "HSR Act")) not later than 10 business
-------
days and not earlier than the next business day following the date such notice
is given for the closing of such purchase.
(d) After the occurrence of any event as a result of which the
Grantee is unconditionally entitled to receive the Tuboscope Termination Fee
pursuant to Section 8.03(c) of the Merger Agreement, the Grantee may (i) at any
time the Option is then exercisable pursuant to the terms of Section 1(a) hereof
elect, in lieu of exercising the Option to purchase Option Shares provided in
Section 1(a) hereof, to send a written notice to the Grantor (the "Cash
----
Exercise Notice") specifying a date not later than 20 business days and not
- ---------------
earlier than 10 business days following the date such notice is given on which
date the Grantor shall pay to the Grantee an amount in cash equal to the Spread
(as hereinafter defined) multiplied by all or such portion of the Option Shares
subject to the Option as Grantee shall specify, or (ii) at any time prior to 30
days after the first anniversary of the Merger Termination Date (as defined in
Section 1(e)), if the Grantee has exercised the Option and purchased the Option
Shares hereunder, Grantee may send a written notice to the Grantor (the "Put
---
Notice") specifying a date not later than 20 business days and not earlier than
- ------
10 business days following the date such notice is given on which date the
Grantee may sell to the Grantor Option Shares purchased hereunder and the
Grantor shall pay to the Grantee an amount in cash equal to the higher of (m)
the Alternative Purchase Price (as hereinafter defined) or (n) the average of
the closing sales prices of the shares of Common Stock on the New York Stock
Exchange (the "NYSE") for the five trading days ending five days prior to the
----
date the Put Notice is given, multiplied by the number of such Option Shares to
be sold by the Grantee to the Grantor on such date (such purchase and sale to be
closed in a manner substantially consistent with the procedures outlined in
Section 3 hereof). As used herein "Spread" shall mean the the highest price per
------
share of Common Stock (including any brokerage commissions, transfer taxes and
soliciting dealers' fees) paid by any person in an Alternative Transaction (as
defined in Section 8.03(g) of the Merger Agreement) (the "Alternative Purchase
--------------------
Price") or (y) the average of the closing sales prices of the shares of Common
- -----
Stock on the NYSE for the five trading days ending five days prior to the date
of the Cash Exercise Notice is given. If the Alternative Purchase Price includes
any property other than cash, the Alternative Purchase Price shall be the sum of
(A) the fixed cash amount, if any, included in the Alternative Purchase Price
plus (B) the fair market value of such other property determined in accordance
with the procedures set forth in Section 7(b) (but using the date of the Cash
Exercise Notice or the Put Notice, as the case may be, is given). Upon exercise
of the Grantee's right to receive cash pursuant to Section 1(d)(i) and the
payment of such cash to the Grantee, the obligations of the Grantor to deliver
Option Shares pursuant to Section 3 shall be terminated with respect to such
number of Option Shares for which the Grantee shall have elected to be paid the
Spread.
(e) The right to exercise the Option shall terminate at the
earliest of (i) the Effective Time (as defined in the Merger Agreement), (ii)
the termination of the Merger
2
EXECUTION COPY
<PAGE>
Agreement pursuant to circumstances under which the Grantee is not entitled to
receive the Tuboscope Termination Fee pursuant to Section 8.03(c) of the Merger
Agreement, (iii) the date on which the Grantee realizes a Total Profit equal to
the Profit Limit (as such terms are defined in Section 10) and (iv) 180 days
after the date (the "Merger Termination Date") on which the Merger Agreement is
-----------------------
terminated pursuant to circumstances under which the Grantee is entitled to
receive the Varco Termination Fee pursuant to Section 8.03(c) of the Merger
Agreement (the date referred to in clause (iv) being hereinafter referred to as
the "Option Expiration Date"); provided that if the Option cannot be exercised
----------------------
or the Option Shares cannot be delivered to Grantee upon such exercise because
the conditions set forth in Section 2(a) or Section 2(b) hereof have not yet
been satisfied, the Option Expiration Date shall be extended until 30 days after
such impediment to exercise has been removed.
2. Conditions to Delivery of Option Shares. The Grantor's obligation to
---------------------------------------
deliver Option Shares upon exercise of the Option is subject to the following
conditions:
(a) No preliminary or permanent injunction or other order issued by
any federal or state court of competent jurisdiction in the United States
prohibiting the delivery of the Option Shares shall be in effect;
(b) Any applicable waiting periods under the HSR Act shall have
expired or been terminated; and
(c) The Grantee shall have become entitled to terminate the Merger
Agreement under circumstances that would entitle the Grantee to receive the
Tuboscope Termination Fee pursuant to Section 8.03(c) of the Merger Agreement.
3. The Closing.
-----------
(a) Any closing hereunder shall take place on the date specified by
the Grantee in its Exercise Notice at 9:00 A.M., local time, at the offices of
Latham & Watkins, 650 Town Center Drive, Costa Mesa, California, or, if the
conditions set forth in Section 2(a) or 2(b) have not then been satisfied, on
the second business day following the satisfaction of such conditions, or at
such other time and place as the parties hereto may agree (the "Closing Date").
-------------
On the Closing Date, the Grantor will deliver to the Grantee a certificate or
certificates representing the Option Shares in the denominations designated by
the Grantee in its Exercise Notice and the Grantee will purchase such Option
Shares from the Grantor at the price per Option Share equal to the Purchase
Price. Unless otherwise specified in this Agreement, any payment made by the
Grantee to the Grantor, or by the Grantor to the Grantee, pursuant to this
Agreement shall be made by certified or official bank check or by wire transfer
of immediately available funds to a bank designated by the party receiving such
funds.
(b) Certificates for the Option Shares delivered on the Closing
Date will have typed or printed thereon a restrictive legend which will read
substantially as follows:
3
EXECUTION COPY
<PAGE>
"THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933 AND MAY BE REOFFERED OR
SOLD ONLY IF SO REGISTERED OR IF AN EXEMPTION FROM SUCH REGISTRATION
IS AVAILABLE. SUCH SECURITIES ARE ALSO SUBJECT TO ADDITIONAL
RESTRICTIONS ON TRANSFER AS SET FORTH IN THE TUBOSCOPE STOCK OPTION
AGREEMENT DATED AS OF MARCH 22, 2000, A COPY OF WHICH MAY BE OBTAINED
FROM THE SECRETARY OF TUBOSCOPE AT ITS PRINCIPAL EXECUTIVE OFFICES."
It is understood and agreed that (i) the reference to restrictions arising under
the Securities Act of 1933, as amended (the "Securities Act"), in the above
--------------
legend will be removed by delivery of substitute certificate(s) without such
reference if such Option Shares have been registered pursuant to the Securities
Act, such Option Shares have been sold in reliance on and in accordance with
Rule 144 under the Securities Act or Grantee has delivered to Grantor a copy of
a letter from the staff of the Securities and Exchange Commission, or an opinion
of counsel in form and substance reasonably satisfactory to Grantor and its
counsel, to the effect that such legend is not required for purposes of the
Securities Act and (ii) the reference to restrictions pursuant to this Agreement
in the above legend will be removed by delivery of substitute certificate(s)
without such reference if the Option Shares evidenced by certificate(s)
containing such reference have been sold or transferred in compliance with the
provisions of this Agreement under circumstances that do not require the
retention of such reference.
4. Representations and Warranties of the Grantor. The Grantor represents
---------------------------------------------
and warrants to the Grantee that: (a) the Grantor is a corporation duly
organized, validly existing and in good standing under the laws of the State of
California and has the requisite corporate power and authority to enter into and
perform this Agreement; (b) the execution and delivery of this Agreement by the
Grantor and the consummation by it of the transactions contemplated hereby have
been duly authorized by the Board of Directors of the Grantor and this Agreement
has been duly executed and delivered by a duly authorized officer of the Grantor
and constitutes a valid and binding obligation of the Grantor, enforceable in
accordance with its terms, subject to bankruptcy, insolvency, fraudulent
transfer, reorganization, moratorium and similar laws of general applicability
relating to or affecting creditors' rights, to general equity principles and to
the California General Corporation Law; (c) the Grantor has taken all necessary
corporate action to authorize and reserve the Option Shares issuable upon
exercise of the Option and the Option Shares, when issued and delivered by the
Grantor upon the exercise of the Option in accordance with the terms of this
Agreement, will be duly authorized, validly issued, fully paid and non-
assessable and free of any lien, security interest or other adverse claim and
free of any preemptive rights; (d) except as otherwise required by the HSR Act
and, except for routine filings under the Securities Exchange Act of 1934, as
amended, and the listing of the Option Shares in accordance with Section 6, the
execution and delivery of this Agreement by the Grantor and the consummation by
it of the transactions contemplated hereby do not require the consent, waiver,
4
EXECUTION COPY
<PAGE>
approval or authorization of or any filing with any person or public authority
and will not violate, require a consent or waiver under, result in a breach of
or the acceleration of any obligation under, or constitute a default under, any
provision of any charter or by-law, indenture, mortgage, lien, lease, agreement,
contract, instrument, order, law, rule, regulation, stock market rule, judgment,
ordinance, decree or restriction by which the Grantor or any of its subsidiaries
or any of their respective properties or assets is bound; and (e) no "fair
price," "moratorium," "control share acquisition" or other form of antitakeover
statute or regulation is or shall be applicable to the acquisition of Option
Shares pursuant to this Agreement.
5. Representations and Warranties of the Grantee. The Grantee represents
---------------------------------------------
and warrants to the Grantor that: (a) the execution and delivery of this
Agreement by the Grantee and the consummation by it of the transactions
contemplated hereby have been duly authorized by all necessary corporate action
on the part of the Grantee and this Agreement has been duly executed and
delivered by a duly authorized officer of the Grantee and constitutes a valid
and binding obligation of the Grantee; and (b) the Grantee is acquiring the
Option and, if and when it exercises the Option, will be acquiring the Option
Shares issuable upon the exercise thereof for its own account and not with a
view to distribution or resale in any manner which would be in violation of the
Securities Act.
6. Listing of Option Shares; HSR Act Filings; Governmental Consents. The
----------------------------------------------------------------
Grantor shall use its best efforts to cause the Option Shares to be approved for
listing on the NYSE, subject to official notice of issuance, prior to the
Closing Date; provided, however, that if the Grantor is unable to effect such
-------- -------
listing on the NYSE by the Closing Date, the Grantor will nevertheless be
obligated to deliver the Option Shares upon the Closing Date. The Grantor shall
as promptly as practicable make all necessary filings with respect to this
Agreement and the Option required under the HSR Act and use its best efforts to
obtain all necessary approvals thereunder as promptly as practicable. Each of
the parties hereto will use its best efforts to obtain consents of all third
parties and governmental authorities, if any, necessary to the consummation of
the transactions contemplated herein.
7. Right of First Refusal. If the Grantee exercises the Option in whole
----------------------
or in part and at any time thereafter and prior to the earlier of (a) the
occurrence of a Change in Control Event (as defined herein) or (b) 30 days after
the first anniversary of the Merger Termination Date, seeks to sell all or any
part of the Option Shares purchased (i) in a transaction registered under the
Securities Act (other than in a registered public offering in which the
underwriters are instructed to achieve a broad public distribution) or (ii) in a
transaction not required to be registered under the Securities Act (other than
in a transfer by operation of law upon consummation of a merger), it shall give
the Grantor (or a designee of the Grantor) the opportunity, in the following
manner, to purchase such Option Shares:
(a) The Grantee shall give notice to the Grantor in writing of its
intent to sell Option Shares (a "Disposition Notice"), specifying the number of
------------------
Option Shares to be sold, the price and, if applicable, the identity of the
proposed transferee and the material terms of any agreement relating thereto.
For purposes of this Section 7, if the Disposition Notice is given with respect
to the sale of the Option Shares pursuant to a tender or exchange officer, it
shall be
5
EXECUTION COPY
<PAGE>
assumed that all Option Shares tendered will be accepted for payment. The
Disposition Notice may be given at any time, including prior to the giving of
any Exercise Notice.
(b) The Grantor or its designee shall have the right, exercisable
by written notice given to the Grantee within five business days after receipt
of a Disposition Notice (or, if applicable, in the case of a proposed sale
pursuant to a tender or exchange offer for shares of Common Stock, by written
notice given to the Grantee at least two business days prior to the then
announced expiration date of such tender or exchange offer (the "Expiration
----------
Date") if such Disposition Notice was given at least four business days prior to
- -----
such Expiration Date), to purchase all, but not less than all, of the Option
Shares specified in the Disposition Notice at the price set forth in the
Disposition Notice. If the purchase price specified in the Disposition Notice
includes any property other than cash, the purchase price to be paid by the
Grantor shall be an amount of cash equal to the sum of (i) the cash included in
the purchase price plus (ii) the fair market value of such other property at the
date of the Disposition Notice. If such other property consists of securities
with an existing public trading market, the average closing price (or the
average closing bid and asked price if closing prices are unavailable) for such
securities on their principal public trading market for the five trading days
ending five days prior to the date of the Disposition Notice shall be deemed to
equal the fair market value of such property. If such other property consists of
something other than cash or securities with an existing public trading market
and, at the time of the closing referred to in paragraph (c) below, agreement on
the value of such other property has not been reached, the higher of (i) the
cash included in the purchase price and (ii) the average closing price of the
Common Stock on the NYSE for the five trading days ending five days prior to the
date of the Disposition Notice shall be used as the per share purchase price;
provided, however, that promptly after the closing, the Grantee and the Grantor
- -------- -------
or its designee, as the case may be, shall settle any additional amounts to be
paid or returned as a result of the determination of fair market value of such
other property made by a nationally recognized investment banking firm selected
by the Grantor and approved by the Grantee within 30 days of the closing. Such
determination shall be final and binding on all parties hereto. If, at the time
of the purchase of any Option Shares by the Grantor (or its designee) pursuant
to this Section 7, a tender or exchange offer is outstanding, then the Grantor
(or its designee) shall agree at the time of such purchase to promptly pay to
Grantee from time to time such additional amounts, if any, so that the
consideration received by Grantee with respect to each Option Share shall be
equal to the highest price paid for a share of Common Stock pursuant to such
tender or exchange, or pursuant to any other tender or exchange offer
outstanding at any time such tender or exchange offer is outstanding.
(c) If the Grantor exercises its right of first refusal hereunder,
the closing of the purchase of the Option Shares with respect to which such
right has been exercised shall take place within five business days after the
notice of such exercise (or, if applicable, in the case of a tender or exchange
offer, no later than one business day prior to the expiration date of the offer
if written notice was given within the time set forth in the parenthetical in
the first sentence of paragraph (b) above); provided, however, that at any time
-------- -------
prior to the closing of the purchase of Option Shares hereunder, the Grantee may
determine not to sell the Option Shares and revoke the Disposition Notice and,
by so doing, cancel the Grantor's right of first refusal with respect to the
6
EXECUTION COPY
<PAGE>
disposition in question. The Grantor (or its designee) shall pay for the Option
Shares by wire transfer of immediately available funds to a bank designated by
the Grantee.
(d) If the Grantor does not exercise its right of first refusal
hereunder within the time specified for such exercise, the Grantee shall be free
for 90 days following the expiration of such time for exercise to sell the
Option Shares (or enter into an agreement to sell the Option Shares) specified
in the Disposition Notice, at the price specified in the Disposition Notice or
any price in excess thereof and otherwise on substantially the same terms set
forth in the Disposition Notice; provided that if such sale is not consummated
within such 90-day period (or the agreement to sell entered into in such 90-day
period is not thereafter performed in accordance with its terms), then the
provisions of this Section 7 will again apply to the sale of such Option Shares.
(e) For purposes of the Agreement, a "Change in Control Event"
-----------------------
shall be deemed to have occurred if (i) any person has acquired beneficial
ownership of more than 50% (excluding the Option Shares) of the outstanding
shares of Common Stock or (ii) the Grantor shall have entered into an agreement,
including without limitation an agreement in principle, providing for a merger
or other business combination involving the Grantor or the acquisition of 30% or
more of the assets of the Grantor and its subsidiaries, taken as a whole.
8. Repurchase of Option Shares. If a Change in Control Event has not
---------------------------
occurred prior to the first anniversary date of the Merger Termination Date,
then beginning on such anniversary date, the Grantor shall have the right to
purchase (the "Repurchase Right") all, but not less than all, of the Option
----------------
Shares at the greater of (i) the Purchase Price, or (ii) the average closing
price of the Common Stock on the NYSE for the five trading days ending five days
prior to the date the Grantor gives written notice of its intention to exercise
the Repurchase Right. If the Grantor does not exercise the Repurchase Right
within 30 days following the first anniversary of the Merger Termination Date,
the Repurchase Right shall terminate. In the event the Grantor wishes to
exercise the Repurchase Right, the Grantor shall send a written notice to the
Grantee specifying a date (not later than 10 business days and not earlier than
two business days following the date such notice is given) for the closing of
such purchase.
9. Registration Rights.
-------------------
(a) In the event that the Grantee shall desire to sell any of the
Option Shares within two years after the purchase of such Option Shares pursuant
to the exercise of the Option, and such sale requires, in the opinion of counsel
to the Grantee, which opinion shall be reasonably satisfactory to the Grantor
and its counsel, registration of such Option Shares under the Securities Act,
the Grantor will cooperate with the Grantee and any underwriters registering
such Option Shares for resale, including, without limitation, promptly filing
and using its best efforts to cause to be declared effective a registration
statement which complies with the requirements of applicable federal and state
securities laws and entering into an underwriting agreement with such
underwriters upon such terms and conditions as are customarily contained in
underwriting agreements with respect to secondary distributions; provided that
the Grantor shall not be required to have declared effective more than two
registration statements hereunder
7
EXECUTION COPY
<PAGE>
and shall be entitled to delay the filing or effectiveness of any registration
statement for up to 120 days in the aggregate if the offering would, in the
judgment of the Board of Directors of the Grantor, require premature disclosure
of any material corporate development or otherwise interfere with or adversely
affect any pending or proposed offering of securities of the Grantor or any
other material transaction involving the Grantor.
(b) If the Common Stock is registered pursuant to the provisions of
this Section 9, the Grantor agrees (i) to furnish copies of the registration
statement and the prospectus relating to the Option Shares covered thereby in
such numbers as the Grantee may from time to time reasonably request and (ii) if
any event shall occur as a result of which it becomes necessary to amend or
supplement any registration statement or prospectus, to prepare and file under
the applicable securities laws such amendments and supplements as may be
necessary to keep available for at least 90 days a prospectus covering the
Common Stock meeting the requirements of such securities laws, and to furnish to
the Grantee such numbers of copies of the registration statement and prospectus
as amended or supplemented as may reasonably be requested. The Grantor shall
bear the cost of the registration, including, but not limited to, all
registration and filing fees, printing expenses, and fees and disbursements of
counsel and accountants for the Grantor, except that the Grantee shall pay the
fees and disbursements of its counsel and the underwriting fees and selling
commissions applicable to the Option Shares sold by the Grantee. The Grantor
shall indemnify and hold harmless Grantee, its affiliates and its officers and
directors from and against any and all losses, claims, damages, liabilities and
expenses arising out of or based upon any statements contained in, omissions or
alleged omissions from, each registration statement filed pursuant to this
paragraph; provided, however, that this provision does not apply to any loss,
-------- -------
liability, claim, damage or expense to the extent it arises out of any statement
or omission made in reliance upon and in conformity with written information
furnished to the Grantor by the Grantee, its affiliates or its officers
expressly for use in any registration statement (or any amendment thereto) or
any preliminary prospectus filed pursuant to this paragraph. The Grantor shall
also indemnify and hold harmless each underwriter and each person who controls
any underwriter within the meaning of either the Securities Act or the
Securities Exchange Act of 1934, as amended, against any and all losses, claims,
damages, liabilities and expenses arising out of or based upon any statements
contained in, omissions or alleged omissions from, each registration statement
filed pursuant to this paragraph; provided, however, that this provision does
-------- -------
not apply to any loss, liability, claim, damage or expense to the extent it
arises out of any statement or omission made in reliance upon and in conformity
with written information furnished to the Grantor by the underwriters expressly
for use in any registration statement (or any amendment thereto) or any
preliminary prospectus filed pursuant to this paragraph.
10. Profit Limitation.
-----------------
(a) Notwithstanding any other provision of this Agreement, in no
event shall the Grantee's Total Profit (as hereinafter defined) exceed
$35,000,000 (the "Profit Limit") and, if it otherwise would exceed such amount,
------------
the Grantee, at its sole election, shall either (i) deliver to the Grantor for
cancellation Option Shares previously purchased by Grantee (valued at the
8
EXECUTION COPY
<PAGE>
average closing price of the Common Stock on the NYSE for the five trading days
ending on the trading date immediately preceding the date of delivery, (ii) pay
cash or deliver other consideration to the Grantor, or (iii) undertake any
combination thereof, so that Grantee's Total Profit shall not exceed the Profit
Limit after taking into account the foregoing actions.
(b) Notwithstanding any other provision of this Agreement, the
Option may not be exercised for a number of Option Shares as would, as of the
date of the Exercise Notice, result in a Notional Total Profit (as defined
below) of more than the Profit Limit and, if exercise of the Option otherwise
would exceed the Profit Limit, the Grantee, at its discretion, may increase the
Purchase Price for that number of Option Shares set forth in the Exercise Notice
so that the Notional Total Profit shall not exceed the Profit Limit; provided
that nothing in this sentence shall restrict any exercise of the Option
permitted hereby on any subsequent date at the Purchase Price set forth in
Section 1(a) hereof.
(c) As used herein, the term "Total Profit" shall mean the
------------
aggregate amount (before taxes) of the following: (i) the amount of cash
received by Grantee pursuant to Section 8.03(c) of the Merger Agreement, (ii)
(x) the amount received by Grantee pursuant to the Grantor's repurchase of
Option Shares pursuant to Sections 1(d), 7 or 8 hereof, less (y) the Grantee's
aggregate purchase price for such Option Shares, (iii) the amount received by
Grantee in respect of a Cash Exercise Notice pursuant to Section 1(d) hereof,
and (iv) (x) the net cash amounts received by Grantee pursuant to the sale of
Option Shares (or any other securities into which such Option Shares are
converted or exchanged) to any unaffiliated party, less (y) the Grantee's
aggregate purchase price for such Option Shares.
(d) As used herein, the term "Notional Total Profit" with respect
---------------------
to any number of Option Shares as to which Grantee may propose to exercise the
Option shall be the Total Profit determined as of the date of the Exercise
Notice assuming that the Option were exercised on such date for such number of
Option Shares and assuming that such Option Shares, together with all other
Option Shares held by Grantee and its affiliates as of such date, were sold for
cash at the closing market price for the Common Stock as of the close of
business on the preceding trading day (less customary brokerage commissions).
11. Expenses. Each party hereto shall pay its own expenses incurred in
--------
connection with this Agreement, except as otherwise specifically provided
herein.
12. Specific Performance. The Grantor acknowledges that if the Grantor
--------------------
fails to perform any of its obligations under this Agreement, immediate and
irreparable harm or injury would be caused to the Grantee for which money
damages would not be an adequate remedy. In such event, the Grantor agrees that
the Grantee shall have the right, in addition to any other rights it may have,
to specific performance of this Agreement. Accordingly, if the Grantee should
institute an action or proceeding seeking specific enforcement of the provisions
hereof, the Grantor hereby waives the claim or defense that the Grantee has an
adequate remedy at law and hereby agrees not to assert in any such action or
proceeding the claim or defense that such a
9
EXECUTION COPY
<PAGE>
remedy at law exists. The Grantor further agrees to waive any requirement for
the securing or posting of any bond in connection with obtaining any such
equitable relief.
13. Notice. All notices, requests, demands and other communications
------
hereunder shall be sent in the manner and to the addresses set forth in the
Merger Agreement.
14. Parties in Interest. Nothing in this Agreement, express or implied,
-------------------
is intended to confer upon any person other than the Grantor or the Grantee, or
their successors or assigns, any rights or remedies under or by reason of this
Agreement.
15. Entire Agreement; Amendments. This Agreement, together with the
----------------------------
Merger Agreement and the other documents referred to therein, contains the
entire agreement between the parties hereto with respect to the subject matter
hereof and supersedes all prior and contemporaneous agreements and
understandings, oral or written, with respect to such transactions. The terms
of this Agreement may be amended, modified or waived only by an agreement in
writing signed by the party against whom such amendment, modification or waiver
is sought to be enforced.
16. Assignment. No party to this Agreement may assign any of its rights
----------
or obligations under this Agreement without the prior written consent of the
other party hereto, except that the Grantee may assign its rights and
obligations hereunder to any direct or indirect wholly-owned subsidiary of the
Grantee (provided that such assignment shall not relieve the Grantee of its
obligations hereunder if such transferee does not perform such obligations).
Any Option Shares sold or transferred by the Grantee to any other person or
entity in compliance with the terms hereof (other than a direct or indirect
wholly-owned subsidiary of the Grantee) shall no longer have the benefit of the
rights provided for herein with respect to such Option Shares (including without
limitation those set forth in Sections 1(d) and 9) and shall no longer be
subject to the restrictions or rights in favor of the Grantor provided for
herein with respect to such Option Shares (including without limitation those
set forth in Sections 7 and 8).
17. Headings. The section headings herein are for convenience only and
--------
shall not affect the construction of this Agreement.
18. Counterparts. This Agreement may be executed in any number of
------------
counterparts, each of which, when executed, shall be deemed to be an original
and all of which together shall constitute one and the same document.
19. Governing Law. This Agreement shall be governed by and construed in
-------------
accordance with the laws of the State of Delaware (regardless of the laws that
might otherwise govern under applicable Delaware principles of conflicts of
law).
20. Survival. All representations and warranties contained in this
--------
Agreement shall survive delivery of and payment for the Option Shares.
10
EXECUTION COPY
<PAGE>
21. Severability. If any term, provision, covenant or restriction of this
------------
Agreement is held by a court of competent jurisdiction to be invalid, void or
unenforceable, the remainder of the terms, provisions, covenants and
restrictions of this Agreement shall remain in full force and effect and shall
in no way be affected, impaired or invalidated.
11
EXECUTION COPY
<PAGE>
IN WITNESS WHEREOF, the Grantee and the Grantor have caused this Agreement
to be duly executed and delivered on the day and year first above written.
TUBOSCOPE INC.
By: /s/ John F. Lauletta
-----------------------------------
Name: John Lauletta
Name: Chief Executive Officer
VARCO INTERNATIONAL, INC.
By: /s/ George Boyadjieff
-----------------------------------
Name: George Boyadjieff
Title: Chief Executive Officer
12
EXECUTION COPY
<PAGE>
VARCO STOCK OPTION AGREEMENT
----------------------------
STOCK OPTION AGREEMENT, dated as of March 22, 2000 (this "Agreement"), by
---------
and between Tuboscope, a Delaware corporation (the "Grantee"), and Varco, a
-------
California corporation (the "Grantor").
-------
WHEREAS, the Grantee and the Grantor are entering into an Agreement and
Plan of Merger, dated as of the date hereof (the "Merger Agreement"), which
----------------
provides, among other things, for the merger (the "Merger") of Grantor with and
------
into the Grantee;
WHEREAS, as a condition to its willingness to enter into the Merger
Agreement, the Grantee has requested that the Grantor grant to the Grantee an
option to purchase certain shares of the authorized and unissued Common Stock of
the Grantor, together with any associated rights under the Rights Agreement,
dated as of November 6, 1997 (the "Varco Rights Agreement"), between Grantor and
-----------------------
Harris Trust Company of California, as amended (the "Common Stock") , upon the
------------
terms and subject to the conditions hereof; and
WHEREAS, in order to induce the Grantee to enter into the Merger Agreement,
the Grantor is willing to grant the Grantee the requested option.
NOW, THEREFORE, in consideration of the representations, warranties and
covenants contained herein and in the Merger Agreement, the parties hereto agree
as follows:
1. The Option; Exercise; Adjustments; Payment of Spread; Termination.
-----------------------------------------------------------------
(a) Contemporaneously herewith the Grantee and the Grantor are entering
into the Merger Agreement, and Grantor has amended the Varco Rights Agreement.
Subject to the other terms and conditions set forth herein, the Grantor hereby
grants to the Grantee an irrevocable option (the "Option") to purchase up to
------
13,023,985 shares (representing approximately 19.9% of the outstanding shares of
Common Stock as of the date hereof) of Common Stock (the "Option Shares") at a
-------------
cash purchase price equal to $14.56 per Option Share (the "Purchase Price").
--------------
Subject to the conditions set forth in Section 2, the Option may be exercised by
the Grantee, in whole or in part, at any time, or from time to time, following
the occurrence of any event as a result of which the Grantee is unconditionally
entitled to receive the Varco Termination Fee (as defined in the Merger
Agreement) pursuant to Section 8.03(e) of the Merger Agreement and prior to the
termination of the Option in accordance with the terms of this Agreement.
(b) Without limiting any restriction on the Grantor contained in this
Agreement or the Merger Agreement, in the event of any change in the number of
issued and outstanding shares of Common Stock by reason of any stock dividend,
stock split, split-up, recapitalization, merger or other change in the corporate
or capital structure of the Grantor, the number and type of Option Shares
subject to the Option and the purchase price per Option Share shall be
appropriately adjusted to restore the Grantee to its rights hereunder, including
its right to purchase Option Shares representing 19.9% of the capital stock of
the Grantor entitled to vote generally for the election of the directors of the
Grantor which is issued and outstanding
EXECUTION COPY
<PAGE>
immediately prior to the exercise of the Option at an aggregate purchase price
equal to the Purchase Price multiplied by 13,023,985.
(c) In the event the Grantee wishes to exercise the Option, the Grantee
shall send a written notice to the Grantor (the "Exercise Notice") specifying
---------------
the total number of Option Shares that the Grantee wishes to purchase and a date
(subject to the requirements of the Hart-Scott-Rodino Antitrust Improvements Act
of 1976, as amended (the "HSR Act")) not later than 10 business days and not
-------
earlier than the next business day following the date such notice is given for
the closing of such purchase.
(d) After the occurrence of any event as a result of which the Grantee
is unconditionally entitled to receive the Varco Termination Fee pursuant to
Section 8.03(e) of the Merger Agreement, the Grantee may (i) at any time the
Option is then exercisable pursuant to the terms of Section 1(a) hereof elect,
in lieu of exercising the Option to purchase Option Shares provided in Section
1(a) hereof, to send a written notice to the Grantor (the "Cash Exercise
-------------
Notice") specifying a date not later than 20 business days and not earlier than
- ------
10 business days following the date such notice is given on which date the
Grantor shall pay to the Grantee an amount in cash equal to the Spread (as
hereinafter defined) multiplied by all or such portion of the Option Shares
subject to the Option as Grantee shall specify, or (ii) at any time prior to 30
days after the first anniversary of the Merger Termination Date (as defined in
Section 1(e)), if the Grantee has exercised the Option and purchased the Option
Shares hereunder, Grantee may send a written notice to the Grantor (the "Put
---
Notice") specifying a date not later than 20 business days and not earlier than
- ------
10 business days following the date such notice is given on which date the
Grantee may sell to the Grantor Option Shares purchased hereunder and the
Grantor shall pay to the Grantee an amount in cash equal to the higher of (m)
the Alternative Purchase Price (as hereinafter defined) or (n) the average of
the closing sales prices of the shares of Common Stock on the New York Stock
Exchange (the "NYSE") for the five trading days ending five days prior to the
----
date the Put Notice is given, multiplied by the number of such Option Shares to
be sold by the Grantee to the Grantor on such date (such purchase and sale to be
closed in a manner substantially consistent with the procedures outlined in
Section 3 hereof). As used herein "Spread" shall mean the excess, if any, over
------
the Purchase Price of the higher of (x) if applicable, the highest price per
share of Common Stock (including any brokerage commissions, transfer taxes and
soliciting dealers' fees) paid by any person in an Alternative Transaction (as
defined in Section 8.03(g) of the Merger Agreement) (the "Alternative Purchase
--------------------
Price") or (y) the average of the closing sales prices of the shares of Common
- -----
Stock on the NYSE for the five trading days ending five days prior to the date
of the Cash Exercise Notice is given. If the Alternative Purchase Price includes
any property other than cash, the Alternative Purchase Price shall be the sum of
(A) the fixed cash amount, if any, included in the Alternative Purchase Price
plus (B) the fair market value of such other property determined in accordance
with the procedures set forth in Section 7(b) (but using the date of the Cash
Exercise Notice or the Put Notice, as the case may be, is given). Upon exercise
of the Grantee's right to receive cash pursuant to Section 1(d)(i) and the
payment of such cash to the Grantee, the obligations of the Grantor to deliver
Option Shares pursuant to Section 3 shall be terminated with respect to such
number of Option Shares for which the Grantee shall have elected to be paid the
Spread.
2
EXECUTION COPY
<PAGE>
(e) The right to exercise the Option shall terminate at the earliest
of (i) the Effective Time (as defined in the Merger Agreement), (ii) the
termination of the Merger Agreement pursuant to circumstances under which the
Grantee is not entitled to receive the Varco Termination Fee pursuant to Section
8.03(e) of the Merger Agreement, (iii) the date on which the Grantee realizes a
Total Profit equal to the Profit Limit (as such terms are defined in Section 10)
and (iv) 180 days after the date (the "Merger Termination Date") on which the
-----------------------
Merger Agreement is terminated pursuant to circumstances under which the Grantee
is entitled to receive the Varco Termination Fee pursuant to Section 8.03(e) of
the Merger Agreement (the date referred to in clause (iv) being hereinafter
referred to as the "Option Expiration Date"); provided that if the Option cannot
----------------------
be exercised or the Option Shares cannot be delivered to Grantee upon such
exercise because the conditions set forth in Section 2(a) or Section 2(b) hereof
have not yet been satisfied, the Option Expiration Date shall be extended until
30 days after such impediment to exercise has been removed.
2. Conditions to Delivery of Option Shares. The Grantor's obligation to
---------------------------------------
deliver Option Shares upon exercise of the Option is subject to the following
conditions:
(a) No preliminary or permanent injunction or other order issued by
any federal or state court of competent jurisdiction in the United States
prohibiting the delivery of the Option Shares shall be in effect;
(b) Any applicable waiting periods under the HSR Act shall have
expired or been terminated; and
(c) The Grantee shall have become entitled to terminate the Merger
Agreement under circumstances that would entitle the Grantee to receive the
Varco Termination Fee pursuant to Section 8.03(e) of the Merger Agreement.
3. The Closing.
-----------
(a) Any closing hereunder shall take place on the date specified by
the Grantee in its Exercise Notice at 9:00 A.M., local time, at the offices of
Pircher, Nichols & Meeks, 1999 Avenue of the Stars, Los Angeles, California, or,
if the conditions set forth in Section 2(a) or 2(b) have not then been
satisfied, on the second business day following the satisfaction of such
conditions, or at such other time and place as the parties hereto may agree (the
"Closing Date"). On the Closing Date, the Grantor will deliver to the Grantee a
------------
certificate or certificates representing the Option Shares in the denominations
designated by the Grantee in its Exercise Notice and the Grantee will purchase
such Option Shares from the Grantor at the price per Option Share equal to the
Purchase Price. Unless otherwise specified in this Agreement, any payment made
by the Grantee to the Grantor, or by the Grantor to the Grantee, pursuant to
this Agreement shall be made by certified or official bank check or by wire
transfer of immediately available funds to a bank designated by the party
receiving such funds.
3
EXECUTION COPY
<PAGE>
(b) Certificates for the Option Shares delivered on the Closing Date
will have typed or printed thereon a restrictive legend which will read
substantially as follows:
"THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933 AND MAY BE REOFFERED OR
SOLD ONLY IF SO REGISTERED OR IF AN EXEMPTION FROM SUCH REGISTRATION
IS AVAILABLE. SUCH SECURITIES ARE ALSO SUBJECT TO ADDITIONAL
RESTRICTIONS ON TRANSFER AS SET FORTH IN THE VARCO STOCK OPTION
AGREEMENT DATED AS OF MARCH 22, 2000, A COPY OF WHICH MAY BE OBTAINED
FROM THE SECRETARY OF VARCO AT ITS PRINCIPAL EXECUTIVE OFFICES."
It is understood and agreed that (i) the reference to restrictions arising under
the Securities Act of 1933, as amended (the "Securities Act"), in the above
--------------
legend will be removed by delivery of substitute certificate(s) without such
reference if such Option Shares have been registered pursuant to the Securities
Act, such Option Shares have been sold in reliance on and in accordance with
Rule 144 under the Securities Act or Grantee has delivered to Grantor a copy of
a letter from the staff of the Securities and Exchange Commission, or an opinion
of counsel in form and substance reasonably satisfactory to Grantor and its
counsel, to the effect that such legend is not required for purposes of the
Securities Act and (ii) the reference to restrictions pursuant to this Agreement
in the above legend will be removed by delivery of substitute certificate(s)
without such reference if the Option Shares evidenced by certificate(s)
containing such reference have been sold or transferred in compliance with the
provisions of this Agreement under circumstances that do not require the
retention of such reference.
4. Representations and Warranties of the Grantor. The Grantor represents
---------------------------------------------
and warrants to the Grantee that: (a) the Grantor is a corporation duly
organized, validly existing and in good standing under the laws of the State of
California and has the requisite corporate power and authority to enter into and
perform this Agreement; (b) the execution and delivery of this Agreement by the
Grantor and the consummation by it of the transactions contemplated hereby have
been duly authorized by the Board of Directors of the Grantor and this Agreement
has been duly executed and delivered by a duly authorized officer of the Grantor
and constitutes a valid and binding obligation of the Grantor, enforceable in
accordance with its terms, subject to bankruptcy, insolvency, fraudulent
transfer, reorganization, moratorium and similar laws of general applicability
relating to or affecting creditors' rights, to general equity principles and to
the California General Corporation Law; (c) the Grantor has taken all necessary
corporate action to authorize and reserve the Option Shares issuable upon
exercise of the Option and the Option Shares, when issued and delivered by the
Grantor upon the exercise of the Option in accordance with the terms of this
Agreement, will be duly authorized, validly issued, fully paid and non-
assessable and free of any lien, security interest or other adverse claim and
free of any preemptive rights; (d) except as otherwise required by the HSR Act
and, except for routine filings under the Securities Exchange Act of 1934, as
amended, and the listing of the Option Shares in accordance with Section 6, the
execution and delivery of this Agreement by the Grantor and the
4
EXECUTION COPY
<PAGE>
consummation by it of the transactions contemplated hereby do not require the
consent, waiver, approval or authorization of or any filing with any person or
public authority and will not violate, require a consent or waiver under, result
in a breach of or the acceleration of any obligation under, or constitute a
default under, any provision of any charter or by-law, indenture, mortgage,
lien, lease, agreement, contract, instrument, order, law, rule, regulation,
stock market rule, judgment, ordinance, decree or restriction by which the
Grantor or any of its subsidiaries or any of their respective properties or
assets is bound; (e) no "fair price," "moratorium," "control share acquisition"
or other form of antitakeover statute or regulation is or shall be applicable to
the acquisition of Option Shares pursuant to this Agreement; and (f) the Varco
Rights Agreement has been amended so that the Grantee is exempt from the
definition of "Acquiring Person" contained in the Varco Rights Agreement, and no
"Shares Acquisition Date" or "Distribution Date" or "Triggering Event" (as such
terms are defined in the Varco Rights Agreement) will occur as a result of the
execution of this Agreement by the Grantor or the exercise of the Option by the
Grantee.
5. Representations and Warranties of the Grantee. The Grantee represents
---------------------------------------------
and warrants to the Grantor that: (a) the execution and delivery of this
Agreement by the Grantee and the consummation by it of the transactions
contemplated hereby have been duly authorized by all necessary corporate action
on the part of the Grantee and this Agreement has been duly executed and
delivered by a duly authorized officer of the Grantee and constitutes a valid
and binding obligation of the Grantee; and (b) the Grantee is acquiring the
Option and, if and when it exercises the Option, will be acquiring the Option
Shares issuable upon the exercise thereof for its own account and not with a
view to distribution or resale in any manner which would be in violation of the
Securities Act.
6. Listing of Option Shares; HSR Act Filings; Governmental Consents. The
----------------------------------------------------------------
Grantor shall use its best efforts to cause the Option Shares to be approved for
listing on the NYSE, subject to official notice of issuance, prior to the
Closing Date; provided, however, that if the Grantor is unable to effect such
-------- -------
listing on the NYSE by the Closing Date, the Grantor will nevertheless be
obligated to deliver the Option Shares upon the Closing Date. The Grantor shall
as promptly as practicable, make all necessary filings with respect to this
Agreement and the Option required under the HSR Act and use its best efforts to
obtain all necessary approvals thereunder as promptly as practicable. Each of
the parties hereto will use its best efforts to obtain consents of all third
parties and governmental authorities, if any, necessary to the consummation of
the transactions contemplated herein.
7. Right of First Refusal. If the Grantee exercises the Option in whole
----------------------
or in part and at any time thereafter and prior to the earlier of (a) the
occurrence of a Change in Control Event (as defined herein) or (b) 30 days after
the first anniversary of the Merger Termination Date, seeks to sell all or any
part of the Option Shares purchased (i) in a transaction registered under the
Securities Act (other than in a registered public offering in which the
underwriters are instructed to achieve a broad public distribution) or (ii) in a
transaction not required to be registered under the Securities Act (other than
in a transfer by operation of law upon consummation of a merger), it shall give
the Grantor (or a designee of the Grantor) the opportunity, in the following
manner, to purchase such Option Shares:
5
EXECUTION COPY
<PAGE>
(a) The Grantee shall give notice to the Grantor in writing
of its intent to sell Option Shares (a "Disposition Notice"), specifying the
------------------
number of Option Shares to be sold, the price and, if applicable, the identity
of the proposed transferee and the material terms of any agreement relating
thereto. For purposes of this Section 7, if the Disposition Notice is given
with respect to the sale of the Option Shares pursuant to a tender or exchange
officer, it shall be assumed that all Option Shares tendered will be accepted
for payment. The Disposition Notice may be given at any time, including prior
to the giving of any Exercise Notice.
(b) The Grantor or its designee shall have the right,
exercisable by written notice given to the Grantee within five business days
after receipt of a Disposition Notice (or, if applicable, in the case of a
proposed sale pursuant to a tender or exchange offer for shares of Common Stock,
by written notice given to the Grantee at least two business days prior to the
then announced expiration date of such tender or exchange offer (the "Expiration
----------
Date") if such Disposition Notice was given at least four business days prior to
- ----
such Expiration Date), to purchase all, but not less than all, of the Option
Shares specified in the Disposition Notice at the price set forth in the
Disposition Notice. If the purchase price specified in the Disposition Notice
includes any property other than cash, the purchase price to be paid by the
Grantor shall be an amount of cash equal to the sum of (i) the cash included in
the purchase price plus (ii) the fair market value of such other property at the
date of the Disposition Notice. If such other property consists of securities
with an existing public trading market, the average closing price (or the
average closing bid and asked price if closing prices are unavailable) for such
securities on their principal public trading market for the five trading days
ending five days prior to the date of the Disposition Notice shall be deemed to
equal the fair market value of such property. If such other property consists
of something other than cash or securities with an existing public trading
market and, at the time of the closing referred to in paragraph (c) below,
agreement on the value of such other property has not been reached, the higher
of (i) the cash included in the purchase price and (ii) the average closing
price of the Common Stock on the NYSE for the five trading days ending five days
prior to the date of the Disposition Notice shall be used as the per share
purchase price; provided, however, that promptly after the closing, the Grantee
-------- -------
and the Grantor or its designee, as the case may be, shall settle any additional
amounts to be paid or returned as a result of the determination of fair market
value of such other property made by a nationally recognized investment banking
firm selected by the Grantor and approved by the Grantee within 30 days of the
closing. Such determination shall be final and binding on all parties hereto.
If, at the time of the purchase of any Option Shares by the Grantor (or its
designee) pursuant to this Section 7, a tender or exchange offer is outstanding,
then the Grantor (or its designee) shall agree at the time of such purchase to
promptly pay to Grantee from time to time such additional amounts, if any, so
that the consideration received by Grantee with respect to each Option Share
shall be equal to the highest price paid for a share of Common Stock pursuant to
such tender or exchange, or pursuant to any other tender or exchange offer
outstanding at any time such tender or exchange offer is outstanding.
(c) If the Grantor exercises its right of first refusal
hereunder, the closing of the purchase of the Option Shares with respect to
which such right has been exercised shall take place within five business days
after the notice of such exercise (or, if applicable, in the case of a tender or
exchange offer, no later than one business day prior to the expiration date of
the offer if
6
EXECUTION COPY
<PAGE>
written notice was given within the time set forth in the parenthetical in the
first sentence of paragraph (b) above); provided, however, that at any time
-------- -------
prior to the closing of the purchase of Option Shares hereunder, the Grantee may
determine not to sell the Option Shares and revoke the Disposition Notice and,
by so doing, cancel the Grantor's right of first refusal with respect to the
disposition in question. The Grantor (or its designee) shall pay for the Option
Shares by wire transfer of immediately available funds to a bank designated by
the Grantee.
(d) If the Grantor does not exercise its right of first
refusal hereunder within the time specified for such exercise, the Grantee shall
be free for 90 days following the expiration of such time for exercise to sell
the Option Shares (or enter into an agreement to sell the Option Shares)
specified in the Disposition Notice, at the price specified in the Disposition
Notice or any price in excess thereof and otherwise on substantially the same
terms set forth in the Disposition Notice; provided that if such sale is not
consummated within such 90-day period (or the agreement to sell entered into in
such 90-day period is not thereafter performed in accordance with its terms),
then the provisions of this Section 7 will again apply to the sale of such
Option Shares.
(e) For purposes of the Agreement, a "Change in Control
-----------------
Event" shall be deemed to have occurred if (i) any person has acquired
- -----
beneficial ownership of more than 50% (excluding the Option Shares) of the
outstanding shares of Common Stock or (ii) the Grantor shall have entered into
an agreement, including without limitation an agreement in principle, providing
for a merger or other business combination involving the Grantor or the
acquisition of 30% or more of the assets of the Grantor and its subsidiaries,
taken as a whole.
8. Repurchase of Option Shares. If a Change in Control Event has
---------------------------
notbeginning on such anniversary date, the Grantor shall have the right to
purchase (the "Repurchase Right") all, but not less than all, of the Option
----------------
Shares at the greater of (i) the Purchase Price, or (ii) the average closing
price of the Common Stock on the NYSE for the five trading days ending five days
prior to the date the Grantor gives written notice of its intention to exercise
the Repurchase Right. If the Grantor does not exercise the Repurchase Right
within 30 days following the first anniversary of the Merger Termination Date,
the Repurchase Right shall terminate. In the event the Grantor wishes to
exercise the Repurchase Right, the Grantor shall send a written notice to the
Grantee specifying a date (not later than 10 business days and not earlier than
two business days following the date such notice is given) for the closing of
such purchase.
9. Registration Rights.
-------------------
(a) In the event that the Grantee shall desire to sell any of
the Option Shares within two years after the purchase of such Option Shares
pursuant to the exercise of the Option, and such sale requires, in the opinion
of counsel to the Grantee, which opinion shall be reasonably satisfactory to the
Grantor and its counsel, registration of such Option Shares under the Securities
Act, the Grantor will cooperate with the Grantee and any underwriters
registering such Option Shares for resale, including, without limitation,
promptly filing and using its best efforts to cause to be declared effective a
registration statement which complies with the
7
EXECUTION COPY
<PAGE>
requirements of applicable federal and state securities laws and entering into
an underwriting agreement with such underwriters upon such terms and conditions
as are customarily contained in underwriting agreements with respect to
secondary distributions; provided that the Grantor shall not be required to have
declared effective more than two registration statements hereunder and shall be
entitled to delay the filing or effectiveness of any registration statement for
up to 120 days in the aggregate if the offering would, in the judgment of the
Board of Directors of the Grantor, require premature disclosure of any material
corporate development or otherwise interfere with or adversely affect any
pending or proposed offering of securities of the Grantor or any other material
transaction involving the Grantor.
(b) If the Common Stock is registered pursuant to the
provisions of this Section 9, the Grantor agrees (i) to furnish copies of the
registration statement and the prospectus relating to the Option Shares covered
thereby in such numbers as the Grantee may from time to time reasonably request
and (ii) if any event shall occur as a result of which it becomes necessary to
amend or supplement any registration statement or prospectus, to prepare and
file under the applicable securities laws such amendments and supplements as may
be necessary to keep available for at least 90 days a prospectus covering the
Common Stock meeting the requirements of such securities laws, and to furnish to
the Grantee such numbers of copies of the registration statement and prospectus
as amended or supplemented as may reasonably be requested. The Grantor shall
bear the cost of the registration, including, but not limited to, all
registration and filing fees, printing expenses, and fees and disbursements of
counsel and accountants for the Grantor, except that the Grantee shall pay the
fees and disbursements of its counsel and the underwriting fees and selling
commissions applicable to the Option Shares sold by the Grantee. The Grantor
shall indemnify and hold harmless Grantee, its affiliates and its officers and
directors from and against any and all losses, claims, damages, liabilities and
expenses arising out of or based upon any statements contained in, omissions or
alleged omissions from, each registration statement filed pursuant to this
paragraph; provided, however, that this provision does not apply to any loss,
-------- -------
liability, claim, damage or expense to the extent it arises out of any statement
or omission made in reliance upon and in conformity with written information
furnished to the Grantor by the Grantee, its affiliates or its officers
expressly for use in any registration statement (or any amendment thereto) or
any preliminary prospectus filed pursuant to this paragraph. The Grantor shall
also indemnify and hold harmless each underwriter and each person who controls
any underwriter within the meaning of either the Securities Act or the
Securities Exchange Act of 1934, as amended, against any and all losses, claims,
damages, liabilities and expenses arising out of or based upon any statements
contained in, omissions or alleged omissions from, each registration statement
filed pursuant to this paragraph; provided, however, that this provision does
-------- -------
not apply to any loss, liability, claim, damage or expense to the extent it
arises out of any statement or omission made in reliance upon and in conformity
with written information furnished to the Grantor by the underwriters expressly
for use in any registration statement (or any amendment thereto) or any
preliminary prospectus filed pursuant to this paragraph.
8
EXECUTION COPY
<PAGE>
10. Profit Limitation.
-----------------
(a) Notwithstanding any other provision of this Agreement,
in no event shall the Grantee's Total Profit (as hereinafter defined) exceed
$35,000,000 (the "Profit Limit") and, if it otherwise would exceed such amount,
------------
the Grantee, at its sole election, shall either (i) deliver to the Grantor for
cancellation Option Shares previously purchased by Grantee (valued at the
average closing price of the Common Stock on the NYSE for the five trading days
ending on the trading date immediately preceding the date of delivery), (ii) pay
cash or deliver other consideration to the Grantor, or (iii) undertake any
combination thereof, so that Grantee's Total Profit shall not exceed the Profit
Limit after taking into account the foregoing actions.
(b) Notwithstanding any other provision of this Agreement,
the Option may not be exercised for a number of Option Shares as would, as of
the date of the Exercise Notice, result in a Notional Total Profit (as defined
below) of more than the Profit Limit and, if exercise of the Option otherwise
would exceed the Profit Limit, the Grantee, at its discretion, may increase the
Purchase Price for that number of Option Shares set forth in the Exercise Notice
so that the Notional Total Profit shall not exceed the Profit Limit; provided
that nothing in this sentence shall restrict any exercise of the Option
permitted hereby on any subsequent date at the Purchase Price set forth in
Section 1(a) hereof.
(c) As used herein, the term "Total Profit" shall mean the
------------
aggregate amount (before taxes) of the following: (i) the amount of cash
received by Grantee pursuant to Section 8.03(e) of the Merger Agreement, (ii)
(x) the amount received by Grantee pursuant to the Grantor's repurchase of
Option Shares pursuant to Sections 1(d), 7 or 8 hereof, less (y) the Grantee's
aggregate purchase price for such Option Shares, (iii) the amount received by
Grantee in respect of a Cash Exercise Notice pursuant to Section 1(d) hereof,
and (iv) (x) the net cash amounts received by Grantee pursuant to the sale of
Option Shares (or any other securities into which such Option Shares are
converted or exchanged) to any unaffiliated party, less (y) the Grantee's
aggregate purchase price for such Option Shares.
(d) As used herein, the term "Notional Total Profit" with
---------------------
respect to any number of Option Shares as to which Grantee may propose to
exercise the Option shall be the Total Profit determined as of the date of the
Exercise Notice assuming that the Option were exercised on such date for such
number of Option Shares and assuming that such Option Shares, together with all
other Option Shares held by Grantee and its affiliates as of such date, were
sold for cash at the closing market price for the Common Stock as of the close
of business on the preceding trading day (less customary brokerage commissions).
11. Expenses. Each party hereto shall pay its own expenses
--------
incurred in connection with this Agreement, except as otherwise specifically
provided herein.
12. Specific Performance. The Grantor acknowledges that if the
--------------------
Grantor fails to perform any of its obligations under this Agreement, immediate
and irreparable harm or injury would be caused to the Grantee for which money
damages would not be an adequate remedy. In such event, the Grantor agrees that
the Grantee shall have the right, in addition to any other rights it may have,
to specific performance of this Agreement. Accordingly, if the Grantee should
9
EXECUTION COPY
<PAGE>
institute an action or proceeding seeking specific enforcement of the provisions
hereof, the Grantor hereby waives the claim or defense that the Grantee has an
adequate remedy at law and hereby agrees not to assert in any such action or
proceeding the claim or defense that such a remedy at law exists. The Grantor
further agrees to waive any requirement for the securing or posting of any bond
in connection with obtaining any such equitable relief.
13. Notice. All notices, requests, demands and other communications
------
hereunder shall be sent in the manner and to the addresses set forth in the
Merger Agreement.
14. Parties in Interest. Nothing in this Agreement, express or
-------------------
implied, is intended to confer upon any person other than the Grantor or the
Grantee, or their successors or assigns, any rights or remedies under or by
reason of this Agreement.
15. Entire Agreement; Amendments. This Agreement, together with the
----------------------------
Merger Agreement and the other documents referred to therein, contains the
entire agreement between the parties hereto with respect to the subject matter
hereof and supersedes all prior and contemporaneous agreements and
understandings, oral or written, with respect to such transactions. The terms
of this Agreement may be amended, modified or waived only by an agreement in
writing signed by the party against whom such amendment, modification or waiver
is sought to be enforced.
16. Assignment. No party to this Agreement may assign any of its
----------
rights or obligations under this Agreement without the prior written consent of
the other party hereto, except that the Grantee may assign its rights and
obligations hereunder to any direct or indirect wholly-owned subsidiary of the
Grantee (provided that such assignment shall not relieve the Grantee of its
obligations hereunder if such transferee does not perform such obligations). Any
Option Shares sold or transferred by the Grantee to any other person or entity
in compliance with the terms hereof (other than a direct or indirect wholly-
owned subsidiary of the Grantee) shall no longer have the benefit of the rights
provided for herein with respect to such Option Shares (including without
limitation those set forth in Sections 1(d) and 9) and shall no longer be
subject to the restrictions or rights in favor of the Grantor provided for
herein with respect to such Option Shares (including without limitation those
set forth in Sections 7 and 8).
17. Headings. The section headings herein are for convenience only
--------
and shall not affect the construction of this Agreement.
18. Counterparts. This Agreement may be executed in any number of
------------
counterparts, each of which, when executed, shall be deemed to be an original
and all of which together shall constitute one and the same document.
19. Governing Law. This Agreement shall be governed by and construed
-------------
in accordance with the laws of the State of Delaware (regardless of the laws
that might otherwise govern under applicable Delaware principles of conflicts of
law).
20. Survival. All representations and warranties contained in this
--------
Agreement shall survive delivery of and payment for the Option Shares.
10
EXECUTION COPY
<PAGE>
21. Severability. If any term, provision, covenant or restriction of
------------
this Agreement is held by a court of competent jurisdiction to be invalid, void
or unenforceable, the remainder of the terms, provisions, covenants and
restrictions of this Agreement shall remain in full force and effect and shall
in no way be affected, impaired or invalidated.
11
EXECUTION COPY
<PAGE>
IN WITNESS WHEREOF, the Grantee and the Grantor have caused this Agreement
to be duly executed and delivered on the day and year first above written.
TUBOSCOPE INC.
By: /s/ John F. Lauletta
--------------------
Name: John Lauletta
Name: Chief Executive Officer
VARCO INTERNATIONAL, INC.
By: /s/ George Boyadjieff
---------------------
Name: George Boyadjieff
Title: Chief Executive Officer
12
EXECUTION COPY
<PAGE>
EXHIBIT 99.1
Varco and Tuboscope Announce Merger
ORANGE, Calif., March 22 /PRNewswire/ -- Varco International, Inc. (NYSE: VRC -
---
news) and Tuboscope Inc. (NYSE: TBI - news) today announced a merger-of-equals
- ---- --- ----
transaction that will create a combined oilfield equipment and services
organization with leading market positions in each of its major business lines.
The shares of the combined company, which will be called Varco International,
Inc., will be owned equally by the current shareholders of each company. The
combined company had revenue of approximately $1 billion in 1999 and nearly
5,300 employees worldwide as of December 31, 1999.
Under the terms of the definitive merger agreement, which was unanimously
approved by each company's Board of Directors, Tuboscope will issue 0.7125 new
shares in exchange for each share of Varco common stock, resulting in
approximately 94 million shares on a fully diluted basis. Simultaneous with the
closing of the transaction, Tuboscope will change its corporate name to Varco
International, Inc. and list the shares of the combined company on the NYSE for
trading under the symbol ``VRC''. Based on each company's closing price on March
22, 2000, the combined company will have a market capitalization of
approximately $1.8 billion. It is expected that the transaction will be
accounted for as a pooling-of-interests and will be tax free to shareholders.
George Boyadjieff, Chairman and CEO of Varco, who will be Chairman and CEO of
the combined company, said, ``This is a true merger-of-equals transaction that
combines two of the premier franchises in the oilfield services and equipment
sector. Tuboscope and Varco each trace their roots back to the early part of the
20th century when the oil service industry was in its infancy. More importantly,
our companies share complementary strategic objectives and a compatible vision
for the future of our industry and for our new company. The value that this
transaction creates comes from the ability of the combined company to provide a
broader offering of equipment and services on both land and offshore rigs, and
from drilling through well remediation.''
John Lauletta, President and CEO of Tuboscope, who will become President and COO
of the combined company added, ``This should result in strong growth
opportunities as we develop new products and expand services and should result
in greater revenue, cash flow and earnings across the full breadth of activity
in the oilfield service industry. The combined company will draw equally upon
the talent from both organizations to effectively integrate our product and
service offerings for our customers, while enhancing returns for our
shareholders.''
John Lauletta continued, ``We have assumed only a modest amount of cost savings
from consolidation in this transaction as the real value creation of this
combination will come from enhanced revenue opportunities. The combined company
will certainly continue to operate with the same culture of financial discipline
that has been a hallmark of each organization.''
Joseph Winkler, Chief Financial Officer of Tuboscope, who will become Chief
Financial Officer of the combined company said, ``The merger is expected to be
accretive to earnings and cash flow per share for shareholders of both companies
in the first full year of the combination. In addition, with a market
capitalization of $1.8 billion, liquidity will be significantly increased for
<PAGE>
current and prospective shareholders. The combination of a strong equity
currency and a liquid balance sheet with significant debt capacity should
provide a strong financial position for the combined company.''
The ten member Board of Directors of the combined company will consist of five
representatives each from Varco and Tuboscope, including the former Chairman of
Tuboscope, L.E. Simmons, as a non-executive director.
The transaction is expected to be completed during the second quarter of 2000
and is subject to stockholder and regulatory approvals, including expiration of
the applicable waiting period under the Hart-Scott-Rodino Act, and other
customary conditions. Varco and Tuboscope intend to file a joint proxy statement
with the Securities and Exchange Commission shortly.
Tuboscope was advised by Credit Suisse First Boston Corporation which brought
the two companies together, and Varco was advised by J.P. Morgan & Co.
Incorporated.
A joint conference call will be held Thursday morning, March 23rd at 7 A.M.
Pacific Time (9 A.M. Central Time). The dial-in number for the call is
712.257.3091 and the identification code is 3710620.
The foregoing contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act
of 1934. The forward-looking statements are those that do not state historical
facts and are inherently subject to risk and uncertainties. The forward-looking
statements contained herein are based on current expectations and entail various
risks and uncertainties that could cause actual results to differ materially
from those projected in the forward- looking statements. Such risks and
uncertainties include, among others, the cyclical nature of the oilfield
services industry, risks associated with the Company's significant foreign
operations, compliance with environmental laws, risks associated with growth
through acquisitions and other factors discussed in each of the Company's Annual
Report on Form 10-K.
SOURCE: Varco International, Inc.
